



**Australian Government**

**Department of Health  
and Aged Care**



# Schedule of Pharmaceutical Benefits

Efficient Funding of Chemotherapy

**Effective 1 January 2024**



# Contents

<b>Summary of Changes</b> .....	<b>3</b>
<b>About the Supplement</b> .....	<b>5</b>
Symbols used in the Efficient Funding of Chemotherapy supplement .....	5
Remuneration arrangements.....	5
<b>Pharmaceutical Benefits Schedules</b> .....	<b>6</b>
Chemotherapy items for Private Hospital use .....	8
Chemotherapy items for Public Hospital use.....	83
Related Pharmaceutical Benefits for Public Hospital use.....	159
<b>Index of Manufacturers' Code</b> .....	<b>171</b>
<b>Generic/Proprietary Index</b> .....	<b>173</b>

---

# Summary of Changes

These changes to the Schedule of Pharmaceutical Benefits are effective from 1 January 2024. The Schedule is updated on the first day of each month and is available on the internet at [www.pbs.gov.au](http://www.pbs.gov.au).

## Efficient Funding of Chemotherapy (Private Hospital)

### Additions

#### Addition – Item

13793Y **OBINUTUZUMAB**,  
obinutuzumab 1 g/40 mL injection, 40 mL vial (*Gazyva*)

### Deletions

#### Deletion – Brand

12219D *Bortezomib-AFT, AE* – **BORTEZOMIB**, bortezomib 3.5 mg injection, 1 vial

### Alterations

#### Alteration – Note

12120X **PEMBROLIZUMAB**,  
pembrolizumab 100 mg/4 mL injection, 4 mL vial (*Keytruda*)

#### Alteration – Restriction

12120X **PEMBROLIZUMAB**,  
pembrolizumab 100 mg/4 mL injection, 4 mL vial (*Keytruda*)

### Advance Notices

#### 1 February 2024

#### Deletion – Brand

7244G *CIPLA BLEOMYCIN, LR* – **BLEOMYCIN**, bleomycin sulfate 15 000 international units injection, 1 vial

7249M *MEDITAB IRINOTECAN, LR* – **IRINOTECAN**, irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial

7249M *MEDITAB IRINOTECAN, LR* – **IRINOTECAN**, irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 2 mL vial

7250N *Pfizer Australia Pty Ltd, PF* – **METHOTREXATE**, methotrexate 1 g/10 mL injection, 10 mL vial

7251P *Pfizer Australia Pty Ltd, PF* – **METHOTREXATE**, methotrexate 1 g/10 mL injection, 10 mL vial

## Efficient Funding of Chemotherapy (Public Hospital)

### Additions

#### Addition – Item

13787P **OBINUTUZUMAB**,  
obinutuzumab 1 g/40 mL injection, 40 mL vial (*Gazyva*)

### Deletions

#### Deletion – Brand

12227M *Bortezomib-AFT, AE* – **BORTEZOMIB**, bortezomib 3.5 mg injection, 1 vial

---

## Alterations

### Alteration – Note

12130K **PEMBROLIZUMAB**,  
pembrolizumab 100 mg/4 mL injection, 4 mL vial (*Keytruda*)

### Alteration – Restriction

12130K **PEMBROLIZUMAB**,  
pembrolizumab 100 mg/4 mL injection, 4 mL vial (*Keytruda*)

## Advance Notices

**1 February 2024**

### Deletion – Brand

4433H *CIPLA BLEOMYCIN, LR* – **BLEOMYCIN**, bleomycin sulfate 15 000 international units injection, 1 vial  
4451G *MEDITAB IRINOTECAN, LR* – **IRINOTECAN**, irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial  
4451G *MEDITAB IRINOTECAN, LR* – **IRINOTECAN**, irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 2 mL vial  
4502Y *Pfizer Australia Pty Ltd, PF* – **METHOTREXATE**, methotrexate 1 g/10 mL injection, 10 mL vial  
4512L *Pfizer Australia Pty Ltd, PF* – **METHOTREXATE**, methotrexate 1 g/10 mL injection, 10 mL vial

## Related Pharmaceutical Benefits for Public Hospital use

### Deletions

#### Deletion – Brand

5857G *APO-Ondansetron ODT, TX* – **ONDANSETRON**, ondansetron 4 mg orally disintegrating tablet, 4  
5967C *Ondansetron APOTEX, GX* – **ONDANSETRON**, ondansetron 4 mg tablet, 4  
5858H *APO-Ondansetron ODT, TX* – **ONDANSETRON**, ondansetron 8 mg orally disintegrating tablet, 4  
5968D *Ondansetron APOTEX, GX* – **ONDANSETRON**, ondansetron 8 mg tablet, 4

## Advance Notices

**1 February 2024**

### Deletion – Brand

5857G *Ondansetron AN ODT, EA* – **ONDANSETRON**, ondansetron 4 mg orally disintegrating tablet, 4  
5858H *Ondansetron AN ODT, EA* – **ONDANSETRON**, ondansetron 8 mg orally disintegrating tablet, 4  
5967C *Ondansetron AN, EA* – **ONDANSETRON**, ondansetron 4 mg tablet, 4  
5968D *Ondansetron AN, EA* – **ONDANSETRON**, ondansetron 8 mg tablet, 4

---

# About the Supplement

The Schedule of Pharmaceutical Benefits – Efficient Funding of Chemotherapy supplement lists items distributed under section 100 of the National Health Act 1953.

The Supplement is published and is effective on the first day of each month. For detailed information about the prescribing and supply of chemotherapy benefits go to [www.pbs.gov.au](http://www.pbs.gov.au)

For information about the operational aspects of the Efficient Funding of Chemotherapy, such as, claiming, authority applications and stationery supplies contact Services Australia at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

This supplement is split into three parts:

**Chemotherapy items for private hospital use.** This includes items subject to the revised arrangements, ie. chemotherapy drugs administered through infusion or injection

**Chemotherapy items for public hospital use.** This includes items subject to the revised arrangements, ie. chemotherapy drugs administered through infusion or injection

*PBS products available for private and public hospital use may be dispensed in accordance with the relevant section 100 special arrangements through community pharmacy.*

**Related pharmaceutical benefits for public hospital use.** This includes items such as antiemetics, antinauseants, immunostimulants and detoxifying agents for antineoplastic treatment

## Symbols used in the Efficient Funding of Chemotherapy supplement

*	An asterisk in the dispensed price column indicates that the manufacturer's pack does not coincide with the maximum quantity
‡	A double dagger in the maximum quantity column indicates where the maximum quantity has been determined to match the manufacturer's pack. These packs cannot be broken and the maximum quantity should be supplied and claimed
<sup>a</sup> or <sup>b</sup>	Located immediately before brand names of an item indicates that the brands are equivalent for the purposes of substitution. These brands may be interchanged without differences in clinical effect

## Remuneration arrangements

Fees payable per item claimed:

### Section 90 Community Pharmacy (incl. section 92 approved practitioners)

- Ready Prepared Dispensing Fee (\$8.37)
- Preparation fee (\$88.62)
- Distribution fee (\$29.15)
- Diluent fee (\$5.77)

### Section 94 Approved Public Hospital Authority

- Preparation fee (\$88.62)

### Section 94 Approved Private Hospital Authority

- Ready Prepared Dispensing Fee (\$8.37)
- Preparation fee (\$88.62)
- Distribution fee (\$29.15) (not payable where the drug is trastuzumab)
- Diluent fee (\$5.77)

---

# Pharmaceutical Benefits Schedules



# Chemotherapy items for Private Hospital use

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS .....	9
ANTINEOPLASTIC AGENTS .....	9
ALKYLATING AGENTS .....	9
ANTIMETABOLITES .....	10
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS .....	12
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES .....	15
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES.....	16
OTHER ANTINEOPLASTIC AGENTS .....	75

■ ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

■ ANTINEOPLASTIC AGENTS

ALKYLATING AGENTS

*Nitrogen mustard analogues*

■ BENDAMUSTINE

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required (STREAMLINED)**

**7972**

Previously untreated stage III or IV mantle cell lymphoma

Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must be CD20 positive, **AND**
- The treatment must be in combination with rituximab, **AND**
- The condition must be previously untreated, **AND**
- The condition must be symptomatic, **AND**
- The treatment must be for induction treatment purposes only, **AND**
- Patient must not receive more than 6 cycles (12 doses) of treatment under this restriction, **AND**
- Patient must not be eligible for stem cell transplantation.

**Authority required (STREAMLINED)**

**7943**

Previously untreated stage II bulky or stage III or IV indolent non-Hodgkin's lymphoma

Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must be CD20 positive, **AND**
- The condition must be previously untreated, **AND**
- The condition must be symptomatic, **AND**
- The treatment must be for induction treatment purposes only, **AND**
- The treatment must be in combination with rituximab or obinutuzumab, **AND**
- The treatment must not exceed 6 cycles (12 doses) with this drug under this restriction.

**Authority required (STREAMLINED)**

**7944**

Follicular lymphoma

Treatment Phase: Re-induction treatment

**Clinical criteria:**

- The condition must be CD20 positive, **AND**
- The condition must be refractory to treatment with rituximab for this condition, **AND**
- The condition must be symptomatic, **AND**
- The treatment must be for re-induction treatment purposes only, **AND**
- The treatment must be in combination with obinutuzumab, **AND**
- The treatment must not exceed 6 cycles (12 doses) with this drug under this restriction.

The condition is considered rituximab-refractory if the patient experiences less than a partial response or progression of disease within 6 months after completion of a prior rituximab-containing regimen.

**Injection**

10763L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	11	..	*1298.43	31.60	Bendamustine Juno [JU] (bendamustine hydrochloride 100 mg injection, 1 vial) Bendamustine Juno [JU] (bendamustine hydrochloride 25 mg injection, 1 vial) Bendamustine Sandoz [SZ] (bendamustine hydrochloride 100 mg injection, 1 vial) Bendamustine Sandoz [SZ] (bendamustine hydrochloride 25 mg injection, 1 vial) Bendamustine Viatrix [AF] (bendamustine hydrochloride 100 mg injection, 1 vial) Bendamustine Viatrix [AF] (bendamustine hydrochloride 25 mg injection, 1 vial) Ribomustin [JC] (bendamustine hydrochloride 100 mg injection, 1 vial) Ribomustin [JC] (bendamustine hydrochloride 25 mg injection, 1 vial)

## ■ CYCLOPHOSPHAMIDE

### Injection

7226H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	2800 mg	17	..	*188.46	31.60	CYCLOPHOSPHAMIDE-REACH [RQ] (cyclophosphamide 1 g injection, 1 vial) CYCLOPHOSPHAMIDE-REACH [RQ] (cyclophosphamide 500 mg injection, 1 vial) Endoxan [BX] (cyclophosphamide 1 g injection, 1 vial) Endoxan [BX] (cyclophosphamide 2 g injection, 1 vial) Endoxan [BX] (cyclophosphamide 500 mg injection, 1 vial)

## ■ IFOSFAMIDE

### Injection

7248L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	4000 mg	19	..	*287.03	31.60	Holoxan [BX] (ifosfamide 1 g injection, 1 vial) Holoxan [BX] (ifosfamide 2 g injection, 1 vial)

## ANTIMETABOLITES

### *Folic acid analogues*

## ■ METHOTREXATE

### Injection

7250N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	250 mg	5	..	*157.76	31.60	DBL Methotrexate [PF] (methotrexate 1 g/10 mL injection, 10 mL vial) DBL Methotrexate [PF] (methotrexate 5 mg/2 mL injection, 5 x 2 mL vials) DBL Methotrexate [PF] (methotrexate 50 mg/2 mL injection, 5 x 2 mL vials) DBL Methotrexate [PF] (methotrexate 500 mg/20 mL injection, 20 mL vial) Methotrexate Accord [OD] (methotrexate 1 g/10 mL injection, 10 mL vial) Methotrexate Ebewe [SZ] (methotrexate 5 g/50 mL injection, 50 mL vial) Pfizer Australia Pty Ltd [PF] (methotrexate 1 g/10 mL injection, 10 mL vial)

## ■ METHOTREXATE

### Restricted benefit

Patients receiving treatment with a high dose regimen

### Injection

7251P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	20000 mg	..	..	*895.87	31.60	DBL Methotrexate [PF] (methotrexate 1 g/10 mL injection, 10 mL vial) DBL Methotrexate [PF] (methotrexate 5 mg/2 mL injection, 5 x 2 mL vials) DBL Methotrexate [PF] (methotrexate 50 mg/2 mL injection, 5 x 2 mL vials) DBL Methotrexate [PF] (methotrexate 500 mg/20 mL injection, 20 mL vial) Methotrexate Accord [OD] (methotrexate 1 g/10 mL injection, 10 mL vial) Methotrexate Ebewe [SZ] (methotrexate 5 g/50 mL injection, 50 mL vial) Pfizer Australia Pty Ltd [PF] (methotrexate 1 g/10 mL injection, 10 mL vial)

## ■ PEMETREXED

### Injection

7255W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1100 mg	5	..	*191.09	31.60	Pemetrexed Accord [OD] (pemetrexed 1 g injection, 1 vial) Pemetrexed Accord [OD] (pemetrexed 100 mg injection, 1 vial) Pemetrexed Accord [OD] (pemetrexed 500 mg injection, 1 vial) Pemetrexed APOTEX [TX] (pemetrexed 500 mg injection, 1 vial) Pemetrexed Ever Pharma [IT] (pemetrexed 1 g/40 mL injection, 40 mL vial)

Pemetrexed Ever Pharma [IT] (pemetrexed 100 mg/4 mL injection, 4 mL vial)  
 Pemetrexed Ever Pharma [IT] (pemetrexed 500 mg/20 mL injection, 20 mL vial)  
 Pemetrexed SUN [RA] (pemetrexed 1 g injection, 1 vial)  
 Pemetrexed SUN [RA] (pemetrexed 100 mg injection, 1 vial)  
 Pemetrexed SUN [RA] (pemetrexed 500 mg injection, 1 vial)

▪ **PRALATREXATE**

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required**

Relapsed or chemotherapy refractory Peripheral T-cell Lymphoma  
 Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be relapsed or chemotherapy refractory, **AND**
- Patient must have undergone appropriate prior front-line curative intent chemotherapy.

**Injection**

11271F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	80 mg	5	..	*4331.91	31.60	Folotyn [MF] (pralatrexate 20 mg/mL injection, 1 mL vial)

▪ **PRALATREXATE**

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required**

Relapsed or chemotherapy refractory Peripheral T-cell Lymphoma  
 Treatment Phase: Continuing treatment

**Clinical criteria:**

- The condition must be relapsed or chemotherapy refractory, **AND**
- Patient must not develop progressive disease whilst receiving PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition.

**Injection**

11278N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	80 mg	11	..	*4331.91	31.60	Folotyn [MF] (pralatrexate 20 mg/mL injection, 1 mL vial)

▪ **RALTITREXED**

**Injection**

7256X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	7 mg	8	..	*1189.35	31.60	Tomudex [PF] (raltitrexed 2 mg injection, 1 vial)

*Purine analogues*

▪ **CLADRIBINE**

**Authority required (STREAMLINED)**

**6265**

Hairy cell leukaemia

**Injection**

7225G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	17 mg	6	..	*952.49	31.60	Leustatin [IX] (cladribine 10 mg/10 mL injection, 10 mL vial) Litak [AF] (cladribine 10 mg/5 mL injection, 5 mL vial)

▪ **FLUDARABINE**

**Note** Pharmaceutical benefits that have the form fludarabine phosphate 50 mg injection and pharmaceutical benefits that have the form fludarabine phosphate 50 mg/2 mL injection are equivalent for the purposes of substitution.

**Injection**

7233Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	55 mg	29	..	*196.49	31.60	Fludarabine Ebewe [SZ] (fludarabine phosphate 50 mg/2 mL injection, 5 x 2 mL vials) Fludarabine Juno [JO] (fludarabine phosphate 50 mg injection, 1 vial)

*Pyrimidine analogues*

## ■ CYTARABINE

### Injection

7227J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	7000 mg	15	..	*941.11	31.60	Pfizer Australia Pty Ltd [PF] (cytarabine 100 mg/5 mL injection, 5 x 5 mL vials)

## ■ FLUOROURACIL

### Restricted benefit

Patients requiring administration of fluorouracil by intravenous infusion

### Injection

7234R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	5500 mg	11	..	*159.43	31.60	Fluorouracil Accord [OC] (fluorouracil 1 g/20 mL injection, 20 mL vial) Fluorouracil Accord [OC] (fluorouracil 2.5 g/50 mL injection, 50 mL vial) Fluorouracil Accord [OC] (fluorouracil 5 g/100 mL injection, 100 mL vial) Fluorouracil Accord [OC] (fluorouracil 500 mg/10 mL injection, 10 mL vial) Fluorouracil Ebewe [SZ] (fluorouracil 1 g/20 mL injection, 20 mL vial) Fluorouracil Ebewe [SZ] (fluorouracil 5 g/100 mL injection, 100 mL vial)

## ■ FLUOROURACIL

### Restricted benefit

Patients requiring administration of fluorouracil by intravenous injection

### Injection

7239B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	23	..	*137.83	31.60	Fluorouracil Accord [OC] (fluorouracil 1 g/20 mL injection, 20 mL vial) Fluorouracil Accord [OC] (fluorouracil 2.5 g/50 mL injection, 50 mL vial) Fluorouracil Accord [OC] (fluorouracil 5 g/100 mL injection, 100 mL vial) Fluorouracil Accord [OC] (fluorouracil 500 mg/10 mL injection, 10 mL vial) Fluorouracil Ebewe [SZ] (fluorouracil 1 g/20 mL injection, 20 mL vial) Fluorouracil Ebewe [SZ] (fluorouracil 5 g/100 mL injection, 100 mL vial)

## ■ GEMCITABINE

**Caution** Pharmaceutical benefits containing gemcitabine may have different concentrations.

### Injection

7246J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3000 mg	17	..	*195.84	31.60	DBL Gemcitabine Injection [PF] (gemcitabine 1 g/26.3 mL injection, 26.3 mL vial) DBL Gemcitabine Injection [PF] (gemcitabine 2 g/52.6 mL injection, 52.6 mL vial)

## PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS

### *Vinca alkaloids and analogues*

## ■ VINBLASTINE

### Injection

7261E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	20 mg	17	..	*206.27	31.60	DBL Vinblastine [PF] (vinblastine sulfate 10 mg/10 mL injection, 5 x 10 mL vials)

## ■ VINCRIStINE

### Injection

7262F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	2 mg	7	..	*149.99	31.60	DBL Vincristine Sulfate [PF] (vincristine sulfate 1 mg/mL injection, 5 x 1 mL vials)

▪ **VINOURELBINE**

**Injection**

7263G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	70 mg	7	..	*194.67	31.60	Navelbine [FB] (vinorelbine 10 mg/mL injection, 1 mL vial) Navelbine [FB] (vinorelbine 50 mg/5 mL injection, 5 mL vial) Vinorelbine Ebewe [SZ] (vinorelbine 10 mg/mL injection, 1 mL vial) Vinorelbine Ebewe [SZ] (vinorelbine 50 mg/5 mL injection, 5 mL vial)

*Podophyllotoxin derivatives*

▪ **ETOPOSIDE**

**Injection**

7237X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	440 mg	14	..	*328.11	31.60	Etopophos [LM] (etoposide phosphate 1.136 g (etoposide 1 g) injection, 1 vial) Etoposide Ebewe [SZ] (etoposide 100 mg/5 mL injection, 5 x 5 mL vials)

*Taxanes*

▪ **CABAZITAXEL**

**Note** Where the term 'novel hormonal drug' appears in this restriction, it refers to: (i) abiraterone, (ii) apalutamide, (iii) darolutamide, (iv) enzalutamide.

**Authority required (STREAMLINED)**

**13207**

Castration resistant metastatic carcinoma of the prostate

**Clinical criteria:**

- The treatment must be in combination with prednisone or prednisolone, **AND**
- The condition must be resistant to treatment with docetaxel; OR
- Patient must have a documented intolerance necessitating permanent treatment withdrawal or a contraindication to docetaxel, **AND**
- The treatment must not be used in combination with a novel hormonal drug, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- Patient must not receive PBS-subsidised cabazitaxel if progressive disease develops while on cabazitaxel.

**Injection**

7236W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	55 mg	5	..	*286.58	31.60	Cabazitaxel Accord [OC] (cabazitaxel 60 mg/3 mL injection, 3 mL vial) Cabazitaxel Ever Pharma [IT] (cabazitaxel 60 mg/6 mL injection, 6 mL vial) Cabazitaxel Juno [JU] (cabazitaxel 60 mg/1.5 mL injection [1.5 mL vial] (& inert substance diluent [4.5 mL vial], 1 pack) MSN Cabazitaxel [RQ] (cabazitaxel 60 mg/1.5 mL injection [1.5 mL vial] (& inert substance diluent [4.5 mL vial], 1 pack)

▪ **DOCETAXEL**

**Note** Pharmaceutical benefits that have the forms docetaxel solution concentrate for I.V. infusion 80 mg in 4 mL and docetaxel solution concentrate for I.V. infusion 80 mg in 8 mL are equivalent for the purposes of substitution.

**Note** Pharmaceutical benefits that have the forms docetaxel solution concentrate for I.V. infusion 160 mg in 8 mL and docetaxel solution concentrate for I.V. infusion 160 mg in 16 mL are equivalent for the purposes of substitution.

**Injection**

10158P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	250 mg	5	..	*199.55	31.60	DBL Docetaxel Concentrated Injection [PF] (docetaxel 160 mg/16 mL injection, 16 mL vial) DBL Docetaxel Concentrated Injection [PF] (docetaxel 80 mg/8 mL injection, 8 mL vial) Docetaxel Accord [OC] (docetaxel 160 mg/8 mL injection, 8 mL vial) Docetaxel Accord [OC] (docetaxel 80 mg/4 mL injection, 4 mL vial)

▪ **NANOPARTICLE ALBUMIN-BOUND PACLITAXEL**

**Authority required (STREAMLINED)**

**6106**

Metastatic breast cancer

**Authority required (STREAMLINED)**

**6119**

HER2 positive breast cancer

**Injection**

7270P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	580 mg	5	..	*2220.39	31.60	Abraxane [TS] (paclitaxel (as nanoparticle albumin-bound) 100 mg injection, 1 vial)

**■ NANOPARTICLE ALBUMIN-BOUND PACLITAXEL**

**Note** Special Pricing Arrangements apply.

**Note** Not for use as neoadjuvant or adjuvant therapy.

**Authority required (STREAMLINED)****4657**

Stage IV (metastatic) adenocarcinoma of the pancreas

**Clinical criteria:**

- The treatment must be in combination with gemcitabine, **AND**
  - The condition must not have been treated previously with PBS-subsidised therapy, **AND**
  - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.
- A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.

**Injection**

10150F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	275 mg	11	..	*1176.15	31.60	Abraxane [TS] (paclitaxel (as nanoparticle albumin-bound) 100 mg injection, 1 vial)

**■ PACLITAXEL****Injection**

7254T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	450 mg	3	..	*206.49	31.60	Paclitaxel Accord [OC] (paclitaxel 300 mg/50 mL injection, 50 mL vial) Paclitaxel Ebewe [SZ] (paclitaxel 300 mg/50 mL injection, 50 mL vial)

***Topoisomerase 1 (TOP1) inhibitors*****■ IRINOTECAN**

**Note** In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.

**Injection**

7249M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	800 mg	11	..	*202.91	31.60	Irinotecan Accord [OC] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) Irinotecan Accord [OC] (irinotecan hydrochloride trihydrate 500 mg/25 mL injection, 25 mL vial) Irinotecan Alphapharm [AF] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) Irinotecan Alphapharm [AF] (irinotecan hydrochloride trihydrate 500 mg/25 mL injection, 25 mL vial) IRINOTECAN BAXTER [BX] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) MEDITAB IRINOTECAN [LR] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) MEDITAB IRINOTECAN [LR] (irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 2 mL vial) Omegapharm Irinotecan [OE] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) Omegapharm Irinotecan [OE] (irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 2 mL vial)

**■ TOPOTECAN****Injection**

7260D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3500 mcg	17	..	*164.44	31.60	Hycamtin [SZ] (topotecan 4 mg injection, 5 vials) Topotecan Accord [OC] (topotecan 4 mg/4 mL injection, 5 x 4 mL vials)

***Other plant alkaloids and natural products*****■ TRABECTEDIN**

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)****14196**

Advanced (unresectable and/or metastatic) leiomyosarcoma or liposarcoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have an ECOG performance status of 2 or less, **AND**
- Patient must have received prior chemotherapy treatment including an anthracycline, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The condition must be one of the following subtypes for patients with liposarcoma: (i) dedifferentiated, (ii) myxoid, (iii) round-cell, (iv) pleomorphic.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

**Injection**

13348M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3250 mcg	3	..	*3414.11	31.60	Yondelis [ZL] (trabectedin 1 mg injection, 1 vial)

▪ **TRABECTEDIN**

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14197**

Advanced (unresectable and/or metastatic) leiomyosarcoma or liposarcoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

**Authority required (STREAMLINED)**

**14188**

Advanced (unresectable and/or metastatic) leiomyosarcoma or liposarcoma

Treatment Phase: Transitioning from non-PBS to PBS-subsidised treatment - Grandfather arrangements

**Clinical criteria:**

- Patient must have been receiving treatment with this drug for this condition prior to 1 August 2023, **AND**
- Patient must have had a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 2 at the time non-PBS supply was initiated, **AND**
- Patient must have received chemotherapy treatment including an anthracycline, prior to initiating non-PBS-subsidised treatment, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The condition must be one of the following subtypes for patients with liposarcoma: (i) dedifferentiated, (ii) myxoid, (iii) round-cell, (iv) pleomorphic.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Injection**

13344H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3250 mcg	7	..	*3414.11	31.60	Yondelis [ZL] (trabectedin 1 mg injection, 1 vial)

**CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES**

*Anthracyclines and related substances*

▪ **DOXORUBICIN**

**Injection/intravesical**

7229L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	135 mg	11	..	*169.14	31.60	Adriamycin [PF] (doxorubicin hydrochloride 200 mg/100 mL injection, 100 mL vial) Adriamycin [PF] (doxorubicin hydrochloride 50 mg/25 mL injection, 25 mL vial) Doxorubicin ACC [OC] (doxorubicin hydrochloride 200 mg/100 mL injection, 100 mL vial)

▪ **DOXORUBICIN HYDROCHLORIDE (AS PEGYLATED LIPOSOMAL)**

**Injection**

7230M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	100 mg	5	..	*800.27	31.60	Caelyx [BX] (doxorubicin hydrochloride (as pegylated liposomal) 20 mg/10 mL injection, 10 mL vial) Caelyx [BX] (doxorubicin hydrochloride (as pegylated liposomal) 50 mg/25 mL injection, 25 mL vial)

Liposomal Doxorubicin SUN [RA] (doxorubicin hydrochloride (as pegylated liposomal) 20 mg/10 mL injection, 10 mL vial)  
Liposomal Doxorubicin SUN [RA] (doxorubicin hydrochloride (as pegylated liposomal) 50 mg/25 mL injection, 25 mL vial)

## ▪ EPIRUBICIN

### Injection/intravesical

7231N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	220 mg	5	..	*312.31	31.60	Epirubicin Accord [OC] (epirubicin hydrochloride 200 mg/100 mL injection, 100 mL vial)

## ▪ IDARUBICIN

### Restricted benefit

Acute myelogenous leukaemia (AML)

### Injection

7247K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	30 mg	5	..	*313.89	31.60	Zavedos Solution [PF] (idarubicin hydrochloride 5 mg/5 mL injection, 5 mL vial)

## ▪ MITOZANTRONE

### Injection

7252Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	30 mg	5	..	*225.81	31.60	Mitozantrone Ebewe [SZ] (mitozantrone 20 mg/10 mL injection, 10 mL vial) Onkotrone [BX] (mitozantrone 20 mg/10 mL injection, 10 mL vial) Onkotrone [BX] (mitozantrone 25 mg/12.5 mL injection, 12.5 mL vial)

### Other cytotoxic antibiotics

## ▪ BLEOMYCIN

### Restricted benefit

Germ cell neoplasms

### Restricted benefit

Lymphoma

### Injection

7244G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	30000 iu	11	..	*213.03	31.60	CIPLA BLEOMYCIN [LR] (bleomycin sulfate 15 000 international units injection, 1 vial) DBL Bleomycin Sulfate [PF] (bleomycin sulfate 15 000 international units injection, 1 vial)

## MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

### CD20 (Clusters of Differentiation 20) inhibitors

## ▪ OBINUTUZUMAB

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### Authority required

Stage II bulky or Stage III/IV follicular lymphoma

Treatment Phase: Maintenance therapy

### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug under the previously untreated initial restriction, **AND**
- The condition must be CD20 positive, **AND**
- Patient must have demonstrated a partial or complete response to PBS subsidised induction treatment with this drug for this condition, **AND**
- The treatment must be maintenance therapy, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed 12 doses or 2 years duration of treatment, whichever comes first, under this restriction, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

**Injection**

11455X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	5	..	*4720.79	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

▪ **OBINUTUZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Stage II bulky or Stage III/IV follicular lymphoma

Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must be CD20 positive, **AND**
- The condition must be previously untreated, **AND**
- The condition must be symptomatic, **AND**
- The treatment must be for induction treatment purposes only, **AND**
- The treatment must be in combination with chemotherapy, **AND**
- The treatment must not exceed 10 doses for induction treatment with this drug for this condition.

A patient may only qualify for PBS-subsidised initiation treatment once in a lifetime under:

- i) the previously untreated induction treatment restriction; or
- ii) the rituximab-refractory re-induction restriction.

**Injection**

11456Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	9	..	*4720.79	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

▪ **OBINUTUZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Follicular lymphoma

Treatment Phase: Re-induction treatment

**Clinical criteria:**

- Patient must not have previously received PBS-subsidised obinutuzumab, **AND**
- The condition must be CD20 positive, **AND**
- The condition must be refractory to treatment with rituximab for this condition, **AND**
- The condition must be symptomatic, **AND**
- The treatment must be for re-induction treatment purposes only, **AND**
- The treatment must be in combination with bendamustine, **AND**
- The treatment must not exceed 8 doses for re-induction treatment with this drug for this condition.

The condition is considered rituximab-refractory if the patient experiences less than a partial response or progression of disease within 6 months after completion of a prior rituximab-containing regimen.

A patient may only qualify for PBS-subsidised initiation treatment once in a lifetime under:

- i) the previously untreated induction treatment restriction; or
- ii) the rituximab-refractory re-induction restriction.

**Injection**

11460E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	7	..	*4720.79	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

▪ **OBINUTUZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Follicular lymphoma

Treatment Phase: Maintenance therapy

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug under the rituximab refractory initial restriction, **AND**
- The condition must be CD20 positive, **AND**
- The condition must have been refractory to treatment with rituximab, **AND**
- Patient must have demonstrated a partial or complete response to PBS-subsidised re-induction treatment with this drug for this condition, **AND**

- The treatment must be maintenance therapy, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed 12 doses or 2 years duration of treatment, whichever comes first, under this restriction, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

**Injection**

11473W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	5	..	*4720.79	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

**▪ OBINUTUZUMAB**

**Note** A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required (STREAMLINED)****11015**

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Treatment Phase: For combination use with venetoclax treatment cycles 1 to 6 inclusive in first-line therapy

**Clinical criteria:**

- The condition must be untreated, **AND**
- The treatment must be in combination with PBS-subsidised venetoclax.

**Injection**

12193R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	8	..	*4720.79	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

**▪ OBINUTUZUMAB**

**Note** A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required (STREAMLINED)****14764**

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Treatment Phase: For combination use with acalabrutinib from treatment cycles 2 to 7 inclusive in first-line therapy

**Clinical criteria:**

- The condition must be untreated, **AND**
- The treatment must be in combination with PBS-subsidised acalabrutinib (refer to Product Information for timing of obinutuzumab and acalabrutinib doses).

**Injection**

13793Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	5	..	*4720.79	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

**▪ OBINUTUZUMAB**

**Note** The latest International Workshop on CLL (iwCLL) provides guidance on various aspects of management of CLL/SLL.

Notably, two of these are:

- (1) when to treat versus when to monitor the patient without therapy - see 'Indications for treatment' section; and
- (2) recognising progressive disease - see 'Definition of response, relapse, and refractory disease' section.

See the following literature reference for details:

Hallek, M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. **Blood** vol. 131, 25 (2018): 2745-2760.

**Note** Obinutuzumab is not to be used as monotherapy or in combination with anti-cancer drugs other than chlorambucil under this restriction. For use with venetoclax, refer to the separate listing for this purpose.

**Note** A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required (STREAMLINED)****14326**

Chronic lymphocytic leukaemia (CLL)

Treatment Phase: Combination use with chlorambucil only

**Clinical criteria:**

- The condition must be CD20 positive, **AND**
- The condition must be previously untreated, **AND**
- The treatment must be in combination with chlorambucil, **AND**
- The treatment must only be prescribed for a patient with active disease in accordance with the International Workshop on CLL (iwCLL) guidance (latest version) in relation to when to prescribe drug treatment for this condition.

Treatment must be discontinued in patients who experience disease progression whilst on this treatment.

**Injection**

10418H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	7	..	*4720.79	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

▪ **RITUXIMAB**

**Note** Prescribing/pharmacy claiming: prescribe/claim this benefit through the Section 100 Highly Specialised Drugs Program PBS item code(s) when administered for non-oncology indications. Prescribe/claim this benefit through the Efficient Funding of Chemotherapy PBS item code(s) when administered for oncology indications.

**Injection**

13090Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	800 mg	11	..	*482.67	31.60	Riximyo [SZ] (rituximab 100 mg/10 mL injection, 2 x 10 mL vials) Riximyo [SZ] (rituximab 500 mg/50 mL injection, 50 mL vial) Ruxience [PF] (rituximab 100 mg/10 mL injection, 10 mL vial) Ruxience [PF] (rituximab 500 mg/50 mL injection, 50 mL vial) Truxima [EW] (rituximab 100 mg/10 mL injection, 2 x 10 mL vials) Truxima [EW] (rituximab 500 mg/50 mL injection, 50 mL vial)

**CD22 (Clusters of Differentiation 22) inhibitors**

▪ **INOTUZUMAB OZOGAMICIN**

**Caution** Careful monitoring of patients is required due to risk of developing hepatotoxicity, including life-threatening hepatic veno-occlusive disease, and the increased risk of post-haematopoietic stem cell transplant non-relapse mortality observed in patients treated with inotuzumab.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Note** A complete remission is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a full recovery of peripheral blood counts with platelets of greater than 100,000 per microliter, and absolute neutrophil count (ANC) of greater than 1,000 per microliter.

**Note** A complete remission with partial haematological recovery is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a partial recovery of peripheral blood counts with platelets of greater than 50,000 per microliter, and absolute neutrophil count (ANC) of greater than 500 per microliter.

**Note** Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time when an assessment is required must cease PBS-subsidised therapy with this agent.

**Authority required**

Acute lymphoblastic leukaemia

Treatment Phase: Consolidation treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised induction treatment with this drug for this condition, **AND**
- Patient must have achieved a complete remission; OR
- Patient must have achieved a complete remission with partial haematological recovery, **AND**
- The treatment must not be more than 5 treatment cycles under this restriction in a lifetime, **AND**
- Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The treatment must not exceed 0.5mg per m<sup>2</sup> for all doses within a treatment cycle

Treatment with this drug for this condition must not exceed 6 treatment cycles in a lifetime.

**Injection**

11668D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	2820 mcg	4	..	*40010.22	31.60	Besponsa [PF] (inotuzumab ozogamicin 1 mg injection, 1 vial)

▪ **INOTUZUMAB OZOGAMICIN**

**Caution** Careful monitoring of patients is required due to risk of developing hepatotoxicity, including life-threatening hepatic veno-occlusive disease, and the increased risk of post-haematopoietic stem cell transplant non-relapse mortality observed in patients treated with inotuzumab.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patients are eligible to receive a loading dose for the first dose of a treatment cycle while receiving induction treatment. Two prescriptions are required, the first prescription for the loading dose at a dose no higher than 0.8mg per m<sup>2</sup>, and the second prescription for two doses at a dose no higher than 0.5mg per m<sup>2</sup>. Both prescriptions must be submitted with the initial application.

- Note** Once a patient achieves complete remission or complete remission with partial haematological recovery, a new prescription must be written under the consolidation treatment phase.
- Note** A complete remission is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a full recovery of peripheral blood counts with platelets of greater than 100,000 per microliter, and absolute neutrophil count (ANC) of greater than 1,000 per microliter.
- Note** A complete remission with partial haematological recovery is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a partial recovery of peripheral blood counts with platelets of greater than 50,000 per microliter, and absolute neutrophil count (ANC) of greater than 500 per microliter.
- Note** Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time when an assessment is required must cease PBS-subsidised therapy with this agent.
- Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au). Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos).  
Or mailed to:  
Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

#### **Authority required**

Acute lymphoblastic leukaemia

Treatment Phase: Induction treatment

#### **Clinical criteria:**

- The condition must be relapsed or refractory B-precursor cell ALL, with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, **AND**
- Patient must have received intensive combination chemotherapy for initial treatment of ALL or for subsequent salvage therapy, **AND**
- Patient must not have received more than 1 line of salvage therapy, **AND**
- Patient must have previously received a tyrosine kinase inhibitor (TKI) if the condition is Philadelphia chromosome positive, **AND**
- The condition must be CD22-positive, **AND**
- The condition must have more than 5% blasts in bone marrow, **AND**
- The treatment must not be more than 3 treatment cycles under this restriction in a lifetime.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The authority application must be made in writing and must include:

- (1) two completed authority prescription forms;
- (2) a completed Acute Lymphoblastic Leukaemia PBS Authority Application - Supporting Information Form; and
- (3) evidence that the condition is CD22-positive; and
- (4) date of most recent chemotherapy, and if this was the initial chemotherapy regimen or salvage therapy, including what line of salvage; and
- (5) a copy of the most recent bone marrow biopsy report of no more than one month old at the time of application.

The treatment must not exceed 0.8mg per m<sup>2</sup> for the first dose of a treatment cycle (Day 1), and 0.5mg per m<sup>2</sup> for subsequent doses (Days 8 and 15) within a treatment cycle.

Treatment with this drug for this condition must not exceed 6 treatment cycles in a lifetime.

#### **Injection**

11673J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3384 mcg	2	..	*53302.99	31.60	Besponsa [PF] (inotuzumab ozogamicin 1 mg injection, 1 vial)

#### ***CD38 (Clusters of Differentiation 38) inhibitors***

#### **▪ DARATUMUMAB**

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### **Authority required**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Continuing treatment of second-line drug therapy for weeks 10 to 24 (administered every 3 weeks)

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with bortezomib and dexamethasone, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition. Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

12225K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1920 mg	4	..	*11979.26	31.60	Darzalex [JC] (daratumumab 100 mg/5 mL injection, 5 mL vial) Darzalex [JC] (daratumumab 400 mg/20 mL injection, 20 mL vial)

▪ **DARATUMUMAB**

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Continuing treatment of second-line drug therapy from week 25 until disease progression (administered every 4 weeks)

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

12226L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1920 mg	5	..	*11979.26	31.60	Darzalex [JC] (daratumumab 100 mg/5 mL injection, 5 mL vial) Darzalex [JC] (daratumumab 400 mg/20 mL injection, 20 mL vial)

▪ **DARATUMUMAB**

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Initial treatment as second-line drug therapy for weeks 1 to 9 (administered once weekly)

**Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with bortezomib and dexamethasone, **AND**
- Patient must have progressive disease after only one prior therapy (i.e. use must be as second-line drug therapy; use as third-line drug therapy or beyond is not PBS-subsidised).

**Treatment criteria:**

- Patient must be undergoing treatment with this drug in one of the following situations: (i) for the first time, irrespective of whether the diagnosis has been reclassified (i.e. the diagnosis has changed between multiple myeloma/amyloidosis), (ii) changing the drug's form (intravenous/subcutaneous) within the first 9 weeks of treatment for the same PBS indication.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

Details of: the histological diagnosis of multiple myeloma; prior treatments including name(s) of drug(s) and date of most recent treatment cycle; the basis of the diagnosis of progressive disease or failure to respond; and which disease activity parameters will be used to assess response, must be documented in the patient's medical records.

Confirmation of eligibility for treatment with current diagnostic reports of at least one of the following must be documented in the patient's medical records:

- (a) the level of serum monoclonal protein; or
- (b) Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or
- (c) the serum level of free kappa and lambda light chains; or
- (d) bone marrow aspirate or trephine; or
- (e) if present, the size and location of lytic bone lesions (not including compression fractures); or
- (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or
- (g) if present, the level of hypercalcaemia, corrected for albumin concentration.

As these parameters must be used to determine response, results for either (a) or (b) or (c) should be documented for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) must be documented in the patient's medical records. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be documented in the patient's medical records.

A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner.

A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity, with the exception to this being the need to attain a sufficient response for stem cell transplantation to proceed. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.

## Injection

12230Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1920 mg	8	..	*11979.26	31.60	Darzalex [JC] (daratumumab 100 mg/5 mL injection, 5 mL vial) Darzalex [JC] (daratumumab 400 mg/20 mL injection, 20 mL vial)

## ■ DARATUMUMAB

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### Authority required

Relapsed and/or refractory multiple myeloma

Treatment Phase: Grandfather treatment - Transitioning from non-PBS to PBS-subsidised supply

**Clinical criteria:**

- Patient must have received non-PBS-subsidised treatment with this drug for this condition prior to 1 January 2021, **AND**
- Patient must have met all initial treatment PBS-eligibility criteria applying to a non-grandfathered patient prior to having commenced treatment with this drug, which are: (i) the condition was confirmed by histological diagnosis, (ii) the treatment is/was being used as part of triple combination therapy with bortezomib and dexamethasone, (iii) the condition progressed (see definition of progressive disease below) after one prior therapy, but not after more than two prior lines of therapies (i.e. this drug was commenced as second-line treatment), (iv) the treatment was/is not to be used in combination with another PBS-subsidised drug indicated for this condition outside of the intended combination where stated, and (v) the patient had never been treated with this drug, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

Details of: the histological diagnosis of multiple myeloma; prior treatments including name(s) of drug(s) and date of most recent treatment cycle; the basis of the diagnosis of progressive disease or failure to respond; and which disease activity parameters will be used to assess response, must be documented in the patient's medical records.

Confirmation of eligibility for treatment with current diagnostic reports of at least one of the following must be documented in the patient's medical records:

- (a) the level of serum monoclonal protein; or
- (b) Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or
- (c) the serum level of free kappa and lambda light chains; or
- (d) bone marrow aspirate or trephine; or
- (e) if present, the size and location of lytic bone lesions (not including compression fractures); or
- (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or
- (g) if present, the level of hypercalcaemia, corrected for albumin concentration.

As these parameters must be used to determine response, results for either (a) or (b) or (c) should be documented for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) must be documented in the patient's medical records. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be documented in the patient's medical records.

A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner.

A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity, with the exception to this being the need to attain a sufficient response for stem cell transplantation to proceed. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.

**Injection**

12221F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1920 mg	7	..	*11979.26	31.60	Darzalex [JC] (daratumumab 100 mg/5 mL injection, 5 mL vial) Darzalex [JC] (daratumumab 400 mg/20 mL injection, 20 mL vial)

**HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors**

▪ **PERTUZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Authority required**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have evidence of human epidermal growth factor receptor 2 (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) either in the primary tumour or a metastatic lesion, confirmed through a pathology report from an Approved Pathology Authority, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must not have received prior anti-HER2 therapy for this condition, **AND**
- Patient must not have received prior chemotherapy for this condition, **AND**
- The treatment must be in combination with trastuzumab and a taxane, **AND**
- The treatment must not be in combination with nab-paclitaxel, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

Details (date, unique identifying number/code, or provider number) of the pathology report from an Approved Pathology Authority confirming evidence of HER2 gene amplification in the primary tumour or a metastatic lesion by in situ hybridisation (ISH) must be provided at the time of application.

The pathology report must be documented in the patient's medical records.

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to seeking the initial authority approval.

### Injection

10334X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	840 mg	..	..	*6051.13	31.60	Perjeta [RO] (pertuzumab 420 mg/14 mL injection, 14 mL vial)

### ▪ PERTUZUMAB

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** The criterion that limits breaks in treatment with pertuzumab under this restriction has been temporarily modified due to the current risk of COVID-19. This allows an extended break in therapy with PBS-subsidised pertuzumab in patients who are at risk of COVID-19.

#### **Authority required**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have previously been issued with an authority prescription for this drug for this condition, **AND**
- Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug, **AND**
- The treatment must be in combination with trastuzumab, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.

The treatment must not exceed a lifetime total of one course. However, treatment breaks are permitted. A patient who has a treatment break in PBS-subsidised treatment with this drug for reasons other than disease progression is eligible to continue to receive PBS-subsidised treatment with this drug.

Where a patient has had a treatment break the length of the break is measured from the date the most recent treatment was stopped to the date of the application for further treatment.

### Injection

10308M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	420 mg	3	..	*3091.52	31.60	Perjeta [RO] (pertuzumab 420 mg/14 mL injection, 14 mL vial)

### ▪ TRASTUZUMAB

**Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

#### **Authority required (STREAMLINED)**

**10296**

Early HER2 positive breast cancer

Treatment Phase: Initial treatment (weekly regimen)

#### **Clinical criteria:**

- Patient must have undergone surgery (adjuvant) or be preparing for surgery (neoadjuvant), **AND**
  - The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
  - Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR
  - Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance.
- HER2 positivity must be demonstrated by in situ hybridisation (ISH).

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

**Injection**

7264H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	500 mg	..	..	*486.43	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

▪ **TRASTUZUMAB**

**Note** Increased maximum quantity will be authorised where a patient requires a new loading dose due to a break in therapy of more than 1 week but less than 6 weeks from the last dose or a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required (STREAMLINED)**

**10213**

Early HER2 positive breast cancer

Treatment Phase: Continuing treatment (weekly regimen)

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
- Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR
- Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance.

**Injection**

7265J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	250 mg	9	..	*346.04	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

▪ **TRASTUZUMAB**

**Note** Increased maximum quantity will be authorised where a patient requires a new loading dose due to a break in therapy of more than 1 week but less than 6 weeks from the last dose or a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required (STREAMLINED)**

**10294**

Early HER2 positive breast cancer

Treatment Phase: Continuing treatment (3 weekly regimen)

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
- Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR
- Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance.

**Injection**

7267L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	750 mg	3	..	*729.71	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

## ■ TRASTUZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum quantity will be authorised where a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

### Authority required (STREAMLINED)

**9349**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Continuing treatment

#### Clinical criteria:

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

Where a patient has a break in trastuzumab therapy of more than 1 week from when the last dose was due, a new loading dose may be required.

### Injection

10383L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	750 mg	3	..	*729.71	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

## ■ TRASTUZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum quantity will be authorised where a patient's weight is greater than 125 kg.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

### Authority required (STREAMLINED)

**9353**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Initial treatment

#### Clinical criteria:

- Patient must have evidence of human epidermal growth factor receptor 2 (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) either in the primary tumour or a metastatic lesion, **AND**
- The treatment must not be in combination with nab-paclitaxel, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

### Injection

10402L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	..	..	*870.10	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

## ■ TRASTUZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum quantity will be authorised where a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

### Authority required (STREAMLINED)

**9573**

Metastatic (Stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction

Treatment Phase: Initial treatment

#### Clinical criteria:

- Patient must have evidence of human epidermal growth factor receptor 2 (HER2) positivity as demonstrated by immunohistochemistry 2+ or more in tumour material, **AND**

- Patient must have evidence of HER2 gene amplification as demonstrated by in situ hybridisation results based on more than 6 copies of HER2 in the same tumour tissue sample, **AND**
  - Patient must have evidence of HER2 gene amplification as demonstrated by in situ hybridisation results based on the ratio of HER2 to chromosome 17 being more than 2 in the same tumour tissue sample, **AND**
  - Patient must commence treatment in combination with platinum based chemotherapy and capecitabine; OR
  - Patient must commence treatment in combination with platinum based chemotherapy and 5 fluorouracil, **AND**
  - Patient must not have previously received this drug for this condition, **AND**
  - Patient must not have received prior chemotherapy for this condition, **AND**
  - Patient must have a WHO performance status of 2 or less, **AND**
  - The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.
- Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

**Injection**

10589H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	..	..	*870.10	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

▪ **TRASTUZUMAB**

- Note** No increase in the maximum number of repeats may be authorised.
- Note** Increased maximum quantity will be authorised where a patient requires a new loading dose due to a break in therapy of more than 1 week but less than 6 weeks from the last dose or a patient's weight is greater than 125 kg.
- Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required (STREAMLINED)**

**9571**

Metastatic (Stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

**Injection**

10597R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	750 mg	3	..	*729.71	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

▪ **TRASTUZUMAB**

- Note** No increase in the maximum number of repeats may be authorised.
- Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.
- Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required (STREAMLINED)**

**10293**

Early HER2 positive breast cancer

Treatment Phase: Initial treatment (3 weekly regimen)

**Clinical criteria:**

- Patient must have undergone surgery (adjuvant) or be preparing for surgery (neoadjuvant), **AND**
  - The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
  - Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR
  - Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance.
- HER2 positivity must be demonstrated by in situ hybridisation (ISH).

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

## Injection

7266K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	..	..	*870.10	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

### ■ TRASTUZUMAB DERUXTECAN

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### **Authority required**

Metastatic (Stage IV) HER2 positive breast cancer

#### **Clinical criteria:**

- Patient must have evidence of human epidermal growth factor (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) in either the primary tumour/a metastatic lesion - establish this finding once only with the first PBS prescription, **AND**
- The condition must have progressed following treatment with at least one prior HER2 directed regimen for metastatic breast cancer; **OR**
- The condition must have, at the time of treatment initiation with this drug, progressed during/within 6 months following adjuvant treatment with a HER2 directed therapy, **AND**
- Patient must have, at the time of initiating treatment with this drug, a WHO performance status no higher than 1, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication, **AND**
- The treatment must not be prescribed where any of the following is present: (i) left ventricular ejection fraction of less than 50%, (ii) symptomatic heart failure; confirm cardiac function testing for the first PBS prescription only.

#### **Treatment criteria:**

- Patient must be undergoing initial treatment with this drug - the following are true: (i) this is the first prescription for this drug, (ii) this prescription seeks no more than 3 repeat prescriptions; **OR**
- Patient must be undergoing continuing treatment with drug - the following are true: (i) there has been an absence of further disease progression whilst on active treatment with this drug, (ii) this prescription does not seek to re-treat after disease progression, (iii) this prescription seeks no more than 8 repeat prescriptions.

Confirm that the following information is documented/retained in the patient's medical records once only with the first PBS prescription:

- 1) Evidence of HER2 gene amplification (evidence obtained in relation to past PBS treatment is acceptable).
- 2) Details of prior HER2 directed drug regimens prescribed for the patient.
- 3) Cardiac function test results (evidence obtained in relation to past PBS treatment is acceptable).

## Injection

13713R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	675 mg	8	..	*17827.63	31.60	Enhertu [AP] (trastuzumab deruxtecan 100 mg injection, 1 vial)

### ■ TRASTUZUMAB EMTANSINE

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

#### **Authority required**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have evidence of human epidermal growth factor receptor 2 (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) either in the primary tumour or a metastatic lesion, confirmed through a pathology report from an Approved Pathology Authority, **AND**
- The condition must have progressed following treatment with pertuzumab and trastuzumab in combination; **OR**
- The condition must have progressed during or within 6 months of completing adjuvant therapy with trastuzumab, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**

- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

The following information must be provided by the prescriber at the time of application:

(a) details (date, unique identifying number/code or provider number) of the pathology report from an Approved Pathology Authority confirming evidence of HER2 gene amplification in the primary tumour or a metastatic lesion by in situ hybridisation (ISH).

(b) dates of treatment with trastuzumab and pertuzumab;

(c) date of demonstration of progression following treatment with trastuzumab and pertuzumab; or

(d) date of demonstration of progression and date of completion of adjuvant trastuzumab treatment.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.

All reports must be documented in the patient's medical records.

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to seeking the initial authority approval.

**Authority required**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for metastatic (Stage IV) HER2 positive breast cancer, **AND**
- Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.

The treatment must not exceed a lifetime total of one continuous course for this PBS indication.

**Injection**

10281D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	450 mg	8	..	*7412.41	31.60	Kadcyla [RO] (trastuzumab emtansine 100 mg injection, 1 vial) Kadcyla [RO] (trastuzumab emtansine 160 mg injection, 1 vial)

**▪ TRASTUZUMAB EMTANSINE**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.

**Authority required**

Early HER2 positive breast cancer

Treatment Phase: Initial adjuvant treatment

**Clinical criteria:**

- The treatment must be prescribed within 12 weeks after surgery, **AND**
- Patient must have, prior to commencing treatment with this drug, evidence of residual invasive cancer in the breast and/or axillary lymph nodes following completion of surgery, as demonstrated by a pathology report, **AND**
- Patient must have completed systemic neoadjuvant therapy that included trastuzumab and taxane-based chemotherapy prior to surgery, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
- The treatment must not extend beyond 42 weeks (14 cycles) duration under the initial and the continuing treatment restrictions combined.

Authority applications for initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include:

(a) details (date, unique identifying number/code or provider number) of the pathology report from an Approved Pathology Authority demonstrating evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes following completion of surgery.

The pathology report must be documented in the patient's medical records.

If the application is submitted through HPOS form upload or mail, it must include:

- (i) A completed authority prescription form; and
- (ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health

Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)  
 Or mailed to:  
 Services Australia  
 Complex Drugs  
 Reply Paid 9826  
 HOBART TAS 7001

**Authority required**

Early HER2 positive breast cancer  
 Treatment Phase: Continuing adjuvant treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
- The treatment must not extend beyond 42 weeks (14 cycles) duration under the initial and the continuing treatment restrictions combined.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Injection**

11956G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	450 mg	6	..	*7412.41	31.60	Kadcyla [RO] (trastuzumab emtansine 100 mg injection, 1 vial) Kadcyla [RO] (trastuzumab emtansine 160 mg injection, 1 vial)

*EGFR (Epidermal Growth Factor Receptor) inhibitors*

▪ **CETUXIMAB**

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12470**

Metastatic colorectal cancer  
 Treatment Phase: Continuing treatment

**Clinical criteria:**

- The treatment must be in combination with PBS-subsidised encorafenib for this condition.

**Injection**

12817N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	550 mg	11	..	*1765.62	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12483**

Metastatic colorectal cancer  
 Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be in combination with PBS-subsidised encorafenib for this condition.

**Injection**

12821T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	880 mg	..	..	*2582.49	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** A maximum lifetime supply for this indication is limited to a maximum of 8 treatments per site and to 10 treatments per site for patients in whom radiotherapy is interrupted.

**Authority required (STREAMLINED)**

**4788**

Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx  
 Treatment Phase: Continuing treatment

**Clinical criteria:**

- The treatment must be in combination with radiotherapy, **AND**
- Patient must be unable to tolerate cisplatin; OR
- Patient must have a contraindication to cisplatin according to the TGA-approved Product Information.

**Injection**

7240C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	550 mg	5	..	*1765.62	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required (STREAMLINED)**

**4794**

Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be for the week prior to radiotherapy, **AND**
- Patient must have a contraindication to cisplatin according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**4785**

Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be in combination with radiotherapy, **AND**
- Patient must be unable to tolerate cisplatin.

**Injection**

7223E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	880 mg	..	..	*2582.49	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** Special Pricing Arrangements apply.

**Note** This drug is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.

**Authority required (STREAMLINED)**

**12045**

Metastatic colorectal cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have RAS wild-type metastatic colorectal cancer, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The condition must have failed to respond to first-line chemotherapy; OR
- The condition must have progressed following first-line treatment with pembrolizumab for dMMR mCRC, **AND**
- The treatment must be as monotherapy; OR
- The treatment must be in combination with chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on panitumumab are not eligible to receive PBS-subsidised cetuximab.

Patients who have developed intolerance to panitumumab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised cetuximab.

**Authority required (STREAMLINED)**

**4908**

Metastatic colorectal cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have RAS wild-type metastatic colorectal cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must be previously untreated, **AND**
- The treatment must be in combination with first-line chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

**Injection**

7242E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	880 mg	..	..	*2582.49	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** Special Pricing Arrangements apply.

**Note** This drug is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.

**Note** This drug is not PBS-subsidised when chemotherapy partners are switched whilst maintaining an anti-EGFR antibody backbone in the face of progressive disease.

**Note** The treatment must not exceed a single course of therapy with this drug for metastatic colorectal cancer in a patient's lifetime.

**Authority required (STREAMLINED)**

**4912**

Metastatic colorectal cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have received an initial authority prescription for this drug for first-line treatment of RAS wild-type metastatic colorectal cancer, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must be in combination with first-line chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

**Injection**

10265G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	550 mg	18	..	*1765.62	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** Special Pricing Arrangements apply.

**Note** This drug is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.

**Note** This drug is not PBS-subsidised when chemotherapy partners are switched whilst maintaining an anti-EGFR antibody backbone in the face of progressive disease.

**Note** The treatment must not exceed a single course of therapy with this drug for metastatic colorectal cancer in a patient's lifetime.

**Authority required (STREAMLINED)**

**12016**

Metastatic colorectal cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of first-line chemotherapy; OR
- Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of treatment with first-line pembrolizumab for dMMR mCRC, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must be as monotherapy; OR
- The treatment must be in combination with chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on panitumumab are not eligible to receive PBS-subsidised cetuximab.

Patients who have developed intolerance to panitumumab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised cetuximab.

**Injection**

7273T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	550 mg	11	..	*1765.62	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **PANITUMUMAB**

**Note** This drug is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.

**Authority required (STREAMLINED)**

**12066**

Metastatic colorectal cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have RAS wild-type metastatic colorectal cancer, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The condition must have failed to respond to first-line chemotherapy; OR
- The condition must have progressed following first-line treatment with pembrolizumab for dMMR mCRC, **AND**
- The treatment must be as monotherapy; OR
- The treatment must be in combination with chemotherapy, **AND**

- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition. Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab. Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.

**Authority required (STREAMLINED)**

**12035**

Metastatic colorectal cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of first-line chemotherapy; OR
- Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of treatment with first-line pembrolizumab for dMMR mCRC, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must be as monotherapy; OR
- The treatment must be in combination with chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab.

Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.

**Note** This drug is not PBS-subsidised when chemotherapy partners are switched whilst maintaining an anti-EGFR antibody backbone in the face of progressive disease.

**Note** The treatment must not exceed a single course of therapy with this drug for metastatic colorectal cancer in a patient's lifetime.

**Injection**

10069Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	720 mg	5	..	*3977.99	31.60	Vectibix [AN] (panitumumab 100 mg/5 mL injection, 5 mL vial) Vectibix [AN] (panitumumab 400 mg/20 mL injection, 20 mL vial)

**▪ PANITUMUMAB**

**Note** Special Pricing Arrangements apply.

**Note** Panitumumab is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.

**Authority required (STREAMLINED)**

**5526**

Metastatic colorectal cancer

Treatment Phase: Initial Treatment

**Clinical criteria:**

- Patient must have RAS wild-type metastatic colorectal cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must be previously untreated, **AND**
- The treatment must be in combination with first-line chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab.

Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.

**Authority required (STREAMLINED)**

**5452**

Metastatic colorectal cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have received an initial authority prescription for panitumumab for first-line treatment of RAS wild-type metastatic colorectal cancer, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must be in combination with first-line chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab.

Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.

**Note** This drug is not PBS-subsidised when chemotherapy partners are switched whilst maintaining an anti-EGFR antibody backbone in the face of progressive disease.

**Note** The treatment must not exceed a single course of therapy with this drug for metastatic colorectal cancer in a patient's lifetime.

**Injection**

10508C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	720 mg	9	..	*3977.99	31.60	Vectibix [AN] (panitumumab 100 mg/5 mL injection, 5 mL vial) Vectibix [AN] (panitumumab 400 mg/20 mL injection, 20 mL vial)

**PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors****▪ ATEZOLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)****10297**

Locally advanced or metastatic non-small cell lung cancer

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- Patient must have stable or responding disease.

**Injection**

11297N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	7	..	*6973.74	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

**▪ ATEZOLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)****10216**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing first-line treatment of metastatic disease - 3 weekly treatment regimen

**Treatment criteria:**

- Patient must be undergoing combination treatment with bevacizumab until disease progression, unless not tolerated.

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug in this line of treatment, **AND**
- Patient must have stable or responding disease.

**Injection**

11801D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	7	..	*6973.74	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

**▪ ATEZOLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)****10215**

Locally advanced or metastatic non-small cell lung cancer

Treatment Phase: Continuing treatment - 4 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have stable or responding disease.

**Injection**

11957H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	5	..	*9710.45	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

**▪ ATEZOLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)****10257**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing first-line treatment of metastatic disease, as monotherapy, where concomitant bevacizumab has ceased due to intolerance - 4 weekly treatment regimen

**Clinical criteria:**

- Patient must have experienced intolerance to combination treatment with bevacizumab, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug in this line of treatment, **AND**
- Patient must have stable or responding disease, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Injection**

12098R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	5	..	*9710.45	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

▪ **ATEZOLIZUMAB**

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**13443**

Locally advanced or metastatic non-small cell lung cancer  
Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The condition must have progressed on or after prior platinum based chemotherapy; OR
- The condition must have progressed after treatment with tepotinib.

**Injection**

11309F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	5	..	*6973.74	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

▪ **ATEZOLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10206**

Extensive-stage small cell lung cancer  
Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be previously untreated, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be in combination with etoposide and a platinum-based antineoplastic drug.

**Injection**

11927R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	3	..	*6973.74	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

▪ **ATEZOLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10521**

Extensive-stage small cell lung cancer  
Treatment Phase: Continuing treatment - 3 weekly treatment regimen

**Clinical criteria:**

- The treatment must be as monotherapy, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

**Injection**

11928T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	4	..	*6973.74	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

## ▪ ATEZOLIZUMAB

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### Authority required (STREAMLINED)

**13446**

Locally advanced or metastatic non-small cell lung cancer

Treatment Phase: Initial treatment - 4 weekly treatment regimen

#### Clinical criteria:

- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The condition must have progressed on or after prior platinum based chemotherapy; OR
- The condition must have progressed after treatment with tepotinib.

### Injection

11940K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	3	..	*9710.45	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

## ▪ ATEZOLIZUMAB

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### Authority required (STREAMLINED)

**10509**

Extensive-stage small cell lung cancer

Treatment Phase: Continuing treatment - 4 weekly treatment regimen

#### Clinical criteria:

- The treatment must be as monotherapy, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

### Injection

12076N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	3	..	*9710.45	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

## ▪ ATEZOLIZUMAB

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### Authority required (STREAMLINED)

**10917**

Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma

Treatment Phase: Continuing treatment of hepatocellular carcinoma - 3 weekly treatment regimen

#### Treatment criteria:

- Patient must be undergoing combination treatment with bevacizumab until disease progression, unless not tolerated.

#### Clinical criteria:

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - Patient must not have developed disease progression while being treated with this drug for this condition.
- PBS supply of this drug must be through only one of the two continuing treatment regimens at any given time

### Injection

12155R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	8	..	*6973.74	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

## ▪ ATEZOLIZUMAB

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** Increased repeats of up to 11 may be requested for doses of 840 mg administered every 2 weeks

**Note** Special Pricing Arrangements apply.

### Authority required (STREAMLINED)

**10972**

Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma

Treatment Phase: Continuing treatment where bevacizumab is discontinued - 4 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - Patient must not have developed disease progression while being treated with this drug for this condition.
- PBS supply of this drug must be through only one of the two continuing treatment regimens at any given time

**Injection**

12159Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	5	..	*9710.45	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

▪ **ATEZOLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**13451**

Resected early stage (Stage II to IIIA) non-small cell lung cancer (NSCLC)

Treatment Phase: 1,680 mg administered once every 4 weeks, or 840 mg every 2 weeks

**Population criteria:**

- Patient must be both: (i) initiating treatment, (ii) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy; OR
- Patient must be continuing existing PBS-subsidised treatment with this drug; OR
- Patient must be both: (i) transitioning from existing non-PBS to PBS subsidised supply of this drug, (ii) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy at the time this drug was initiated.

**Clinical criteria:**

- Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug.

**AND**

- The treatment must be for the purpose of adjuvant therapy following all of: (i) surgical resection, (ii) platinum-based chemotherapy, **AND**
- The condition must have/have had, at treatment commencement, an absence of each of the following gene abnormalities confirmed via tumour material sampling: (i) an activating epidermal growth factor receptor (EGFR) gene mutation, (ii) an anaplastic lymphoma kinase (ALK) gene rearrangement, **AND**
- The condition must have/have had, at treatment commencement, confirmation of programmed cell death ligand 1 (PD-L1) expression on at least 50% of tumour cells, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment that does not occur beyond the following, whichever comes first: (i) the first instance of disease progression/recurrence, (ii) 12 months in total for this condition from the first administered dose; mark any remaining repeat prescriptions with the words 'cancelled' where (i)/(ii) has occurred.

**Injection**

13170E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	5	..	*9710.45	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

▪ **ATEZOLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**13442**

Resected early stage (Stage II to IIIA) non-small cell lung cancer (NSCLC)

Treatment Phase: 1,200 mg administered once every 3 weeks

**Population criteria:**

- Patient must be both: (i) initiating treatment, (ii) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy; OR
- Patient must be continuing existing PBS-subsidised treatment with this drug; OR
- Patient must be both: (i) transitioning from existing non-PBS to PBS subsidised supply of this drug, (ii) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy at the time this drug was initiated.

**Clinical criteria:**

- Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug.

**AND**

- The treatment must be for the purpose of adjuvant therapy following all of: (i) surgical resection, (ii) platinum-based chemotherapy, **AND**
- The condition must have/have had, at treatment commencement, an absence of each of the following gene abnormalities confirmed via tumour material sampling: (i) an activating epidermal growth factor receptor (EGFR) gene mutation, (ii) an anaplastic lymphoma kinase (ALK) gene rearrangement, **AND**

- The condition must have/have had, at treatment commencement, confirmation of programmed cell death ligand 1 (PD-L1) expression on at least 50% of tumour cells, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment that does not occur beyond the following, whichever comes first: (i) the first instance of disease progression/recurrence, (ii) 12 months in total for this condition from the first administered dose; mark any remaining repeat prescriptions with the words 'cancelled' where (i)/(ii) has occurred.

**Injection**

13172G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	7	..	*6973.74	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

**■ ATEZOLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)****13448**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment 1

**Treatment criteria:**

- Patient must be undergoing combination treatment with bevacizumab and platinum-doublet chemotherapy.

**Clinical criteria:**

- The condition must be non-squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene mutation or an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material.

**Authority required (STREAMLINED)****10125**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment 2

**Treatment criteria:**

- Patient must be undergoing combination treatment with bevacizumab and platinum-doublet chemotherapy.

**Clinical criteria:**

- The condition must be non-squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must have evidence of an activating epidermal growth factor receptor (EGFR) gene mutation or of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material, **AND**
- Patient must have progressive disease following treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) OR an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer.

**Injection**

11792P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	5	..	*6973.74	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

**■ ATEZOLIZUMAB**

**Caution** The safety of atezolizumab in combination with bevacizumab has not been established in patients who have incompletely treated varices, variceal bleeding within the previous 6 months or who are at high risk of bleeding. Patients should be assessed for risk of variceal bleeding prior to treatment with this combination.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)****10939**

Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma

Treatment Phase: Initial treatment

**Treatment criteria:**

- Patient must be undergoing combination treatment with bevacizumab and atezolizumab until disease progression, unless not tolerated.

**Clinical criteria:**

- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must not be suitable for transarterial chemoembolisation, **AND**
- Patient must have Child Pugh class A, **AND**
- The condition must be untreated with systemic therapy; **OR**
- Patient must have developed intolerance to a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) of a severity necessitating permanent treatment withdrawal.

**Injection**

12167J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	3	..	*6973.74	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

▪ **AVELUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**8947**

Stage IV (metastatic) Merkel Cell Carcinoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed a total of 9 doses at a maximum dose of 10 mg per kg every 2 weeks under this restriction.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Injection**

11679Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	8	..	*8390.07	31.60	Bavencio [SG] (avelumab 200 mg/10 mL injection, 10 mL vial)

▪ **AVELUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10023**

Stage IV (metastatic) Merkel Cell Carcinoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a maximum dose of 10 mg per kg every 2 weeks under this restriction.

**Injection**

11685B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	11	..	*8390.07	31.60	Bavencio [SG] (avelumab 200 mg/10 mL injection, 10 mL vial)

▪ **AVELUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**13290**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Maintenance therapy - Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Injection**

13132E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	800 mg	11	..	*5637.35	31.60	Bavencio [SG] (avelumab 200 mg/10 mL injection, 10 mL vial)

## ■ AVELUMAB

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

#### **13313**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Maintenance therapy - Initial treatment

#### **Clinical criteria:**

- Patient must have received first-line platinum-based chemotherapy, **AND**
- Patient must not have progressive disease following first-line platinum-based chemotherapy, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

### **Authority required (STREAMLINED)**

#### **13303**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Maintenance therapy - Grandfathering treatment

#### **Clinical criteria:**

- Patient must have received non-PBS-subsidised treatment with this drug for this PBS indication prior to 1 October 2022, **AND**
- Patient must have received first-line platinum-based chemotherapy prior to initiation of non-PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have progressive disease following first-line platinum-based chemotherapy, **AND**
- Patient must have had a WHO performance status of 0 or 1 prior to initiation of non-PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

### **Injection**

13123Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	800 mg	7	..	*5637.35	31.60	Bavencio [SG] (avelumab 200 mg/10 mL injection, 10 mL vial)

## ■ CEMIPILIMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

#### **13373**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The treatment must not exceed a total of 35 cycles or up to 24 months of treatment under both initial and continuing treatment restrictions, whichever comes first.

### **Injection**

13162R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	350 mg	6	..	*7523.97	31.60	Libtayo [SW] (cemiplimab 350 mg/7 mL injection, 7 mL vial)

## ■ CEMIPILIMAB

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

#### **13766**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death 1 (PD-1) inhibitor or a programmed cell death ligand 1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must express programmed cell death ligand 1 (PD-L1) with a tumour proportion score (TPS) of at least 50% in the tumour sample. **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The treatment must not exceed a total of 7 doses under this restriction.

**Injection**

13160P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	350 mg	6	..	*7523.97	31.60	Libtayo [SW] (cemiplimab 350 mg/7 mL injection, 7 mL vial)

▪ **CEMIPLIMAB**

**Caution** In the first few months after starting immunotherapy, a transient tumour flare may occur that may be mistaken as disease progression despite an overall positive response to treatment.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Authority required**

Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)

Treatment Phase: Initial treatment covering the first 3 treatment cycles

**Clinical criteria:**

- The condition must be unsuitable for each of: (i) curative surgical resection, (ii) curative radiotherapy, **AND**
- Patient must have had a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Injection**

13135H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	350 mg	2	..	*7523.97	31.60	Libtayo [SW] (cemiplimab 350 mg/7 mL injection, 7 mL vial)

▪ **CEMIPLIMAB**

**Caution** In the first few months after starting immunotherapy, a transient tumour flare may occur that may be mistaken as disease progression despite an overall positive response to treatment.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Authority required**

Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised therapy with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must not be undergoing treatment with this drug as a PBS benefit where the treatment duration extends beyond the following, whichever comes first: (i) disease progression despite treatment with this drug, (ii) 24 months from treatment initiation; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

**Authority required**

Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

**Clinical criteria:**

- Patient must have received non-PBS-subsidised therapy with this drug for this condition prior to 1 November 2022, **AND**
- The condition must be unsuitable for each of: (i) curative surgical resection, (ii) curative radiotherapy, **AND**
- Patient must have had a WHO performance status of 0 or 1 prior to initiation of non-PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must not be undergoing treatment with this drug as a PBS benefit where the treatment duration extends beyond the following, whichever comes first: (i) disease progression despite treatment with this drug, (ii) 24 months from treatment initiation; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Injection**

13153G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	350 mg	7	..	*7523.97	31.60	Libtayo [SW] (cemiplimab 350 mg/7 mL injection, 7 mL vial)

▪ **DURVALUMAB**

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10126**

Unresectable Stage III non-small cell lung cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have received platinum based chemoradiation therapy, **AND**
- The condition must not have progressed following platinum based chemoradiation therapy, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must not have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

**Authority required (STREAMLINED)**

**12271**

Unresectable Stage III non-small cell lung cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The treatment must not exceed 12 months in total for this condition under the initial and continuing restriction combined, **AND**
- The treatment must be once in a lifetime with this drug for this condition.

**Injection**

11911X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1500 mg	4	..	*11619.27	31.60	Imfinzi [AP] (durvalumab 120 mg/2.4 mL injection, 2.4 mL vial)
						Imfinzi [AP] (durvalumab 500 mg/10 mL injection, 10 mL vial)

▪ **DURVALUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14708**

Locally advanced, metastatic or recurrent biliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer)

**Population criteria:**

- Patient must have either of the following at treatment initiation: (i) locally advanced biliary tract cancer that is untreated with systemic anti-cancer therapy in the unresectable setting, (ii) metastatic biliary tract cancer that is untreated with systemic anti-cancer therapy in the metastatic setting.

**Clinical criteria:**

- Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug, **AND**
- The treatment must be/have been initiated with both: (i) gemcitabine, (ii) cisplatin (refer to Product Information of gemcitabine and cisplatin for dosing information), **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

**Injection**

13745K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1500 mg	5	..	*11619.27	31.60	Imfinzi [AP] (durvalumab 120 mg/2.4 mL injection, 2.4 mL vial)
						Imfinzi [AP] (durvalumab 500 mg/10 mL injection, 10 mL vial)

▪ **DURVALUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10509**

Extensive-stage small cell lung cancer  
Treatment Phase: Continuing treatment - 4 weekly treatment regimen

**Clinical criteria:**

- The treatment must be as monotherapy, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

**Injection**

13766M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1500 mg	5	..	*11619.27	31.60	Imfinzi [AP] (durvalumab 120 mg/2.4 mL injection, 2.4 mL vial)
						Imfinzi [AP] (durvalumab 500 mg/10 mL injection, 10 mL vial)

▪ **DURVALUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10206**

Extensive-stage small cell lung cancer  
Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be previously untreated, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be in combination with etoposide and a platinum-based antineoplastic drug.

**Injection**

13779F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1500 mg	3	..	*11619.27	31.60	Imfinzi [AP] (durvalumab 120 mg/2.4 mL injection, 2.4 mL vial)
						Imfinzi [AP] (durvalumab 500 mg/10 mL injection, 10 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**11477**

Locally advanced or metastatic non-small cell lung cancer  
Treatment Phase: Continuing treatment as second-line drug therapy

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- Patient must have stable or responding disease.  
Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11152Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial)
						Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**9299**

Stage IV clear cell variant renal cell carcinoma (RCC)  
Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.  
Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11157F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial)

Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ NIVOLUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### **Authority required (STREAMLINED)**

#### **9252**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must have stable or responding disease, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

#### **Injection**

11425H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ NIVOLUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### **Authority required (STREAMLINED)**

#### **9321**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Maintenance treatment

#### **Clinical criteria:**

- Patient must have previously received of up to maximum 4 doses of PBS-subsidised combined therapy with nivolumab and ipilimumab as induction for this condition, **AND**
- The treatment must be as monotherapy for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

#### **Injection**

11626X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ NIVOLUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

#### **Authority required (STREAMLINED)**

#### **10155**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must not have experienced disease progression whilst on adjuvant PD-1 inhibitor treatment or disease recurrence within 6 months of completion of adjuvant PD-1 inhibitor treatment if treated for resected Stage IIIB, IIIC, IIID or IV melanoma, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

#### **Injection**

10775D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	8	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13445**

Locally advanced or metastatic non-small cell lung cancer

Treatment Phase: Initial treatment as second-line drug therapy

**Clinical criteria:**

- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The condition must have progressed on or after prior platinum based chemotherapy; OR
- The condition must have progressed after treatment with tepotinib.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11143L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	8	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**9216**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The condition must have progressed within 6 months of the last dose of prior platinum based chemotherapy, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor for this condition.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11434T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	8	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** Response Evaluation Criteria In Solid Tumours (RECIST) is defined as follows:

Complete response (CR) is disappearance of all target lesions.

Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions.

Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions.

Stable disease (SD) is small changes that do not meet above criteria.

**Authority required (STREAMLINED)**

**9312**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Initial Treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**

- Patient must have progressive disease according to the Response Evaluation Criteria in Solid Tumours (RECIST) following prior treatment with a tyrosine kinase inhibitor; OR
- Patient must have developed intolerance to a tyrosine kinase inhibitor of a severity necessitating permanent treatment withdrawal, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

### Injection

11159H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	8	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ NIVOLUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required (STREAMLINED)

##### 13433

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial combination treatment (with ipilimumab) as first-line drug therapy

#### Clinical criteria:

- The condition must be squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must be in combination with platinum-based chemotherapy for the first two cycles, **AND**
- The treatment must be in combination with ipilimumab.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

#### Authority required (STREAMLINED)

##### 11468

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing combination treatment (with ipilimumab) of first-line drug therapy

#### Clinical criteria:

- The condition must be squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed 24 months in total, measured from the initial dose, or, must not extend beyond disease progression, whichever comes first, **AND**
- The treatment must be in combination with ipilimumab.

### Injection

12315E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	360 mg	13	..	*7333.85	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ NIVOLUMAB

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** An increase of number of repeats may be authorised up to 11 if the patient is receiving a weight based dosing of 3mg/kg every 2 weeks.

#### Authority required (STREAMLINED)

##### 11985

Unresectable malignant mesothelioma

**Clinical criteria:**

- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be in combination with PBS-subsidised ipilimumab, unless an intolerance to ipilimumab of a severity necessitating permanent treatment withdrawal of ipilimumab, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a maximum total of 24 months in a lifetime for this condition.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Injection**

12574T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	360 mg	8	..	*7333.85	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Caution** In the first few months after starting immunotherapy, a transient tumour flare may occur that may be mistaken as disease progression despite an overall positive response to treatment.

**Note** The stated maximum amount in this listing is based on this drug's approved Product Information recommended dosing in specific cancer types - the drug may be prescribed in a quantity up to this amount, but need not be this amount for every cancer type. Refer to this drug's approved Product Information (Dose and Method of Administration or Clinical Trials sections) for the recommended dosing in the specific cancer type.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14676**

Advanced or metastatic gastro-oesophageal cancers

**Clinical criteria:**

- Patient must have/have had, at the time of initiating treatment with this drug, a WHO performance status no higher than 1, **AND**
- Patient must be untreated (up until initiating this drug) with programmed cell death-1/ligand-1 (PD-1/PD-L1) inhibitor therapy for gastro-oesophageal cancer.

**Treatment criteria:**

- Patient must not be undergoing treatment with this drug as a PBS benefit where the treatment duration extends beyond the following, whichever comes first: (i) disease progression despite treatment with this drug, (ii) 24 months from treatment initiation; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

**Population criteria:**

- Patient must be in one of the three population subsets described below.

**Population 1**

Conditions: gastric cancer, gastro-oesophageal junction cancer, oesophageal adenocarcinoma

Concomitant therapies: chemotherapy containing at least a fluoropyrimidine drug plus a platinum drug

Line of treatment: first-line drug treatment

Additional clinical finding: HER2 negative

**Population 2**

Condition: oesophageal squamous cell carcinoma (can be recurrent)

Concomitant therapies: chemotherapy containing at least a fluoropyrimidine drug plus a platinum drug

Line of treatment: first-line drug treatment

Additional clinical finding: unresectable

**Population 3**

Condition: oesophageal squamous cell carcinoma (can be recurrent)

Line of treatment: second-line drug treatment after chemotherapy containing at least a fluoropyrimidine drug plus a platinum drug

Additional clinical finding: unresectable

**Injection**

13117J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	13	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** Up to an additional 2 repeat prescriptions (7 in total) may be sought only where dosing is on a 2-weekly schedule in the first 16 weeks of treatment. This listing's stated number of repeat prescriptions is based on 4-weekly dosing.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Adjuvant treatment of stage II or III oesophageal cancer or gastro-oesophageal junction cancer

**Clinical criteria:**

- The condition must have histological evidence confirming a diagnosis of a least one of: (i) adenocarcinoma, (ii) squamous cell cancer; document this evidence in the patient's medical records, **AND**

- The condition must have been treated with neoadjuvant platinum-based chemoradiotherapy, **AND**
- The treatment must be for the purposes of adjuvant use following complete surgical resection that occurred within 16 weeks prior to initiating this drug, **AND**
- The condition must have evidence, through resected specimen, that residual disease meets the Tumour Nodes Metastases (TNM) staging system (as published by the Union for International Cancer Control) of either: (i) at least ypT1, (ii) at least ypN1; document this evidence in the patient's medical records, **AND**
- Patient must have/have had, at the time of initiating treatment with this drug, a WHO performance status no higher than 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with a dosing regimen as set out in the drug's approved Australian Product Information, **AND**
- Patient must not be undergoing PBS-subsidised treatment with this drug where this prescription extends treatment beyond whichever comes first: (i) 12 months from treatment initiation, irrespective of whether initial treatment was PBS-subsidised/non-PBS-subsidised, (ii) disease recurrence despite treatment with this drug; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

**Injection**

13246E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	5	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

**■ NIVOLUMAB**

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note A** prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk score can be calculated here: <https://www.mdcalc.com/imdc-international-metastatic-renal-cell-carcinoma>.

One point is assigned for each of:

- a time of diagnosis to systemic therapy of less than 1 year
- a Karnofsky Performance Status of less than 80%
- a haemoglobin less than the lower limit of normal
- a corrected calcium level greater than the upper limit of normal
- a neutrophil count greater than the upper limit of normal
- a platelet count greater than the upper limit of normal

Stated normal reference ranges may vary depending on the laboratory providing the measurement. 'Normal' here refers to the individual laboratory's stated normal reference range.

Favourable IMDC risk is a score of 0.

Intermediate IMDC risk is a score of 1 to 2.

Poor IMDC risk is a score of 3 to 6.

Document any IMDC risk score assessment in the patient's medical records.

**Authority required (STREAMLINED)****14001**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must not have previously been treated, **AND**
- Patient must have a prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk classification score at treatment initiation with this drug of either: (i) 1 to 2 (intermediate risk), (ii) 3 to 6 (poor risk); document the IMDC risk classification score in the patient's medical records, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The treatment must be in combination with PBS-subsidised treatment with ipilimumab as induction for this condition. Induction treatment with nivolumab must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks. The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Injection**

11627Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	360 mg	3	..	*7333.85	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

**■ NIVOLUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma  
Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be adjuvant to complete surgical resection, **AND**
- Patient must have a WHO performance status of 1 or less, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received prior PBS-subsidised treatment for this condition, **AND**
- The treatment must commence within 12 weeks of complete resection, **AND**
- Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy. Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required**

Resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma  
Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously been issued with an authority prescription for this drug for adjuvant treatment following complete surgical resection, **AND**
- Patient must not have experienced disease recurrence, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy. Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11906P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	5	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**9298**

Unresectable Stage III or Stage IV malignant melanoma  
Treatment Phase: Continuing treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have previously been issued with an authority prescription for this drug for this condition, **AND**
- Patient must have stable or responding disease. Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Authority required (STREAMLINED)**

**13839**

Unresectable Stage III or Stage IV malignant melanoma  
Treatment Phase: Maintenance treatment

**Clinical criteria:**

- Patient must have previously received of up to maximum 4 doses of PBS-subsidised combined therapy with nivolumab and ipilimumab as induction for this condition, **AND**
- The treatment must be as monotherapy for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this PBS indication.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.  
The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Authority required (STREAMLINED)**

**13863**

Unresectable Stage III or Stage IV malignant melanoma  
Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements for maintenance treatment

**Clinical criteria:**

- Patient must have previously received of up to maximum 4 doses of PBS-subsidised ipilimumab combined therapy with non-PBS-subsidised nivolumab as induction for this condition prior to 1 March 2023, **AND**
- The treatment must be as monotherapy for this condition, **AND**

- Patient must not have developed disease progression while receiving treatment with this drug for this PBS indication. Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Maintenance treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

### Injection

10748Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9734.47	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ NIVOLUMAB

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required (STREAMLINED)

**13853**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Induction treatment

#### **Clinical criteria:**

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, **AND**
- The condition must not be ocular or uveal melanoma, **AND**
- The treatment must be in combination with PBS-subsidised treatment with ipilimumab as induction for this condition. Induction treatment with nivolumab must not exceed a total of 4 doses at a maximum dose of 1 mg per kg every 3 weeks. Induction treatment with ipilimumab must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

#### Authority required (STREAMLINED)

**13852**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements for combination induction therapy

#### **Clinical criteria:**

- Patient must have received non-PBS-subsidised treatment with nivolumab in combination with ipilimumab for this PBS indication prior to 1 March 2023, **AND**
- Patient must have had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to commencing non-PBS-subsidised treatment, **AND**
- The condition must not be ocular or uveal melanoma, **AND**
- The treatment must be in combination with PBS-subsidised treatment with ipilimumab as induction for this condition. Induction treatment with nivolumab must not exceed a total of 4 doses at a maximum dose of 1 mg per kg every 3 weeks. Induction treatment with ipilimumab must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Maintenance treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

### Injection

11532Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	120 mg	3	..	*2532.57	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ PEMBROLIZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

#### Authority required (STREAMLINED)

**10705**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

#### **Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have previously been issued with an authority prescription for this drug for this condition, **AND**
- Patient must have stable or responding disease.

**Injection**

10424P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	7	..	*7886.47	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**10701**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Continuing treatment - 6 weekly treatment regimen

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have previously been issued with an authority prescription for this drug for this condition, **AND**
- Patient must have stable or responding disease.

**Injection**

12123C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	3	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14727**

Stage II or Stage III triple negative breast cancer

**Clinical criteria:**

- The treatment must be initiated in combination with neoadjuvant chemotherapy, **AND**
- The condition must not have progressed/recurred whilst on treatment with this drug.

**Treatment criteria:**

- Patient must not be undergoing treatment with this drug beyond 52 cumulative weeks under this restriction, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 7 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 4 repeat prescriptions.

**Injection**

13739D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	7	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**10696**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must not have experienced disease progression whilst on adjuvant PD-1 inhibitor treatment or disease recurrence within 6 months of completion of adjuvant PD-1 inhibitor treatment if treated for resected Stage IIIB, IIIC, IIID or IV melanoma, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed a total of 6 doses under this restriction.

**Injection**

10475H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	5	..	*7886.47	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

**■ PEMBROLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)****10689**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Initial treatment - 6 weekly treatment regimen

**Clinical criteria:**

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must not have experienced disease progression whilst on adjuvant PD-1 inhibitor treatment or disease recurrence within 6 months of completion of adjuvant PD-1 inhibitor treatment if treated for resected Stage IIIB, IIIC, IIID or IV melanoma, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed a total of 3 doses under this restriction.

**Injection**

12122B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	2	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

**■ PEMBROLIZUMAB**

**Note** A Combined Positive Score (CPS) is determined by:

The number of PD-L1-stained cells (tumour cells, lymphocytes, macrophages) divided by the number of all viable tumour cells (i.e. the total number of: PD-L1-positive tumour cells plus PD-L1-negative tumour cells).

Although the result of the CPS calculation can exceed 100, the maximum score is defined as CPS 100.

A minimum of 100 viable tumour cells in the PD-L1-stained slide is required for the specimen to be considered adequate for PD-L1 evaluation.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)****14324**

Recurrent, unresectable or metastatic triple negative breast cancer

**Clinical criteria:**

- The condition must have been (up until this drug therapy) untreated in the unresectable/metastatic disease stage, **AND**
- The condition must have been (up until this drug therapy) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy in breast cancer, **AND**
- Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation, **AND**
- The treatment must be in combination with chemotherapy, **AND**
- The condition must have both: (i) programmed cell death ligand 1 (PD-L1) expression confirmed by a validated test, (ii) a Combined Positive Score (CPS) of at least 10 at treatment initiation.

**Treatment criteria:**

- Patient must be undergoing initial treatment with this drug - this is the first prescription for this drug; OR
- Patient must be undergoing continuing treatment with this drug - both the following are true: (i) the condition has not progressed on active treatment with this drug, (ii) this prescription does not extend PBS subsidy beyond 24 cumulative months from the first administered dose, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Injection**

13626E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13726**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have undergone an autologous stem cell transplant (ASCT) for this condition and have experienced relapsed or refractory disease post ASCT; OR
- Patient must not be suitable for ASCT for this condition and have experienced relapsed or refractory disease following at least 2 prior treatments for this condition, **AND**
- Patient must not have received prior treatment with a PD-1 (programmed cell death-1) inhibitor for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required (STREAMLINED)**

**13741**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Injection**

11352L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13727**

Relapsed or refractory primary mediastinal B-cell lymphoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be diagnosed as primary mediastinal B-cell lymphoma through histological investigation combined with at least one of: (i) positron emission tomography - computed tomography (PET-CT) scan, (ii) PET scan, (iii) CT scan, **AND**
- Patient must have been treated with rituximab-based chemotherapy for this condition, **AND**
- Patient must be experiencing relapsed/refractory disease, **AND**
- Patient must be autologous stem cell transplant (ASCT) ineligible following a single line of treatment; OR
- Patient must have undergone an autologous stem cell transplant (ASCT); OR
- Patient must have been treated with at least 2 chemotherapy treatment lines for this condition, one of which must include rituximab-based chemotherapy, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required (STREAMLINED)****13732**

Relapsed or refractory primary mediastinal B-cell lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Injection**

12126F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

**■ PEMBROLIZUMAB****Note** No increase in the maximum quantity or number of units may be authorised.**Note** No increase in the maximum number of repeats may be authorised.**Note** Special Pricing Arrangements apply.**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.**Authority required (STREAMLINED)****13431**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must not exceed a total of 7 doses under this restriction.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.**Authority required (STREAMLINED)****13432**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a total of 35 cycles or up to 24 months of treatment under both initial and continuing treatment restrictions, whichever comes first.

**Injection**

11492W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	6	..	*7886.47	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

**■ PEMBROLIZUMAB****Note** No increase in the maximum quantity or number of units may be authorised.**Note** No increase in the maximum number of repeats may be authorised.**Note** Special Pricing Arrangements apply.**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13739**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The condition must have progressed on or after prior platinum based chemotherapy; OR
- The condition must have progressed on or within 12 months of completion of adjuvant platinum-containing chemotherapy following cystectomy for localised muscle-invasive urothelial cancer; OR
- The condition must have progressed on or within 12 months of completion of neoadjuvant platinum-containing chemotherapy prior to cystectomy for localised muscle-invasive urothelial cancer, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13736**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Injection**

11632F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13436**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment - 6 weekly treatment regimen

**Clinical criteria:**

- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must not exceed a total of 4 doses under this restriction.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13437**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)  
Treatment Phase: Continuing treatment - 6 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a total of 18 cycles or up to 24 months of treatment under both initial and continuing treatment restrictions, whichever comes first.

**Injection**

12121Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	3	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required**

Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma

Treatment Phase: Initial treatment - 6 weekly treatment regimen

**Clinical criteria:**

- The treatment must be adjuvant to complete surgical resection, **AND**
- Patient must have a WHO performance status of 1 or less, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received prior PBS-subsidised treatment for this condition, **AND**
- The treatment must commence within 12 weeks of complete resection, **AND**
- Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required**

Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma

Treatment Phase: Continuing treatment - 6 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously been issued with an authority prescription for this drug for adjuvant treatment following complete surgical resection, **AND**
- Patient must not have experienced disease recurrence, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy.

**Injection**

12125E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	3	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Unresectable or metastatic deficient mismatch repair (dMMR) colorectal cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must be untreated for this PBS indication (i.e untreated for each of: (i) unresectable disease, (ii) metastatic disease), **AND**
- Patient must not have received prior treatment for colorectal cancer with each of: (i) a programmed cell death-1 (PD-1) inhibitor, (ii) a programmed cell death ligand-1 (PD-L1) inhibitor, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must have deficient mismatch repair (dMMR) colorectal cancer, as determined by immunohistochemistry test.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required**

Unresectable or metastatic deficient mismatch repair (dMMR) colorectal cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have progressive disease while receiving PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Injection**

12605K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Stage IIIB, Stage IIIC or Stage IIID malignant melanoma

Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- The treatment must be in addition to complete surgical resection, **AND**
- Patient must have a WHO performance status of 1 or less, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received prior PBS-subsidised treatment for this condition, **AND**
- The treatment must commence within 12 weeks of complete resection, **AND**
- Patient must not have received more than 12 months of therapy (irrespective of whether therapy has been partly PBS-subsidised/non-PBS-subsidised).

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** Commencing treatment within 12 weeks of complete resection means either 12 weeks after resection or 12 weeks prior to resection.

Where non-PBS-subsidised supply has occurred, the total amount of PBS-subsidised supply is intended to be the balance of 18 doses less the number of non-PBS-subsidised doses.

**Authority required**

Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

**Treatment criteria:**

- Patient must be undergoing continuing PBS-subsidised treatment commenced through an 'Initial treatment' listing.

**Clinical criteria:**

- Patient must not have experienced disease recurrence, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received more than 12 months of therapy (irrespective of whether therapy has been partly PBS-subsidised/non-PBS-subsidised).

**Injection**

12120X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	7	..	*7886.47	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)****14027**

Advanced, metastatic or recurrent endometrial carcinoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have received prior treatment with platinum-based chemotherapy, **AND**
- The condition must be untreated with each of: (i) programmed cell death-1/ligand-1 (PD-1/PDL-1) inhibitor therapy, (ii) tyrosine kinase inhibitor therapy, **AND**
- Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation.

**Treatment criteria:**

- Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR
- Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)****14044**

Advanced, metastatic or recurrent endometrial carcinoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR
- Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Authority required (STREAMLINED)****14028**

Advanced, metastatic or recurrent endometrial carcinoma

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

**Clinical criteria:**

- Patient must have received non-PBS-subsidised treatment with this drug for this condition prior to 1 June 2023, **AND**
- The treatment must be occurring in a patient where each of the following is true: (i) the patient had received prior treatment with platinum-based chemotherapy, (ii) the patient was untreated at treatment initiation with each of: (a) programmed cell death-1/ligand-1 (PD-1/PDL-1) inhibitor therapy, (b) tyrosine kinase inhibitor therapy, (iii) the patient's WHO performance status was no higher than 1 at treatment initiation, (iv) this drug is being prescribed in either: (a) a combination of pembrolizumab plus lenvatinib only, (b) as monotherapy where there was a contraindication/intolerance to the other drug in the combination - document the details in the patient's medical records, (v) disease progression has not occurred whilst on treatment, (vi) this prescription does not extend treatment beyond 24 months from the first administered dose.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Injection**

13287H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14403**

Advanced carcinoma of the cervix

Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be at least one of (i) persistent carcinoma, (ii) recurrent carcinoma, (iii) metastatic carcinoma of the cervix, **AND**
- The condition must be unsuitable for curative treatment with either of (i) surgical resection, (ii) radiation, **AND**
- Patient must have WHO performance status no higher than 1, **AND**
- Patient must not have received prior treatment for this PBS indication.

**Treatment criteria:**

- Patient must be undergoing concomitant treatment with chemotherapy, containing a minimum of: (i) a platinum-based chemotherapy agent, plus (ii) paclitaxel, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required (STREAMLINED)**

**14404**

Advanced carcinoma of the cervix

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The condition must not have progressed while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed a total of (i) 24 months, (ii) 35 doses (based on a 3-weekly dose regimen), (iii) 17 doses (based on a 6-weekly dose regimen) whichever comes first from the first dose of this drug regardless if it was PBS/non-PBS subsidised.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required (STREAMLINED)**

**14405**

Advanced carcinoma of the cervix

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

**Clinical criteria:**

- Patient must be currently receiving non-PBS-subsidised treatment with this drug for this condition, with treatment having commenced prior to 1 October 2023, **AND**
- Patient must have met all other PBS eligibility criteria that a non-Grandfather patient would ordinarily be required to meet, meaning that at the time non-PBS supply was commenced, the patient: (i) had either one of (1) persistent carcinoma, (2) recurrent carcinoma, (3) metastatic carcinoma of the cervix; (ii) had a WHO performance status no higher than 1; (iii) was unsuitable for curative treatment with either of (1) surgical resection, (2) radiation; (iv) had not received prior treatment for this PBS indication; (v) was treated concomitantly with platinum-based chemotherapy agent, plus paclitaxel, **AND**
- The condition must not have progressed while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed a total of (i) 24 months, (ii) 35 doses (based on a 3-weekly dose regimen), (iii) 17 doses (based on a 6-weekly dose regimen) whichever comes first from the first dose of this drug regardless if it was PBS/non-PBS subsidised.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Injection**

13645E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

## ■ PEMBROLIZUMAB

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

**13948**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have a prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk classification score at treatment initiation with this drug of either: (i) 1 to 2 (intermediate risk), (ii) 3 to 6 (poor risk); document the IMDC risk classification score in the patient's medical records, **AND**
- The condition must be untreated, **AND**
- Patient must have a WHO performance status of 2 or less.

#### **Treatment criteria:**

- Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR
- Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note A** prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk score can be calculated here: <https://www.mdcalc.com/imdc-international-metastatic-renal-cell-carcinoma>.

One point is assigned for each of:

- a time of diagnosis to systemic therapy of less than 1 year
- a Karnofsky Performance Status of less than 80%
- a haemoglobin less than the lower limit of normal
- a corrected calcium level greater than the upper limit of normal
- a neutrophil count greater than the upper limit of normal
- a platelet count greater than the upper limit of normal

Stated normal reference ranges may vary depending on the laboratory providing the measurement. 'Normal' here refers to the individual laboratory's stated normal reference range.

Favourable IMDC risk is a score of 0.

Intermediate IMDC risk is a score of 1 to 2.

Poor IMDC risk is a score of 3 to 6.

Document any IMDC risk score assessment in the patient's medical records.

### **Authority required (STREAMLINED)**

**13949**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition.

#### **Treatment criteria:**

- Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR
- Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

### **Authority required (STREAMLINED)**

**13986**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

#### **Clinical criteria:**

- Patient must be currently receiving non-PBS-subsidised treatment with this drug for this condition, with treatment having commenced prior to 1 May 2023, **AND**

- Patient must have had a prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk classification score at treatment initiation with this drug of either: (i) 1 to 2 (intermediate risk), (ii) 3 to 6 (poor risk); document the IMDC risk classification score in the patient's medical records if not already documented, **AND**
- The treatment must be occurring in a patient where each of the following is true: (i) the patient's WHO performance status was no higher than 2 at treatment initiation, (ii) this drug is being prescribed in either: (a) a combination of pembrolizumab plus lenvatinib only, (b) as monotherapy where there was a contraindication/intolerance to the other drug in the combination - document the details in the patient's medical records, (iii) the condition was untreated at the time of treatment initiation, (iv) disease progression has not occurred whilst on treatment, (v) treatment is occurring with a dosing regimen specified in this drug's approved Australian Product Information, (vi) this prescription does not extend treatment beyond 24 months from the first administered dose.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note A** prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk score can be calculated here: <https://www.mdcalc.com/imdc-international-metastatic-renal-cell-carcinoma>.

One point is assigned for each of:

- (i) a time of diagnosis to systemic therapy of less than 1 year
- (ii) a Karnofsky Performance Status of less than 80%
- (iii) a haemoglobin less than the lower limit of normal
- (iv) a corrected calcium level greater than the upper limit of normal
- (v) a neutrophil count greater than the upper limit of normal
- (vi) a platelet count greater than the upper limit of normal

Stated normal reference ranges may vary depending on the laboratory providing the measurement. 'Normal' here refers to the individual laboratory's stated normal reference range.

Favourable IMDC risk is a score of 0.

Intermediate IMDC risk is a score of 1 to 2.

Poor IMDC risk is a score of 3 to 6.

Document any IMDC risk score assessment in the patient's medical records.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Injection**

13267G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13735**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be incurable by local therapies in the locally advanced setting, **AND**
- Patient must not have had systemic therapy for this condition in the recurrent or metastatic setting prior to initiating PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have experienced disease recurrence within 6 months of completion of systemic therapy if previously treated in the locally advanced setting, **AND**
- Patient must have had a WHO performance status of 0 or 1, **AND**
- The treatment must be either: (i) the sole PBS-subsidised therapy where the condition expresses programmed cell death ligand 1 (PD-L1) with a combined positive score (CPS) greater than or equal to 20 in the tumour sample, (ii) in combination with platinum-based chemotherapy, unless contraindicated or not tolerated.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13731**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Authority required (STREAMLINED)**

**13738**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

**Clinical criteria:**

- Patient must have previously received non-PBS-subsidised treatment with this drug for this condition prior to 1 October 2022, **AND**
- Patient must not have had systemic therapy for this condition in the recurrent or metastatic setting prior to initiating non-PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have experienced disease recurrence within 6 months of completion of systemic therapy if treated in the locally advanced setting prior to non-PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must have been initiated as non-PBS-subsidised therapy as either: (i) the sole therapy where the condition expressed programmed cell death ligand 1 (PD-L1) with a combined positive score (CPS) greater than or equal to 20 in the tumour sample, (ii) in combination with platinum-based chemotherapy, unless contraindicated or not tolerated, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- Patient must have had a WHO performance status of 0 or 1 prior to initiation of non-PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Note** A patient may only qualify for PBS-subsidised treatment under this restriction once.

**Note** Following completion of the initial PBS subsidised course, further applications for treatment will be assessed under the continuing treatment restriction.

**Injection**

13114F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15641.03	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

**VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors**

▪ **BEVACIZUMAB**

**Injection**

12508H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1800 mg	7	..	*2358.65	31.60	Abevmy [AF] (bevacizumab 100 mg/4 mL injection, 4 mL vial) Abevmy [AF] (bevacizumab 400 mg/16 mL injection, 16 mL vial) Bevaciptin [LR] (bevacizumab 100 mg/4 mL injection, 4 mL vial) Bevaciptin [LR] (bevacizumab 400 mg/16 mL injection, 16 mL vial) Mvasi [AN] (bevacizumab 100 mg/4 mL injection, 4 mL vial) Mvasi [AN] (bevacizumab 400 mg/16 mL injection, 16 mL vial)

**Other monoclonal antibodies and antibody drug conjugates**

▪ **BLINATUMOMAB**

**Caution** Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday). Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au). Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos). Or mailed to:  
Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Authority required**

Acute lymphoblastic leukaemia  
Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must be relapsed or refractory B-precursor cell ALL, with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, **AND**
- The condition must not be present in the central nervous system or testis, **AND**
- Patient must have previously received a tyrosine kinase inhibitor (TKI) if the condition is Philadelphia chromosome positive, **AND**
- Patient must have received intensive combination chemotherapy for initial treatment of ALL or for subsequent salvage therapy, **AND**
- Patient must not have received more than 1 line of salvage therapy, **AND**
- The condition must be one of the following: (i) untreated with this drug for measurable residual disease, (ii) treated with this drug for measurable residual disease, but the condition has not relapsed within 6 months of completing that course of treatment, **AND**
- The condition must have more than 5% blasts in bone marrow, **AND**
- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime.

According to the TGA-approved Product Information, hospitalisation is recommended at minimum for the first 9 days of the first cycle and the first 2 days of the second cycle. For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for 4 or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 651 microgram will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 1. An amount of 784 microgram, which may be obtained under Induction treatment - balance of supply restriction, will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 2.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Acute Lymphoblastic Leukaemia PBS Authority Application - Supporting Information Form; and
- (3) date of most recent chemotherapy, and if this was the initial chemotherapy regimen or salvage therapy, including what line of salvage; and
- (4) if applicable, the date of completion of blinatumomab treatment for measurable residual disease and the date of the patient's subsequent relapse; and
- (5) the percentage blasts in bone marrow count that is no more than 4 weeks old at the time of application.

**Injection**

11116C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	651 mcg	..	..	*67287.75	31.60	Blinicyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)

▪ **BLINATUMOMAB**

**Caution** Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required**

Acute lymphoblastic leukaemia  
Treatment Phase: Induction treatment - balance of supply

**Clinical criteria:**

- The condition must be relapsed or refractory B-precursor cell ALL, with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, **AND**
- The condition must not be present in the central nervous system or testis, **AND**
- Patient must have previously received a tyrosine kinase inhibitor (TKI) if the condition is Philadelphia chromosome positive, **AND**

- Patient must have received insufficient therapy with this agent for this condition under the Induction treatment restriction to complete a maximum of 2 treatment cycles in a lifetime.

According to the TGA-approved Product Information, hospitalisation is recommended at minimum for the first 9 days of the first cycle and the first 2 days of the second cycle. For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for 4 or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 784 mcg will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 2.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

### Injection

11119F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	784 mcg	..	..	*78480.39	31.60	Blinicyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)

### ■ BLINATUMOMAB

**Caution** Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Note** A complete remission is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a full recovery of peripheral blood counts with platelets of greater than 100,000 per microliter, and absolute neutrophil count (ANC) of greater than 1,000 per microliter.

**Note** A complete remission with partial haematological recovery is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a partial recovery of peripheral blood counts with platelets of greater than 50,000 per microliter, and absolute neutrophil count (ANC) of greater than 500 per microliter.

**Note** Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time when an assessment is required must cease PBS-subsidised therapy with this agent.

#### Authority required

Acute lymphoblastic leukaemia

Treatment Phase: Consolidation treatment

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised induction treatment with this drug for this condition, **AND**
- Patient must have achieved a complete remission; OR
- Patient must have achieved a complete remission with partial haematological recovery, **AND**
- The treatment must not be more than 3 treatment cycles under this restriction in a lifetime, **AND**
- Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug.

### Injection

11115B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	784 mcg	2	..	*78480.39	31.60	Blinicyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)

### ■ BLINATUMOMAB

**Caution** Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** A complete remission is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a full recovery of peripheral blood counts with platelets of greater than 100,000 per microliter, and absolute neutrophil count (ANC) of greater than 1,000 per microliter.

#### Authority required

Measurable residual disease of precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL)

Treatment Phase: Initial treatment of measurable residual disease of Pre-B-cell ALL

#### **Treatment criteria:**

- Must be treated by a physician experienced in the treatment of haematological malignancies.

#### **Clinical criteria:**

- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, **AND**
- The condition must not be present in the central nervous system or testis, **AND**
- Patient must have achieved complete remission following intensive combination chemotherapy for initial treatment of acute lymphoblastic leukaemia (ALL) or for subsequent salvage therapy, **AND**
- Patient must have measurable residual disease based on measurement in bone marrow, documented after an interval of at least 2 weeks from the last course of systemic chemotherapy given as intensive combination chemotherapy treatment of ALL/as subsequent salvage therapy, whichever was the later, measured using flow cytometry/molecular methods, **AND**

#### **AND**

- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime.

According to the TGA-approved Product Information, hospitalisation is recommended at minimum for the first 3 days of the first cycle and the first 2 days of the second cycle.

For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for four or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 784 mcg will be sufficient for a continuous infusion of blinatumomab over 28 days in each cycle.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Measurable residual disease positive Acute Lymphoblastic Leukaemia PBS Authority Application - Supporting Information Form; and
- (3) date of most recent chemotherapy, and if this was the initial chemotherapy regimen or salvage therapy; and
- (4) the percentage blasts in bone marrow count that is no more than 4 weeks old at the time of application.

Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time where an assessment is required must cease PBS-subsidised therapy with this agent.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Authority required**

Measurable residual disease of precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL)

Treatment Phase: Continuing treatment of previously measurable residual disease of Pre-B-cell ALL

**Treatment criteria:**

- Must be treated by a physician experienced in the treatment of haematological malignancies.

**Clinical criteria:**

- Patient must have previously received PBS-subsidised initial treatment with this drug for this condition, **AND**
- Patient must have achieved a complete remission, **AND**
- The condition must be negative for measurable residual disease using the same method used to determine initial PBS eligibility, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition, **AND**
- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime.

For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for four or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 784 microgram will be sufficient for a continuous infusion of blinatumomab over 28 days in each cycle.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time where an assessment is required must cease PBS-subsidised therapy with this agent.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Injection**

11867N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	784 mcg	1	..	*78480.39	31.60	Blinicyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)

**▪ BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Authority required**

CD30 positive systemic anaplastic large cell lymphoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be for curative intent, **AND**
- Patient must have undergone appropriate prior front-line curative intent chemotherapy, **AND**
- Patient must demonstrate relapsed or chemotherapy-refractory disease, **AND**
- Patient must have responded to PBS-subsidised treatment with this drug if previously used for initial treatment of CD30 positive peripheral T-cell lymphoma, non-cutaneous type, **AND**
- The treatment must not exceed 4 cycles under this restriction.

Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include:

(a) details (date, unique identifying number or provider number) of a histology report showing evidence of the tumour's CD30 positivity; and

(b) The date of initial diagnosis of systemic anaplastic large cell lymphoma; and

(c) Dates of commencement and completion of front-line curative intent chemotherapy; and

(d) a declaration of whether the patient's disease is relapsed or refractory, and the date and means by which the patient's disease was assessed as being relapsed or refractory.

All reports must be documented in the patient's medical records.

If the application is submitted through HPOS form upload or mail, it must include:

(i) A completed authority prescription form; and

(ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

**Injection**

10172J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	3	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

**▪ BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Authority required**

CD30 positive systemic anaplastic large cell lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed 12 cycles under this restriction in a lifetime.

**Injection**

10180T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	11	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

**▪ BRENTUXIMAB VEDOTIN**

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** No increase in the maximum number of repeats may be authorised.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have undergone a primary autologous stem cell transplant (ASCT) for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not receive more than 12 cycles of treatment under this restriction.

The treatment must not exceed a total of 16 cycles of combined initial and continuing treatment in a lifetime.

**Injection**

11067L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	11	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

▪ **BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Authority required**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must not have undergone an autologous stem cell transplant (ASCT) for this condition, **AND**
- Patient must not be suitable for ASCT for this condition; OR
- Patient must not be suitable for treatment with multi-agent chemotherapy for this condition, **AND**
- Patient must have experienced a relapsed CD30+ Hodgkin lymphoma following at least two prior treatments for this condition; OR
- Patient must have experienced a refractory CD30+ Hodgkin lymphoma following at least two prior treatments for this condition, **AND**
- Patient must not receive more than 4 cycles of treatment under this restriction.

Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail.

If the application is submitted through HPOS upload or mail, it must include:

- (a) a completed authority prescription form; and
- (b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

**Injection**

11080E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	3	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

▪ **BRENTUXIMAB VEDOTIN**

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** No increase in the maximum number of repeats may be authorised.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must not have undergone an autologous stem cell transplant (ASCT) for this condition, **AND**
- Patient must not be suitable for ASCT for this condition; OR
- Patient must not be suitable for treatment with multi-agent chemotherapy for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not receive more than 12 cycles of treatment under this restriction.

The treatment must not exceed a total of 16 cycles of combined initial and continuing treatment in a lifetime.

**Injection**

11086L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	11	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

## ▪ BRENTUXIMAB VEDOTIN

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).  
Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)  
Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))  
Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)  
Or mailed to:  
Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

### Authority required

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Initial treatment

### **Clinical criteria:**

- Patient must have undergone a primary autologous stem cell transplant (ASCT), **AND**
- Patient must have experienced a relapsed CD30+ Hodgkin lymphoma post ASCT; OR
- Patient must have experienced a refractory CD30+ Hodgkin lymphoma post ASCT, **AND**
- Patient must not receive more than 4 cycles of treatment under this restriction.

Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail.

If the application is submitted through HPOS upload or mail, it must include:

(a) a completed authority prescription form; and

(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

### **Injection**

11089P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	3	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

## ▪ BRENTUXIMAB VEDOTIN

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).  
Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)  
Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))  
Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)  
Or mailed to:  
Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

### Authority required

CD30 positive cutaneous T-cell lymphoma

Treatment Phase: Initial treatment

### **Clinical criteria:**

- Patient must have pathologically confirmed CD30 positive cutaneous T-cell lymphoma, **AND**
- Patient must have CD30 positivity of at least 3% of malignant cells, **AND**
- Patient must have a diagnosis of mycosis fungoides; OR
- Patient must have a diagnosis of Sezary syndrome; OR
- Patient must have a diagnosis of primary cutaneous anaplastic large cell lymphoma, **AND**
- Patient must have received prior systemic treatment for this condition, **AND**
- The condition must be relapsed or refractory, **AND**
- The treatment must not exceed 4 cycles under this restriction in a lifetime, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

The authority application must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include:

(a) details (date, unique identifying number/code or provider number) of the histopathology report from an Approved Pathology Authority demonstrating the patient has a diagnosis of either mycosis fungoides, Sezary syndrome or primary cutaneous anaplastic large cell lymphoma; and

(b) details (date, unique identifying number/code or provider number) of a histology report on the tumour sample or of a flow cytometric analysis of lymphoma cells of the blood showing CD30 positivity of at least 3% of malignant cells; and

(c) Date of commencement and completion of the most recent prior systemic treatment.

All reports must be documented in the patient's medical records.

If the application is submitted through HPOS form upload or mail, it must include:

(i) A completed authority prescription form; and

(ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

**Injection**

11651F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	180 mg	3	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

▪ **BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Authority required**

CD30 positive cutaneous T-cell lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must have achieved an objective response with this drug, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The treatment must not exceed 12 cycles under this restriction in a lifetime.

An objective response is defined as the demonstration of response by clinical observation of skin lesions, or response by positron-emission tomography (PET) and/or computed tomography (CT) standard criteria.

**Injection**

11661R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	180 mg	11	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

▪ **BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** This product is not PBS-subsidised for the treatment of previously untreated CD30 positive cutaneous T-cell lymphoma.

**Authority required**

CD30 positive peripheral T-cell lymphoma, non-cutaneous type

Treatment Phase: Continuing treatment

**Clinical criteria:**

- The treatment must be in combination with cyclophosphamide, doxorubicin and prednisone, **AND**
- Patient must have completed 6 initial cycles of PBS-subsidised treatment with this drug for this indication, **AND**
- Patient must have achieved at least a partial response to the 6 initial cycles of treatment with a combination of this drug and cyclophosphamide, doxorubicin and prednisone for this indication, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime.

Partial response is defined using Lugano Response Criteria for Non-Hodgkin Lymphoma as:

- (a) Positron emission tomography-based response: lymph nodes and extralymphatic sites - a score of 4 (uptake moderately > liver), or 5 (uptake markedly higher than liver and/or new lesions), with reduced uptake compared with baseline and residual mass(es) of any size; nonmeasured lesions - not applicable; organ enlargement - not applicable; new lesions - none; bone marrow - residual uptake higher than uptake in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in the marrow in the context of a nodal response, consideration should be given to further evaluation with MRI or biopsy or an interval scan; OR
- (b) Computed tomography-based response: lymph nodes and extralymphatic sites - greater than or equal to 50% decrease in the sum of the product of the perpendicular diameters for multiple lesions, of up to six (6) target measurable nodes and

extranodal sites; non-measured lesions - absent/normal, regressed but no increase; new lesions - none; bone marrow - not applicable.

### Injection

12632W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	1	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

#### ▪ BRENTUXIMAB VEDOTIN

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia

Complex Drugs

Reply Paid 9826

HOBART TAS 7001

**Note** This product is not PBS-subsidised for the treatment of previously untreated CD30 positive cutaneous T-cell lymphoma.

#### Authority required

CD30 positive peripheral T-cell lymphoma, non-cutaneous type

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have histological confirmation of CD30 expression in at least 3% of malignant cells, **AND**
- The treatment must be for first line therapy for this condition, **AND**
- The treatment must be for curative intent, **AND**
- The treatment must be in combination with cyclophosphamide, doxorubicin and prednisone, **AND**
- The treatment must not be more than 6 treatment cycles under this restriction in a lifetime.

Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include:

- (a) details (date, unique identifying number/code or provider number) of a histology report on the tumour sample from an Approved Pathology Authority showing CD30 positivity of at least 3% malignant cells; and
- (b) The date of initial diagnosis of Peripheral T-cell lymphoma.

All reports must be documented in the patient's medical records.

If the application is submitted through HPOS form upload or mail, it must include:

- (i) A completed authority prescription form; and
- (ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

### Injection

12656D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	5	..	*19012.59	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

#### ▪ ELOTUZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

#### Authority required

Relapsed and/or refractory multiple myeloma

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with lenalidomide and dexamethasone, **AND**
- Patient must have progressive disease after at least one prior therapy, **AND**
- Patient must have undergone or be ineligible for a stem cell transplant, **AND**
- Patient must not have previously received this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or

- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
  - (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
  - (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
  - (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
  - (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).
- Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

12990Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	9	..	*5151.24	31.60	Empliciti [BQ] (elotuzumab 300 mg injection, 1 vial) Empliciti [BQ] (elotuzumab 400 mg injection, 1 vial)

▪ **ELOTUZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Authority required**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - The treatment must be in combination with lenalidomide and dexamethasone, **AND**
  - Patient must not have developed disease progression while receiving treatment with this drug for this condition. Progressive disease is defined as at least 1 of the following:
    - (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
    - (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
    - (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
    - (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
    - (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
    - (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
    - (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).
- Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

12995Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	5	..	*5151.24	31.60	Empliciti [BQ] (elotuzumab 300 mg injection, 1 vial) Empliciti [BQ] (elotuzumab 400 mg injection, 1 vial)

▪ **ENFORTUMAB VEDOTIN**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14416**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

**Clinical criteria:**

- The condition must have progressed on/following both: (i) platinum-based chemotherapy, (ii) programmed cell death 1/ligand 1 (PD-1/PD-L1) inhibitor therapy; OR
  - The condition must have progressed on/following platinum-based chemotherapy, whilst PD-1/PD-L1 inhibitor therapy resulted in an intolerance that required treatment cessation, **AND**
  - Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug. **AND**
  - The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication.
- Treatment criteria:**
- Patient must be undergoing treatment with this drug for the first time; OR
  - Patient must be undergoing continuing treatment with this drug, with each of the following being true: (i) all other PBS eligibility criteria in this restriction are met, (ii) disease progression is absent.

**Injection**

13634N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	125 mg	8	..	*6341.02	31.60	Padcev [LL] (enfortumab vedotin 20 mg injection, 1 vial) Padcev [LL] (enfortumab vedotin 30 mg injection, 1 vial)

**▪ GEMTUZUMAB OZOGAMICIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Authority required**

Acute Myeloid Leukaemia

Treatment Phase: Induction treatment

**Clinical criteria:**

- Patient must have confirmed CD33-positive AML prior to initiation of treatment, **AND**
  - The condition must be de novo, **AND**
  - The condition must be previously untreated at the time of initiation (except for prior essential treatment with hydroxyurea or leukapheresis for patients with hyperleukocytic AML), **AND**
  - Patient must have confirmed intermediate/favourable cytogenetic risk; OR
  - Patient must have unknown cytogenetic risk due to inconclusive test results, **AND**
  - Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less, **AND**
  - The condition must not be acute promyelocytic leukaemia, **AND**
  - The treatment must be in combination with standard intensive remission induction chemotherapy for this condition, which must include cytarabine and an anthracycline, **AND**
  - The treatment must not be used in combination with a tyrosine kinase inhibitor, **AND**
  - The condition must not be internal tandem duplication (ITD) or tyrosine kinase domain (TKD) FMS tyrosine kinase 3 (FLT3) mutation positive, **AND**
  - Patient must not receive more than 1 induction cycle under this restriction in a lifetime.
- This drug is not PBS-subsidised if it is prescribed to an in-patient in a public hospital setting.

**Injection**

12878T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	5 mg	2	..	*9427.25	31.60	Mylotarg [PF] (gemtuzumab ozogamicin 5 mg injection, 1 vial)

**▪ GEMTUZUMAB OZOGAMICIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Authority required**

Acute Myeloid Leukaemia

Treatment Phase: Consolidation treatment

**Clinical criteria:**

- Patient must have achieved a complete remission following induction treatment with this drug for this condition, **AND**
- The treatment must be in combination with standard intensive remission consolidation chemotherapy for this condition, which must include cytarabine and an anthracycline, **AND**
- Patient must not receive more than 2 consolidation cycles under this restriction in a lifetime.

This drug is not PBS-subsidised if it is prescribed to an in-patient in a public hospital setting.

A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.

Complete remission following induction is defined as fewer than 5% blasts in a normocellular marrow and an absolute neutrophil count of more than  $1.0 \times 10^9$  cells/L with a platelet count of  $100 \times 10^9$ /L or more in the peripheral blood in the absence of transfusion.

Progressive disease is defined as the presence of any of the following:

- a) Leukaemic cells in the CSF;
- b) Re-appearance of circulating blast cells in the peripheral blood, not attributable to overshoot following recovery from myeloablative therapy;
- c) Greater than 5 % blasts in the marrow not attributable to bone marrow regeneration or another cause;
- d) Extramedullary leukaemia.

**Injection**

12904E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	5 mg	1	..	*9427.25	31.60	Mylotarg [PF] (gemtuzumab ozogamicin 5 mg injection, 1 vial)

**▪ IPILIMUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**11478**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial combination treatment (with nivolumab) as first-line drug therapy

**Clinical criteria:**

- The condition must be squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must not have previously been treated for this condition in the metastatic setting, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must be in combination with platinum-based chemotherapy for the first two cycles, **AND**
- The treatment must be in combination with nivolumab.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**11391**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing combination treatment (with nivolumab) of first-line drug therapy

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed 24 months in total, measured from the initial dose, or, must not extend beyond disease progression, whichever comes first, **AND**
- The treatment must be in combination with nivolumab.

**Injection**

12304N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	120 mg	4	..	*17245.95	31.60	Yervoy [BQ] (ipilimumab 50 mg/10 mL injection, 10 mL vial)

■ **IPILIMUMAB**

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**11930**

Unresectable malignant mesothelioma

**Clinical criteria:**

- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be in combination with PBS-subsidised nivolumab for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a maximum total of 24 months in a lifetime for this condition.

**Injection**

12601F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	120 mg	3	..	*17245.95	31.60	Yervoy [BQ] (ipilimumab 50 mg/10 mL injection, 10 mL vial)

■ **IPILIMUMAB**

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note A** prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk score can be calculated here: <https://www.mdcalc.com/imdc-international-metastatic-ccc-database-consortium-risk-model-metastatic-ccc>

renal-cell-carcinoma.

One point is assigned for each of:

- (i) a time of diagnosis to systemic therapy of less than 1 year
- (ii) a Karnofsky Performance Status of less than 80%
- (iii) a haemoglobin less than the lower limit of normal
- (iv) a corrected calcium level greater than the upper limit of normal
- (v) a neutrophil count greater than the upper limit of normal
- (vi) a platelet count greater than the upper limit of normal

Stated normal reference ranges may vary depending on the laboratory providing the measurement. 'Normal' here refers to the individual laboratory's stated normal reference range.

Favourable IMDC risk is a score of 0.

Intermediate IMDC risk is a score of 1 to 2.

Poor IMDC risk is a score of 3 to 6.

Document any IMDC risk score assessment in the patient's medical records.

#### **Authority required (STREAMLINED)**

##### **8555**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Induction treatment

#### **Clinical criteria:**

- The condition must not have previously been treated, **AND**
- The condition must be classified as intermediate to poor risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The treatment must be in combination with PBS-subsidised treatment with nivolumab as induction therapy for this condition.

Induction treatment with ipilimumab must not exceed a total of 4 doses at a maximum dose of 1 mg per kg every 3 weeks.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

#### **Injection**

11644W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	120 mg	3	..	*17245.95	31.60	Yervoy [BQ] (ipilimumab 50 mg/10 mL injection, 10 mL vial)

#### **■ IPILIMUMAB**

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### **Authority required (STREAMLINED)**

##### **6562**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Induction treatment

#### **Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received prior treatment with ipilimumab, **AND**
- The treatment must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Note** For patients who commence therapy with ipilimumab:

(i) Decisions concerning efficacy should await completion of the entire induction regimen (four doses) and should be made in conjunction with established criteria for immunological responses. However induction may be ceased or delayed if symptomatic progressive disease or intolerable adverse events occur and if, in the opinion of the clinician, continuation of treatment poses a risk to the patient;

(ii) Tumour responses may occur beyond the initial 12 week induction phase and evaluation for potential later responses should be undertaken regularly for the first year.

#### **Authority required (STREAMLINED)**

##### **6585**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Re-induction treatment

#### **Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have progressive disease after achieving an initial objective response to the most recent course of ipilimumab treatment (induction or re-induction), **AND**
- The treatment must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

An initial objective response to treatment is defined as either:

(i) sustained stable disease of greater than or equal to 3 months duration measured from at least 2 weeks after the date of completion of the most recent course of ipilimumab; or

(ii) a partial or complete response.

The patient's body weight must be documented in the patient's medical records at the time treatment with ipilimumab is initiated.

**Authority required (STREAMLINED)**

**13841**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Induction treatment

**Clinical criteria:**

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, **AND**
- The condition must not be ocular or uveal melanoma, **AND**
- The treatment must be in combination with PBS-subsidised treatment with nivolumab as induction therapy for this condition.

Induction treatment with nivolumab must not exceed a total of 4 doses at a maximum dose of 1 mg per kg every 3 weeks.

Induction treatment with ipilimumab must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Injection**

2638W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	360 mg	3	..	*45769.35	31.60	Yervoy [BQ] (ipilimumab 200 mg/40 mL injection, 40 mL vial) Yervoy [BQ] (ipilimumab 50 mg/10 mL injection, 10 mL vial)

▪ **SACITUZUMAB GOVITECAN**

**Caution** This medicine contains a cytotoxic component and causes chemotherapy-like toxicity, in particular, it can cause severe or life-threatening neutropenia and severe diarrhoea. For further information, refer to the Product Information.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12656**

Unresectable locally advanced or metastatic triple-negative breast cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have progressive disease following two or more prior systemic therapies, at least one of them in the locally advanced or metastatic setting, **AND**
- The condition must be inoperable, **AND**
- Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation, **AND**
- The treatment must be the sole PBS-subsidised therapy for this PBS indication.

**Injection**

12944G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	7	..	*10669.50	31.60	Trodely [GI] (sacituzumab govitecan 180 mg injection, 1 vial)

▪ **SACITUZUMAB GOVITECAN**

**Caution** This medicine contains a cytotoxic component and causes chemotherapy-like toxicity, in particular, it can cause severe or life-threatening neutropenia and severe diarrhoea. For further information, refer to the Product Information.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12669**

Unresectable locally advanced or metastatic triple-negative breast cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this PBS indication.

**Injection**

12965J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	13	..	*10669.50	31.60	Trodely [GI] (sacituzumab govitecan 180 mg injection, 1 vial)

**OTHER ANTINEOPLASTIC AGENTS**

*Platinum compounds*

## ■ CARBOPLATIN

### Injection

7222D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	900 mg	5	..	*185.81	31.60	Carboplatin Accord [OC] (carboplatin 450 mg/45 mL injection, 45 mL vial)

## ■ CISPLATIN

### Injection

7224F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	220 mg	14	..	*181.57	31.60	Cisplatin Accord [OC] (cisplatin 100 mg/100 mL injection, 100 mL vial) Cisplatin Accord [OC] (cisplatin 50 mg/50 mL injection, 50 mL vial)

## ■ OXALIPLATIN

### Injection

7253R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	300 mg	11	..	*177.44	31.60	Oxaliplatin Accord [OC] (oxaliplatin 100 mg/20 mL injection, 20 mL vial) Oxaliplatin SUN [RA] (oxaliplatin 100 mg/20 mL injection, 20 mL vial) Oxaliplatin SUN [RA] (oxaliplatin 200 mg/40 mL injection, 40 mL vial)

### Proteasome inhibitors

## ■ BORTEZOMIB

### Restricted benefit

Multiple myeloma

### Restricted benefit

Newly diagnosed systemic light chain amyloidosis

Treatment Phase: Administration on Days 1, 8, 15 and 22 of six treatment cycles (28 days per cycle) in total

### Treatment criteria:

- Patient must be undergoing concurrent treatment with PBS-subsidised daratumumab for this PBS indication.

### Injection

12219D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3000 mcg	15	..	*360.09	31.60	Bortezomib [CR] (bortezomib 3.5 mg injection, 1 vial) Bortezomib Accord [OC] (bortezomib 1 mg injection, 1 vial) Bortezomib Accord [OC] (bortezomib 2.5 mg/mL injection, 1 mL vial) Bortezomib Accord [OC] (bortezomib 3.5 mg injection, 1 vial) Bortezomib Accord [OC] (bortezomib 3.5 mg/1.4 mL injection, 1.4 mL vial) Bortezomib Baxter [BX] (bortezomib 3.5 mg injection, 1 vial) Bortezomib Ever Pharma [IT] (bortezomib 2.5 mg/mL injection, 1 mL vial) Bortezomib Ever Pharma [IT] (bortezomib 3.5 mg/1.4 mL injection, 1.4 mL vial) Bortezomib Juno [JU] (bortezomib 2.5 mg injection, 1 vial) Bortezomib Juno [JU] (bortezomib 3.5 mg injection, 1 vial) Bortezomib Sandoz [SZ] (bortezomib 3.5 mg injection, 1 vial) BORTEZOMIB-TEVA [TB] (bortezomib 3.5 mg injection, 1 vial) DBL Bortezomib [PF] (bortezomib 1 mg injection, 1 vial) DBL Bortezomib [PF] (bortezomib 2.5 mg injection, 1 vial) DBL Bortezomib [PF] (bortezomib 3 mg injection, 1 vial) DBL Bortezomib [PF] (bortezomib 3.5 mg injection, 1 vial) Velcade [JC] (bortezomib 1 mg injection, 1 vial) Velcade [JC] (bortezomib 3 mg injection, 1 vial) Velcade [JC] (bortezomib 3.5 mg injection, 1 vial)

## ■ CARFILZOMIB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

### Authority required (STREAMLINED)

**12934**

Multiple myeloma

Treatment Phase: Initial treatment - twice weekly treatment regimen

**Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with dexamethasone, **AND**
- Patient must have progressive disease after at least one prior therapy, **AND**
- Patient must have undergone or be ineligible for a stem cell transplant, **AND**
- Patient must not have previously received this drug for this condition, **AND**
- Patient must not receive more than three cycles of treatment under this restriction.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Authority required (STREAMLINED)**

**12930**

Multiple myeloma

Treatment Phase: Continuing treatment - twice weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with dexamethasone, **AND**
- Patient must not develop disease progression while receiving treatment with this drug for this condition, **AND**
- Patient must not receive more than 3 cycles of treatment per continuing treatment course authorised under this restriction.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

11230C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	120 mg	17	..	*2576.65	31.60	Kyprolis [AN] (carfilzomib 10 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 30 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 60 mg injection, 1 vial)

▪ **CARFILZOMIB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12694**

Multiple myeloma

Treatment Phase: Initial treatment - once weekly treatment regimen

**Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with dexamethasone, **AND**
- Patient must have progressive disease after at least one prior therapy, **AND**
- Patient must have undergone or be ineligible for a stem cell transplant, **AND**
- Patient must not have previously received this drug for this condition, **AND**
- Patient must not receive more than three cycles of treatment under this restriction.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Authority required (STREAMLINED)**

**12849**

Multiple myeloma

Treatment Phase: Continuing treatment - once weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with dexamethasone, **AND**
- Patient must not develop disease progression while receiving treatment with this drug for this condition, **AND**
- Patient must not receive more than 3 cycles of treatment per continuing treatment course authorised under this restriction. Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

12243J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	160 mg	8	..	*3391.57	31.60	Kyprolis [AN] (carfilzomib 10 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 30 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 60 mg injection, 1 vial)

▪ **CARFILZOMIB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14389**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Initial treatment for Cycles 1 to 3

**Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with lenalidomide and dexamethasone, **AND**
- Patient must have progressive disease after at least one prior therapy, **AND**
- Patient must not have previously received this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein. Provide details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of the most recent treatment cycle; the basis of the diagnosis of progressive disease or failure to respond; and which disease activity parameters will be used to assess response once only through the Authority application for lenalidomide.

**Authority required (STREAMLINED)**

**14363**

Relapsed and/or refractory multiple myeloma  
Treatment Phase: Continuing treatment for Cycles 3 to 12

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with lenalidomide and dexamethasone, **AND**
- Patient must not have progressive disease while receiving treatment with this drug for this condition. Progressive disease is defined as at least 1 of the following:
  - (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
  - (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
  - (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
  - (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
  - (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
  - (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
  - (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Authority required (STREAMLINED)**

**14364**

Relapsed and/or refractory multiple myeloma  
Treatment Phase: Continuing treatment for Cycles 13 onwards

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with lenalidomide and dexamethasone, **AND**
- Patient must not have progressive disease while receiving treatment with this drug for this condition. Progressive disease is defined as at least 1 of the following:
  - (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
  - (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
  - (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
  - (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
  - (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
  - (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
  - (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

13637R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	60 mg	17	..	*1354.28	31.60	Kyprolis [AN] (carfilzomib 10 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 30 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 60 mg injection, 1 vial)

*Other antineoplastic agents*

▪ **ARSENIC**

**Authority required (STREAMLINED)**

**6018**

Acute promyelocytic leukaemia  
Treatment Phase: Induction and consolidation treatment

**Clinical criteria:**

- The condition must be characterised by the presence of the t(15:17) translocation or PML/RAR-alpha fusion gene transcript.

**Injection**

10699D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	18 mg	140	..	*250.47	31.60	Arsenic Trioxide Accord [OC] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials)

Arsenic Trioxide-AFT [AE] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL ampoules)  
 Arsenic Trioxide Juno [JU] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials)  
 Phenasen [FF] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials)

## ■ ARSENIC

### **Authority required (STREAMLINED)**

**4793**

Acute promyelocytic leukaemia

Treatment Phase: Induction and consolidation treatment

#### **Clinical criteria:**

- The condition must be characterised by the presence of the t(15:17) translocation or PML/RAR-alpha fusion gene transcript, **AND**
- The condition must be relapsed, **AND**
- Patient must be arsenic naive at induction.

### **Authority required (STREAMLINED)**

**5997**

Acute promyelocytic leukaemia

#### **Clinical criteria:**

- The condition must be characterised by the presence of the t(15:17) translocation or PML/RAR-alpha fusion gene transcript.

## Injection

7241D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	18 mg	89	..	*250.47	31.60	Arsenic Trioxide Accord [OC] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials) Arsenic Trioxide-AFT [AE] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL ampoules) Arsenic Trioxide Juno [JU] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials) Phenasen [FF] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials)

## ■ ERIBULIN

**Note** A patient who has progressive disease with eribulin is no longer eligible for PBS-subsidised eribulin.

### **Authority required (STREAMLINED)**

**4649**

Locally advanced or metastatic breast cancer

#### **Clinical criteria:**

- Patient must have progressive disease, **AND**
- Patient must have failed at least two prior chemotherapeutic regimens for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

## Injection

10140Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3 mg	13	..	*825.48	31.60	Halaven [EI] (eribulin mesilate 1 mg/2 mL injection, 2 mL vial)

## ■ ERIBULIN

**Note** No increase in the maximum number of repeats may be authorised.

### **Authority required (STREAMLINED)**

**7258**

Advanced (unresectable and/or metastatic) liposarcoma

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have an ECOG performance status of 2 or less, **AND**
- The condition must be dedifferentiated, myxoid, round-cell or pleomorphic subtype, **AND**
- Patient must have received prior chemotherapy treatment including an anthracycline and ifosfamide (unless contraindicated) for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

#### **Population criteria:**

- Patient must be aged 18 years or older.

### **Authority required (STREAMLINED)**

**7280**

Advanced (unresectable and/or metastatic) liposarcoma

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - Patient must not develop progressive disease while being treated with this drug for this condition, **AND**
  - The treatment must be the sole PBS-subsidised therapy for this condition.
- Population criteria:**
- Patient must be aged 18 years or older.

**Injection**

11199K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3 mg	7	..	*825.48	31.60	Halaven [E] (eribulin mesilate 1 mg/2 mL injection, 2 mL vial)



---

# Chemotherapy items for Public Hospital use

---

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS .....	85
ANTINEOPLASTIC AGENTS .....	85
ALKYLATING AGENTS .....	85
ANTIMETABOLITES .....	86
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS .....	88
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES .....	91
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES.....	92
OTHER ANTINEOPLASTIC AGENTS .....	151



■ ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

■ ANTINEOPLASTIC AGENTS

ALKYLATING AGENTS

*Nitrogen mustard analogues*

■ BENDAMUSTINE

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required (STREAMLINED)**

**7972**

Previously untreated stage III or IV mantle cell lymphoma

Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must be CD20 positive, **AND**
- The treatment must be in combination with rituximab, **AND**
- The condition must be previously untreated, **AND**
- The condition must be symptomatic, **AND**
- The treatment must be for induction treatment purposes only, **AND**
- Patient must not receive more than 6 cycles (12 doses) of treatment under this restriction, **AND**
- Patient must not be eligible for stem cell transplantation.

**Authority required (STREAMLINED)**

**7943**

Previously untreated stage II bulky or stage III or IV indolent non-Hodgkin's lymphoma

Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must be CD20 positive, **AND**
- The condition must be previously untreated, **AND**
- The condition must be symptomatic, **AND**
- The treatment must be for induction treatment purposes only, **AND**
- The treatment must be in combination with rituximab or obinutuzumab, **AND**
- The treatment must not exceed 6 cycles (12 doses) with this drug under this restriction.

**Authority required (STREAMLINED)**

**7944**

Follicular lymphoma

Treatment Phase: Re-induction treatment

**Clinical criteria:**

- The condition must be CD20 positive, **AND**
- The condition must be refractory to treatment with rituximab for this condition, **AND**
- The condition must be symptomatic, **AND**
- The treatment must be for re-induction treatment purposes only, **AND**
- The treatment must be in combination with obinutuzumab, **AND**
- The treatment must not exceed 6 cycles (12 doses) with this drug under this restriction.

The condition is considered rituximab-refractory if the patient experiences less than a partial response or progression of disease within 6 months after completion of a prior rituximab-containing regimen.

**Injection**

10760H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	11	..	*1239.04	31.60	Bendamustine Juno [JU] (bendamustine hydrochloride 100 mg injection, 1 vial) Bendamustine Juno [JU] (bendamustine hydrochloride 25 mg injection, 1 vial) Bendamustine Sandoz [SZ] (bendamustine hydrochloride 100 mg injection, 1 vial) Bendamustine Sandoz [SZ] (bendamustine hydrochloride 25 mg injection, 1 vial) Bendamustine Viatrix [AF] (bendamustine hydrochloride 100 mg injection, 1 vial) Bendamustine Viatrix [AF] (bendamustine hydrochloride 25 mg injection, 1 vial) Ribomustin [JC] (bendamustine hydrochloride 100 mg injection, 1 vial) Ribomustin [JC] (bendamustine hydrochloride 25 mg injection, 1 vial)

## ■ CYCLOPHOSPHAMIDE

### Injection

4327R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	2800 mg	17	..	*144.39	31.60	CYCLOPHOSPHAMIDE-REACH [RQ] (cyclophosphamide 1 g injection, 1 vial) CYCLOPHOSPHAMIDE-REACH [RQ] (cyclophosphamide 500 mg injection, 1 vial) Endoxan [BX] (cyclophosphamide 1 g injection, 1 vial) Endoxan [BX] (cyclophosphamide 2 g injection, 1 vial) Endoxan [BX] (cyclophosphamide 500 mg injection, 1 vial)

## ■ IFOSFAMIDE

### Injection

4448D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	4000 mg	19	..	*241.58	31.60	Holoxan [BX] (ifosfamide 1 g injection, 1 vial) Holoxan [BX] (ifosfamide 2 g injection, 1 vial)

## ANTIMETABOLITES

### Folic acid analogues

## ■ METHOTREXATE

### Injection

4502Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	250 mg	5	..	*114.12	31.60	DBL Methotrexate [PF] (methotrexate 1 g/10 mL injection, 10 mL vial) DBL Methotrexate [PF] (methotrexate 5 mg/2 mL injection, 5 x 2 mL vials) DBL Methotrexate [PF] (methotrexate 50 mg/2 mL injection, 5 x 2 mL vials) DBL Methotrexate [PF] (methotrexate 500 mg/20 mL injection, 20 mL vial) Methotrexate Accord [OD] (methotrexate 1 g/10 mL injection, 10 mL vial) Methotrexate Ebewe [SZ] (methotrexate 5 g/50 mL injection, 50 mL vial) Pfizer Australia Pty Ltd [PF] (methotrexate 1 g/10 mL injection, 10 mL vial)

## ■ METHOTREXATE

### Restricted benefit

Patients receiving treatment with a high dose regimen

### Injection

4512L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	20000 mg	..	..	*842.02	31.60	DBL Methotrexate [PF] (methotrexate 1 g/10 mL injection, 10 mL vial) DBL Methotrexate [PF] (methotrexate 5 mg/2 mL injection, 5 x 2 mL vials) DBL Methotrexate [PF] (methotrexate 50 mg/2 mL injection, 5 x 2 mL vials) DBL Methotrexate [PF] (methotrexate 500 mg/20 mL injection, 20 mL vial) Methotrexate Accord [OD] (methotrexate 1 g/10 mL injection, 10 mL vial) Methotrexate Ebewe [SZ] (methotrexate 5 g/50 mL injection, 50 mL vial) Pfizer Australia Pty Ltd [PF] (methotrexate 1 g/10 mL injection, 10 mL vial)

## ■ PEMETREXED

### Injection

4600D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1100 mg	5	..	*147.01	31.60	Pemetrexed Accord [OD] (pemetrexed 1 g injection, 1 vial) Pemetrexed Accord [OD] (pemetrexed 100 mg injection, 1 vial) Pemetrexed Accord [OD] (pemetrexed 500 mg injection, 1 vial) Pemetrexed APOTEX [TX] (pemetrexed 500 mg injection, 1 vial) Pemetrexed Ever Pharma [IT] (pemetrexed 1 g/40 mL injection, 40 mL vial)

Pemetrexed Ever Pharma [IT] (pemetrexed 100 mg/4 mL injection, 4 mL vial)  
 Pemetrexed Ever Pharma [IT] (pemetrexed 500 mg/20 mL injection, 20 mL vial)  
 Pemetrexed SUN [RA] (pemetrexed 1 g injection, 1 vial)  
 Pemetrexed SUN [RA] (pemetrexed 100 mg injection, 1 vial)  
 Pemetrexed SUN [RA] (pemetrexed 500 mg injection, 1 vial)

▪ **PRALATREXATE**

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required**

Relapsed or chemotherapy refractory Peripheral T-cell Lymphoma  
 Treatment Phase: Continuing treatment

**Clinical criteria:**

- The condition must be relapsed or chemotherapy refractory, **AND**
- Patient must not develop progressive disease whilst receiving PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition.

**Injection**

11272G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	80 mg	11	..	*4230.62	31.60	Folotyn [MF] (pralatrexate 20 mg/mL injection, 1 mL vial)

▪ **PRALATREXATE**

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required**

Relapsed or chemotherapy refractory Peripheral T-cell Lymphoma  
 Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be relapsed or chemotherapy refractory, **AND**
- Patient must have undergone appropriate prior front-line curative intent chemotherapy.

**Injection**

11293J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	80 mg	5	..	*4230.62	31.60	Folotyn [MF] (pralatrexate 20 mg/mL injection, 1 mL vial)

▪ **RALTITREXED**

**Injection**

4610P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	7 mg	8	..	*1131.46	31.60	Tomudex [PF] (raltitrexed 2 mg injection, 1 vial)

*Purine analogues*

▪ **CLADRIBINE**

**Authority required (STREAMLINED)**

**6265**

Hairy cell leukaemia

**Injection**

4326Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	17 mg	6	..	*897.88	31.60	Leustatin [IX] (cladribine 10 mg/10 mL injection, 10 mL vial) Litak [AF] (cladribine 10 mg/5 mL injection, 5 mL vial)

▪ **FLUDARABINE**

**Note** Pharmaceutical benefits that have the form fludarabine phosphate 50 mg injection and pharmaceutical benefits that have the form fludarabine phosphate 50 mg/2 mL injection are equivalent for the purposes of substitution.

**Injection**

4393F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	55 mg	29	..	*152.30	31.60	Fludarabine Ebewe [SZ] (fludarabine phosphate 50 mg/2 mL injection, 5 x 2 mL vials) Fludarabine Juno [JO] (fludarabine phosphate 50 mg injection, 1 vial)

*Pyrimidine analogues*

## ■ CYTARABINE

### Injection

4357H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	7000 mg	15	..	*886.62	31.60	Pfizer Australia Pty Ltd [PF] (cytarabine 100 mg/5 mL injection, 5 x 5 mL vials)

## ■ FLUOROURACIL

### Restricted benefit

Patients requiring administration of fluorouracil by intravenous infusion

### Injection

4394G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	5500 mg	11	..	*115.76	31.60	Fluorouracil Accord [OC] (fluorouracil 1 g/20 mL injection, 20 mL vial) Fluorouracil Accord [OC] (fluorouracil 2.5 g/50 mL injection, 50 mL vial) Fluorouracil Accord [OC] (fluorouracil 5 g/100 mL injection, 100 mL vial) Fluorouracil Accord [OC] (fluorouracil 500 mg/10 mL injection, 10 mL vial) Fluorouracil Ebewe [SZ] (fluorouracil 1 g/20 mL injection, 20 mL vial) Fluorouracil Ebewe [SZ] (fluorouracil 5 g/100 mL injection, 100 mL vial)

## ■ FLUOROURACIL

### Restricted benefit

Patients requiring administration of fluorouracil by intravenous injection

### Injection

4431F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	23	..	*94.46	31.60	Fluorouracil Accord [OC] (fluorouracil 1 g/20 mL injection, 20 mL vial) Fluorouracil Accord [OC] (fluorouracil 2.5 g/50 mL injection, 50 mL vial) Fluorouracil Accord [OC] (fluorouracil 5 g/100 mL injection, 100 mL vial) Fluorouracil Accord [OC] (fluorouracil 500 mg/10 mL injection, 10 mL vial) Fluorouracil Ebewe [SZ] (fluorouracil 1 g/20 mL injection, 20 mL vial) Fluorouracil Ebewe [SZ] (fluorouracil 5 g/100 mL injection, 100 mL vial)

## ■ GEMCITABINE

**Caution** Pharmaceutical benefits containing gemcitabine may have different concentrations.

### Injection

4439P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3000 mg	17	..	*151.67	31.60	DBL Gemcitabine Injection [PF] (gemcitabine 1 g/26.3 mL injection, 26.3 mL vial) DBL Gemcitabine Injection [PF] (gemcitabine 2 g/52.6 mL injection, 52.6 mL vial)

## PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS

### *Vinca alkaloids and analogues*

## ■ VINBLASTINE

### Injection

4618C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	20 mg	17	..	*161.96	31.60	DBL Vinblastine [PF] (vinblastine sulfate 10 mg/10 mL injection, 5 x 10 mL vials)

## ■ VINCRIStINE

### Injection

4619D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	2 mg	7	..	*106.46	31.60	DBL Vincristine Sulfate [PF] (vincristine sulfate 1 mg/mL injection, 5 x 1 mL vials)

▪ **VINORELBINE**

**Injection**

4620E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	70 mg	7	..	*150.52	31.60	Navelbine [FB] (vinorelbine 10 mg/mL injection, 1 mL vial) Navelbine [FB] (vinorelbine 50 mg/5 mL injection, 5 mL vial) Vinorelbine Ebewe [SZ] (vinorelbine 10 mg/mL injection, 1 mL vial) Vinorelbine Ebewe [SZ] (vinorelbine 50 mg/5 mL injection, 5 mL vial)

*Podophyllotoxin derivatives*

▪ **ETOPOSIDE**

**Injection**

4428C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	440 mg	14	..	*282.12	31.60	Etopophos [LM] (etoposide phosphate 1.136 g (etoposide 1 g) injection, 1 vial) Etoposide Ebewe [SZ] (etoposide 100 mg/5 mL injection, 5 x 5 mL vials)

*Taxanes*

▪ **CABAZITAXEL**

**Note** Where the term 'novel hormonal drug' appears in this restriction, it refers to: (i) abiraterone, (ii) apalutamide, (iii) darolutamide, (iv) enzalutamide.

**Authority required (STREAMLINED)**

**13207**

Castration resistant metastatic carcinoma of the prostate

**Clinical criteria:**

- The treatment must be in combination with prednisone or prednisolone, **AND**
- The condition must be resistant to treatment with docetaxel; OR
- Patient must have a documented intolerance necessitating permanent treatment withdrawal or a contraindication to docetaxel, **AND**
- The treatment must not be used in combination with a novel hormonal drug, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- Patient must not receive PBS-subsidised cabazitaxel if progressive disease develops while on cabazitaxel.

**Injection**

4376H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	55 mg	5	..	*241.15	31.60	Cabazitaxel Accord [OC] (cabazitaxel 60 mg/3 mL injection, 3 mL vial) Cabazitaxel Ever Pharma [IT] (cabazitaxel 60 mg/6 mL injection, 6 mL vial) Cabazitaxel Juno [JU] (cabazitaxel 60 mg/1.5 mL injection [1.5 mL vial] (& inert substance diluent [4.5 mL vial], 1 pack) MSN Cabazitaxel [RQ] (cabazitaxel 60 mg/1.5 mL injection [1.5 mL vial] (& inert substance diluent [4.5 mL vial], 1 pack)

▪ **DOCETAXEL**

**Note** Pharmaceutical benefits that have the forms docetaxel solution concentrate for I.V. infusion 80 mg in 4 mL and docetaxel solution concentrate for I.V. infusion 80 mg in 8 mL are equivalent for the purposes of substitution.

**Note** Pharmaceutical benefits that have the forms docetaxel solution concentrate for I.V. infusion 160 mg in 8 mL and docetaxel solution concentrate for I.V. infusion 160 mg in 16 mL are equivalent for the purposes of substitution.

**Injection**

10148D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	250 mg	5	..	*155.32	31.60	DBL Docetaxel Concentrated Injection [PF] (docetaxel 160 mg/16 mL injection, 16 mL vial) DBL Docetaxel Concentrated Injection [PF] (docetaxel 80 mg/8 mL injection, 8 mL vial) Docetaxel Accord [OC] (docetaxel 160 mg/8 mL injection, 8 mL vial) Docetaxel Accord [OC] (docetaxel 80 mg/4 mL injection, 4 mL vial)

▪ **NANOPARTICLE ALBUMIN-BOUND PACLITAXEL**

**Authority required (STREAMLINED)**

**6106**

Metastatic breast cancer

**Authority required (STREAMLINED)**

**6119**

HER2 positive breast cancer

## Injection

4531L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	580 mg	5	..	*2148.24	31.60	Abraxane [TS] (paclitaxel (as nanoparticle albumin-bound) 100 mg injection, 1 vial)

## ■ NANOPARTICLE ALBUMIN-BOUND PACLITAXEL

**Note** Special Pricing Arrangements apply.

**Note** Not for use as neoadjuvant or adjuvant therapy.

### Authority required (STREAMLINED)

**4657**

Stage IV (metastatic) adenocarcinoma of the pancreas

#### Clinical criteria:

- The treatment must be in combination with gemcitabine, **AND**
  - The condition must not have been treated previously with PBS-subsidised therapy, **AND**
  - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.
- A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.

## Injection

10165B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	275 mg	11	..	*1118.43	31.60	Abraxane [TS] (paclitaxel (as nanoparticle albumin-bound) 100 mg injection, 1 vial)

## ■ PACLITAXEL

### Injection

4567J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	450 mg	3	..	*162.18	31.60	Paclitaxel Accord [OC] (paclitaxel 300 mg/50 mL injection, 50 mL vial) Paclitaxel Ebewe [SZ] (paclitaxel 300 mg/50 mL injection, 50 mL vial)

## *Topoisomerase 1 (TOP1) inhibitors*

## ■ IRINOTECAN

**Note** In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen.

### Injection

4451G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	800 mg	11	..	*158.62	31.60	Irinotecan Accord [OC] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) Irinotecan Accord [OC] (irinotecan hydrochloride trihydrate 500 mg/25 mL injection, 25 mL vial) Irinotecan Alphapharm [AF] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) Irinotecan Alphapharm [AF] (irinotecan hydrochloride trihydrate 500 mg/25 mL injection, 25 mL vial) IRINOTECAN BAXTER [BX] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) MEDITAB IRINOTECAN [LR] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) MEDITAB IRINOTECAN [LR] (irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 2 mL vial) Omegapharm Irinotecan [OE] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) Omegapharm Irinotecan [OE] (irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 2 mL vial)

## ■ TOPOTECAN

### Injection

4617B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3500 mcg	17	..	*120.70	31.60	Hycamtin [SZ] (topotecan 4 mg injection, 5 vials) Topotecan Accord [OC] (topotecan 4 mg/4 mL injection, 5 x 4 mL vials)

## *Other plant alkaloids and natural products*

## ■ TRABECTEDIN

**Note** Special Pricing Arrangements apply.

### Authority required (STREAMLINED)

**14196**

Advanced (unresectable and/or metastatic) leiomyosarcoma or liposarcoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have an ECOG performance status of 2 or less, **AND**
- Patient must have received prior chemotherapy treatment including an anthracycline, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The condition must be one of the following subtypes for patients with liposarcoma: (i) dedifferentiated, (ii) myxoid, (iii) round-cell, (iv) pleomorphic.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

**Injection**

13346K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3250 mcg	3	..	*3325.50	31.60	Yondelis [ZL] (trabectedin 1 mg injection, 1 vial)

▪ **TRABECTEDIN**

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14197**

Advanced (unresectable and/or metastatic) leiomyosarcoma or liposarcoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

**Authority required (STREAMLINED)**

**14188**

Advanced (unresectable and/or metastatic) leiomyosarcoma or liposarcoma

Treatment Phase: Transitioning from non-PBS to PBS-subsidised treatment - Grandfather arrangements

**Clinical criteria:**

- Patient must have been receiving treatment with this drug for this condition prior to 1 August 2023, **AND**
- Patient must have had a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 2 at the time non-PBS supply was initiated, **AND**
- Patient must have received chemotherapy treatment including an anthracycline, prior to initiating non-PBS-subsidised treatment, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The condition must be one of the following subtypes for patients with liposarcoma: (i) dedifferentiated, (ii) myxoid, (iii) round-cell, (iv) pleomorphic.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Injection**

13340D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3250 mcg	7	..	*3325.50	31.60	Yondelis [ZL] (trabectedin 1 mg injection, 1 vial)

**CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES**

*Anthracyclines and related substances*

▪ **DOXORUBICIN**

**Injection/intravesical**

4361M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	135 mg	11	..	*125.34	31.60	Adriamycin [PF] (doxorubicin hydrochloride 200 mg/100 mL injection, 100 mL vial) Adriamycin [PF] (doxorubicin hydrochloride 50 mg/25 mL injection, 25 mL vial) Doxorubicin ACC [OC] (doxorubicin hydrochloride 200 mg/100 mL injection, 100 mL vial)

▪ **DOXORUBICIN HYDROCHLORIDE (AS PEGYLATED LIPOSOMAL)**

**Injection**

4364Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	100 mg	5	..	*747.76	31.60	Caelyx [BX] (doxorubicin hydrochloride (as pegylated liposomal) 20 mg/10 mL injection, 10 mL vial) Caelyx [BX] (doxorubicin hydrochloride (as pegylated liposomal) 50 mg/25 mL injection, 25 mL vial)

Liposomal Doxorubicin SUN [RA] (doxorubicin hydrochloride (as pegylated liposomal) 20 mg/10 mL injection, 10 mL vial)  
Liposomal Doxorubicin SUN [RA] (doxorubicin hydrochloride (as pegylated liposomal) 50 mg/25 mL injection, 25 mL vial)

## ■ EPIRUBICIN

### Injection/intravesical

4375G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	220 mg	5	..	*266.52	31.60	Epirubicin Accord [OC] (epirubicin hydrochloride 200 mg/100 mL injection, 100 mL vial)

## ■ IDARUBICIN

### Restricted benefit

Acute myelogenous leukaemia (AML)

### Injection

4440Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	30 mg	5	..	*268.08	31.60	Zavedos Solution [PF] (idarubicin hydrochloride 5 mg/5 mL injection, 5 mL vial)

## ■ MITOZANTRONE

### Injection

4514N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	30 mg	5	..	*181.22	31.60	Mitozantrone Ebewe [SZ] (mitozantrone 20 mg/10 mL injection, 10 mL vial) Onkotrone [BX] (mitozantrone 20 mg/10 mL injection, 10 mL vial) Onkotrone [BX] (mitozantrone 25 mg/12.5 mL injection, 12.5 mL vial)

### Other cytotoxic antibiotics

## ■ BLEOMYCIN

### Restricted benefit

Germ cell neoplasms

### Restricted benefit

Lymphoma

### Injection

4433H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	30000 iu	11	..	*168.62	31.60	CIPLA BLEOMYCIN [LR] (bleomycin sulfate 15 000 international units injection, 1 vial) DBL Bleomycin Sulfate [PF] (bleomycin sulfate 15 000 international units injection, 1 vial)

## MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

### CD20 (Clusters of Differentiation 20) inhibitors

## ■ OBINUTUZUMAB

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### Authority required

Follicular lymphoma

Treatment Phase: Re-induction treatment

### **Clinical criteria:**

- Patient must not have previously received PBS-subsidised obinutuzumab, **AND**
  - The condition must be CD20 positive, **AND**
  - The condition must be refractory to treatment with rituximab for this condition, **AND**
  - The condition must be symptomatic, **AND**
  - The treatment must be for re-induction treatment purposes only, **AND**
  - The treatment must be in combination with bendamustine, **AND**
  - The treatment must not exceed 8 doses for re-induction treatment with this drug for this condition.
- The condition is considered rituximab-refractory if the patient experiences less than a partial response or progression of disease within 6 months after completion of a prior rituximab-containing regimen.

A patient may only qualify for PBS-subsidised initiation treatment once in a lifetime under:

- i) the previously untreated induction treatment restriction; or
- ii) the rituximab-refractory re-induction restriction.

**Injection**

11457B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	7	..	*4614.14	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

▪ **OBINUTUZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Stage II bulky or Stage III/IV follicular lymphoma

Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must be CD20 positive, **AND**
- The condition must be previously untreated, **AND**
- The condition must be symptomatic, **AND**
- The treatment must be for induction treatment purposes only, **AND**
- The treatment must be in combination with chemotherapy, **AND**
- The treatment must not exceed 10 doses for induction treatment with this drug for this condition.

A patient may only qualify for PBS-subsidised initiation treatment once in a lifetime under:

- i) the previously untreated induction treatment restriction; or
- ii) the rituximab-refractory re-induction restriction.

**Injection**

11458C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	9	..	*4614.14	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

▪ **OBINUTUZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Stage II bulky or Stage III/IV follicular lymphoma

Treatment Phase: Maintenance therapy

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug under the previously untreated initial restriction, **AND**
- The condition must be CD20 positive, **AND**
- Patient must have demonstrated a partial or complete response to PBS subsidised induction treatment with this drug for this condition, **AND**
- The treatment must be maintenance therapy, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed 12 doses or 2 years duration of treatment, whichever comes first, under this restriction, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

**Injection**

11462G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	5	..	*4614.14	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

▪ **OBINUTUZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Follicular lymphoma

Treatment Phase: Maintenance therapy

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug under the rituximab refractory initial restriction, **AND**
- The condition must be CD20 positive, **AND**
- The condition must have been refractory to treatment with rituximab, **AND**
- Patient must have demonstrated a partial or complete response to PBS-subsidised re-induction treatment with this drug for this condition, **AND**
- The treatment must be maintenance therapy, **AND**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed 12 doses or 2 years duration of treatment, whichever comes first, under this restriction, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

### Injection

11468N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	5	..	*4614.14	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

### ■ OBINUTUZUMAB

**Note** A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

#### Authority required (STREAMLINED)

**11015**

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Treatment Phase: For combination use with venetoclax treatment cycles 1 to 6 inclusive in first-line therapy

#### **Clinical criteria:**

- The condition must be untreated, **AND**
- The treatment must be in combination with PBS-subsidised venetoclax.

### Injection

12204H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	8	..	*4614.14	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

### ■ OBINUTUZUMAB

**Note** A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

#### Authority required (STREAMLINED)

**14764**

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Treatment Phase: For combination use with acalabrutinib from treatment cycles 2 to 7 inclusive in first-line therapy

#### **Clinical criteria:**

- The condition must be untreated, **AND**
- The treatment must be in combination with PBS-subsidised acalabrutinib (refer to Product Information for timing of obinutuzumab and acalabrutinib doses).

### Injection

13787P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	5	..	*4614.14	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

### ■ OBINUTUZUMAB

**Note** The latest International Workshop on CLL (iwCLL) provides guidance on various aspects of management of CLL/SLL.

Notably, two of these are:

- (1) when to treat versus when to monitor the patient without therapy - see 'Indications for treatment' section; and
- (2) recognising progressive disease - see 'Definition of response, relapse, and refractory disease' section.

See the following literature reference for details:

Hallek, M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. **Blood** vol. 131, 25 (2018): 2745-2760.

**Note** Obinutuzumab is not to be used as monotherapy or in combination with anti-cancer drugs other than chlorambucil under this restriction. For use with venetoclax, refer to the separate listing for this purpose.

**Note** A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

#### Authority required (STREAMLINED)

**14326**

Chronic lymphocytic leukaemia (CLL)

Treatment Phase: Combination use with chlorambucil only

#### **Clinical criteria:**

- The condition must be CD20 positive, **AND**
  - The condition must be previously untreated, **AND**
  - The treatment must be in combination with chlorambucil, **AND**
  - The treatment must only be prescribed for a patient with active disease in accordance with the International Workshop on CLL (iwCLL) guidance (latest version) in relation to when to prescribe drug treatment for this condition.
- Treatment must be discontinued in patients who experience disease progression whilst on this treatment.

**Injection**

10407R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	7	..	*4614.14	31.60	Gazyva [RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial)

▪ **RITUXIMAB**

**Note** Prescribing/pharmacy claiming: prescribe/claim this benefit through the Section 100 Highly Specialised Drugs Program PBS item code(s) when administered for non-oncology indications. Prescribe/claim this benefit through the Efficient Funding of Chemotherapy PBS item code(s) when administered for oncology indications.

**Injection**

13102N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	800 mg	11	..	*434.52	31.60	Riximyo [SZ] (rituximab 100 mg/10 mL injection, 2 x 10 mL vials) Riximyo [SZ] (rituximab 500 mg/50 mL injection, 50 mL vial) Ruxience [PF] (rituximab 100 mg/10 mL injection, 10 mL vial) Ruxience [PF] (rituximab 500 mg/50 mL injection, 50 mL vial) Truxima [EW] (rituximab 100 mg/10 mL injection, 2 x 10 mL vials) Truxima [EW] (rituximab 500 mg/50 mL injection, 50 mL vial)

*CD22 (Clusters of Differentiation 22) inhibitors*

▪ **INOTUZUMAB OZOGAMICIN**

**Caution** Careful monitoring of patients is required due to risk of developing hepatotoxicity, including life-threatening hepatic veno-occlusive disease, and the increased risk of post-haematopoietic stem cell transplant non-relapse mortality observed in patients treated with inotuzumab.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Note** A complete remission is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a full recovery of peripheral blood counts with platelets of greater than 100,000 per microliter, and absolute neutrophil count (ANC) of greater than 1,000 per microliter.

**Note** A complete remission with partial haematological recovery is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a partial recovery of peripheral blood counts with platelets of greater than 50,000 per microliter, and absolute neutrophil count (ANC) of greater than 500 per microliter.

**Note** Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time when an assessment is required must cease PBS-subsidised therapy with this agent.

**Authority required**

Acute lymphoblastic leukaemia

Treatment Phase: Consolidation treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised induction treatment with this drug for this condition, **AND**
- Patient must have achieved a complete remission; OR
- Patient must have achieved a complete remission with partial haematological recovery, **AND**
- The treatment must not be more than 5 treatment cycles under this restriction in a lifetime, **AND**
- Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The treatment must not exceed 0.5mg per m<sup>2</sup> for all doses within a treatment cycle

Treatment with this drug for this condition must not exceed 6 treatment cycles in a lifetime.

**Injection**

11680R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	2820 mcg	4	..	*39416.34	31.60	Besponsa [PF] (inotuzumab ozogamicin 1 mg injection, 1 vial)

▪ **INOTUZUMAB OZOGAMICIN**

**Caution** Careful monitoring of patients is required due to risk of developing hepatotoxicity, including life-threatening hepatic veno-occlusive disease, and the increased risk of post-haematopoietic stem cell transplant non-relapse mortality observed in patients treated with inotuzumab.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patients are eligible to receive a loading dose for the first dose of a treatment cycle while receiving induction treatment. Two prescriptions are required, the first prescription for the loading dose at a dose no higher than 0.8mg per m<sup>2</sup>, and the second prescription for two doses at a dose no higher than 0.5mg per m<sup>2</sup>. Both prescriptions must be submitted with the initial application.

**Note** Once a patient achieves complete remission or complete remission with partial haematological recovery, a new prescription must be written under the consolidation treatment phase.

**Note** A complete remission is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a full recovery of peripheral blood counts with platelets of greater than 100,000 per microliter, and absolute neutrophil count (ANC) of greater than 1,000 per microliter.

**Note** A complete remission with partial haematological recovery is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a partial recovery of peripheral blood counts with platelets of greater than 50,000 per microliter, and absolute neutrophil count (ANC) of greater than 500 per microliter.

**Note** Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time when an assessment is required must cease PBS-subsidised therapy with this agent.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  
Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)  
Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)  
Or mailed to:  
Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

#### **Authority required**

Acute lymphoblastic leukaemia  
Treatment Phase: Induction treatment

#### **Clinical criteria:**

- The condition must be relapsed or refractory B-precursor cell ALL, with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, **AND**
- Patient must have received intensive combination chemotherapy for initial treatment of ALL or for subsequent salvage therapy, **AND**
- Patient must not have received more than 1 line of salvage therapy, **AND**
- Patient must have previously received a tyrosine kinase inhibitor (TKI) if the condition is Philadelphia chromosome positive, **AND**
- The condition must be CD22-positive, **AND**
- The condition must have more than 5% blasts in bone marrow, **AND**
- The treatment must not be more than 3 treatment cycles under this restriction in a lifetime.

This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The authority application must be made in writing and must include:

- (1) two completed authority prescription forms;
- (2) a completed Acute Lymphoblastic Leukaemia PBS Authority Application - Supporting Information Form; and
- (3) evidence that the condition is CD22-positive; and
- (4) date of most recent chemotherapy, and if this was the initial chemotherapy regimen or salvage therapy, including what line of salvage; and
- (5) a copy of the most recent bone marrow biopsy report of no more than one month old at the time of application.

The treatment must not exceed 0.8mg per m<sup>2</sup> for the first dose of a treatment cycle (Day 1), and 0.5mg per m<sup>2</sup> for subsequent doses (Days 8 and 15) within a treatment cycle.

Treatment with this drug for this condition must not exceed 6 treatment cycles in a lifetime.

#### **Injection**

11696N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3384 mcg	2	..	*52525.58	31.60	Besponsa [PF] (inotuzumab ozogamicin 1 mg injection, 1 vial)

#### ***CD38 (Clusters of Differentiation 38) inhibitors***

#### **■ DARATUMUMAB**

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### **Authority required**

Relapsed and/or refractory multiple myeloma  
Treatment Phase: Continuing treatment of second-line drug therapy for weeks 10 to 24 (administered every 3 weeks)

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - The treatment must be in combination with bortezomib and dexamethasone, **AND**
  - Patient must not have developed disease progression while receiving treatment with this drug for this condition.
- Progressive disease is defined as at least 1 of the following:
- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or

- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).
- Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

### Injection

12220E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1920 mg	4	..	*11772.42	31.60	Darzalex [JC] (daratumumab 100 mg/5 mL injection, 5 mL vial) Darzalex [JC] (daratumumab 400 mg/20 mL injection, 20 mL vial)

### ▪ DARATUMUMAB

- Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.
- Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.
- Note** No increase in the maximum number of repeats may be authorised.
- Note** Special Pricing Arrangements apply.

#### Authority required

Relapsed and/or refractory multiple myeloma

Treatment Phase: Initial treatment as second-line drug therapy for weeks 1 to 9 (administered once weekly)

#### **Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with bortezomib and dexamethasone, **AND**
- Patient must have progressive disease after only one prior therapy (i.e. use must be as second-line drug therapy; use as third-line drug therapy or beyond is not PBS-subsidised).

#### **Treatment criteria:**

- Patient must be undergoing treatment with this drug in one of the following situations: (i) for the first time, irrespective of whether the diagnosis has been reclassified (i.e. the diagnosis has changed between multiple myeloma/amyloidosis), (ii) changing the drug's form (intravenous/subcutaneous) within the first 9 weeks of treatment for the same PBS indication.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

Details of: the histological diagnosis of multiple myeloma; prior treatments including name(s) of drug(s) and date of most recent treatment cycle; the basis of the diagnosis of progressive disease or failure to respond; and which disease activity parameters will be used to assess response, must be documented in the patient's medical records.

Confirmation of eligibility for treatment with current diagnostic reports of at least one of the following must be documented in the patient's medical records:

- (a) the level of serum monoclonal protein; or
- (b) Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or
- (c) the serum level of free kappa and lambda light chains; or
- (d) bone marrow aspirate or trephine; or
- (e) if present, the size and location of lytic bone lesions (not including compression fractures); or
- (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or
- (g) if present, the level of hypercalcaemia, corrected for albumin concentration.

As these parameters must be used to determine response, results for either (a) or (b) or (c) should be documented for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g)

must be documented in the patient's medical records. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be documented in the patient's medical records.

A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner.

A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity, with the exception to this being the need to attain a sufficient response for stem cell transplantation to proceed. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.

## Injection

12228N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1920 mg	8	..	*11772.42	31.60	Darzalex [JC] (daratumumab 100 mg/5 mL injection, 5 mL vial) Darzalex [JC] (daratumumab 400 mg/20 mL injection, 20 mL vial)

### ■ DARATUMUMAB

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required

Relapsed and/or refractory multiple myeloma

Treatment Phase: Continuing treatment of second-line drug therapy from week 25 until disease progression (administered every 4 weeks)

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition. Progressive disease is defined as at least 1 of the following:
  - (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
  - (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
  - (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
  - (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
  - (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
  - (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
  - (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

## Injection

12231R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1920 mg	5	..	*11772.42	31.60	Darzalex [JC] (daratumumab 100 mg/5 mL injection, 5 mL vial) Darzalex [JC] (daratumumab 400 mg/20 mL injection, 20 mL vial)

### ■ DARATUMUMAB

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required

Relapsed and/or refractory multiple myeloma

Treatment Phase: Grandfather treatment - Transitioning from non-PBS to PBS-subsidised supply

**Clinical criteria:**

- Patient must have received non-PBS-subsidised treatment with this drug for this condition prior to 1 January 2021, **AND**
- Patient must have met all initial treatment PBS-eligibility criteria applying to a non-grandfathered patient prior to having commenced treatment with this drug, which are: (i) the condition was confirmed by histological diagnosis, (ii) the treatment is/was being used as part of triple combination therapy with bortezomib and dexamethasone, (iii) the condition progressed (see definition of progressive disease below) after one prior therapy, but not after more than two prior lines of therapies (i.e. this drug was commenced as second-line treatment), (iv) the treatment was/is not to be used in combination with another PBS-subsidised drug indicated for this condition outside of the intended combination where stated, and (v) the patient had never been treated with this drug, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

Details of: the histological diagnosis of multiple myeloma; prior treatments including name(s) of drug(s) and date of most recent treatment cycle; the basis of the diagnosis of progressive disease or failure to respond; and which disease activity parameters will be used to assess response, must be documented in the patient's medical records.

Confirmation of eligibility for treatment with current diagnostic reports of at least one of the following must be documented in the patient's medical records:

- (a) the level of serum monoclonal protein; or
- (b) Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or
- (c) the serum level of free kappa and lambda light chains; or
- (d) bone marrow aspirate or trephine; or
- (e) if present, the size and location of lytic bone lesions (not including compression fractures); or
- (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or
- (g) if present, the level of hypercalcaemia, corrected for albumin concentration.

As these parameters must be used to determine response, results for either (a) or (b) or (c) should be documented for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) must be documented in the patient's medical records. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be documented in the patient's medical records.

A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner.

A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity, with the exception to this being the need to attain a sufficient response for stem cell transplantation to proceed. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.

**Injection**

12229P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1920 mg	7	..	*11772.42	31.60	Darzalex [JC] (daratumumab 100 mg/5 mL injection, 5 mL vial) Darzalex [JC] (daratumumab 400 mg/20 mL injection, 20 mL vial)

**HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors**

▪ **PERTUZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Authority required**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have evidence of human epidermal growth factor receptor 2 (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) either in the primary tumour or a metastatic lesion, confirmed through a pathology report from an Approved Pathology Authority, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must not have received prior anti-HER2 therapy for this condition, **AND**
- Patient must not have received prior chemotherapy for this condition, **AND**
- The treatment must be in combination with trastuzumab and a taxane, **AND**
- The treatment must not be in combination with nab-paclitaxel, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

Details (date, unique identifying number/code, or provider number) of the pathology report from an Approved Pathology Authority confirming evidence of HER2 gene amplification in the primary tumour or a metastatic lesion by in situ hybridisation (ISH) must be provided at the time of application.

The pathology report must be documented in the patient's medical records.

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to seeking the initial authority approval.

### Injection

10267J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	840 mg	..	..	*5926.12	31.60	Perjeta [RO] (pertuzumab 420 mg/14 mL injection, 14 mL vial)

### ▪ PERTUZUMAB

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** The criterion that limits breaks in treatment with pertuzumab under this restriction has been temporarily modified due to the current risk of COVID-19. This allows an extended break in therapy with PBS-subsidised pertuzumab in patients who are at risk of COVID-19.

#### Authority required

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have previously been issued with an authority prescription for this drug for this condition, **AND**
- Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug, **AND**
- The treatment must be in combination with trastuzumab, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.

The treatment must not exceed a lifetime total of one course. However, treatment breaks are permitted. A patient who has a treatment break in PBS-subsidised treatment with this drug for reasons other than disease progression is eligible to continue to receive PBS-subsidised treatment with this drug.

Where a patient has had a treatment break the length of the break is measured from the date the most recent treatment was stopped to the date of the application for further treatment.

### Injection

10333W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	420 mg	3	..	*3007.37	31.60	Perjeta [RO] (pertuzumab 420 mg/14 mL injection, 14 mL vial)

### ▪ TRASTUZUMAB

**Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

#### Authority required (STREAMLINED)

**10296**

Early HER2 positive breast cancer

Treatment Phase: Initial treatment (weekly regimen)

#### **Clinical criteria:**

- Patient must have undergone surgery (adjuvant) or be preparing for surgery (neoadjuvant), **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
- Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR
- Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance.

HER2 positivity must be demonstrated by in situ hybridisation (ISH).

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

**Injection**

4632T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	500 mg	..	..	*467.00	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

▪ **TRASTUZUMAB**

**Note** Increased maximum quantity will be authorised where a patient requires a new loading dose due to a break in therapy of more than 1 week but less than 6 weeks from the last dose or a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required (STREAMLINED)**

**10213**

Early HER2 positive breast cancer

Treatment Phase: Continuing treatment (weekly regimen)

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
- Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR
- Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance.

**Injection**

4639E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	250 mg	9	..	*328.55	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

▪ **TRASTUZUMAB**

**Note** Increased maximum quantity will be authorised where a patient requires a new loading dose due to a break in therapy of more than 1 week but less than 6 weeks from the last dose or a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required (STREAMLINED)**

**10294**

Early HER2 positive breast cancer

Treatment Phase: Continuing treatment (3 weekly regimen)

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
- Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR
- Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance.

**Injection**

4703M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	750 mg	3	..	*706.93	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

## ■ TRASTUZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum quantity will be authorised where a patient's weight is greater than 125 kg.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

### Authority required (STREAMLINED)

**9353**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have evidence of human epidermal growth factor receptor 2 (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) either in the primary tumour or a metastatic lesion, **AND**
- The treatment must not be in combination with nab-paclitaxel, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

### **Injection**

10391X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	..	..	*845.38	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

## ■ TRASTUZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum quantity will be authorised where a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

### Authority required (STREAMLINED)

**9349**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

Where a patient has a break in trastuzumab therapy of more than 1 week from when the last dose was due, a new loading dose may be required.

### **Injection**

10401K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	750 mg	3	..	*706.93	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

## ■ TRASTUZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum quantity will be authorised where a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

### Authority required (STREAMLINED)

**9573**

Metastatic (Stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have evidence of human epidermal growth factor receptor 2 (HER2) positivity as demonstrated by immunohistochemistry 2+ or more in tumour material, **AND**

- Patient must have evidence of HER2 gene amplification as demonstrated by in situ hybridisation results based on more than 6 copies of HER2 in the same tumour tissue sample, **AND**
  - Patient must have evidence of HER2 gene amplification as demonstrated by in situ hybridisation results based on the ratio of HER2 to chromosome 17 being more than 2 in the same tumour tissue sample, **AND**
  - Patient must commence treatment in combination with platinum based chemotherapy and capecitabine; OR
  - Patient must commence treatment in combination with platinum based chemotherapy and 5 fluorouracil, **AND**
  - Patient must not have previously received this drug for this condition, **AND**
  - Patient must not have received prior chemotherapy for this condition, **AND**
  - Patient must have a WHO performance status of 2 or less, **AND**
  - The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.
- Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

**Injection**

10581X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	..	..	*845.38	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

▪ **TRASTUZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum quantity will be authorised where a patient requires a new loading dose due to a break in therapy of more than 1 week but less than 6 weeks from the last dose or a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required (STREAMLINED)**

**9571**

Metastatic (Stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

**Injection**

10588G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	750 mg	3	..	*706.93	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

▪ **TRASTUZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.

**Note** Authority applications for increased quantities/ repeats (where relevant) may be made by telephone to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required (STREAMLINED)**

**10293**

Early HER2 positive breast cancer

Treatment Phase: Initial treatment (3 weekly regimen)

**Clinical criteria:**

- Patient must have undergone surgery (adjuvant) or be preparing for surgery (neoadjuvant), **AND**
  - The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
  - Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR
  - Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance.
- HER2 positivity must be demonstrated by in situ hybridisation (ISH).

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

### Injection

4650R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1000 mg	..	..	*845.38	31.60	Herzuma [EW] (trastuzumab 150 mg injection, 1 vial) Herzuma [EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack) Kanjinti [JU] (trastuzumab 150 mg injection, 1 vial) Kanjinti [JU] (trastuzumab 420 mg injection, 1 vial) Ogivri [AF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 150 mg injection, 1 vial) Trazimera [PF] (trastuzumab 60 mg injection, 1 vial)

### ■ TRASTUZUMAB DERUXTECAN

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### **Authority required**

Metastatic (Stage IV) HER2 positive breast cancer

#### **Clinical criteria:**

- Patient must have evidence of human epidermal growth factor (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) in either the primary tumour/a metastatic lesion - establish this finding once only with the first PBS prescription, **AND**
- The condition must have progressed following treatment with at least one prior HER2 directed regimen for metastatic breast cancer; **OR**
- The condition must have, at the time of treatment initiation with this drug, progressed during/within 6 months following adjuvant treatment with a HER2 directed therapy, **AND**
- Patient must have, at the time of initiating treatment with this drug, a WHO performance status no higher than 1, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication, **AND**
- The treatment must not be prescribed where any of the following is present: (i) left ventricular ejection fraction of less than 50%, (ii) symptomatic heart failure; confirm cardiac function testing for the first PBS prescription only.

#### **Treatment criteria:**

- Patient must be undergoing initial treatment with this drug - the following are true: (i) this is the first prescription for this drug, (ii) this prescription seeks no more than 3 repeat prescriptions; **OR**
- Patient must be undergoing continuing treatment with drug - the following are true: (i) there has been an absence of further disease progression whilst on active treatment with this drug, (ii) this prescription does not seek to re-treat after disease progression, (iii) this prescription seeks no more than 8 repeat prescriptions.

Confirm that the following information is documented/retained in the patient's medical records once only with the first PBS prescription:

- 1) Evidence of HER2 gene amplification (evidence obtained in relation to past PBS treatment is acceptable).
- 2) Details of prior HER2 directed drug regimens prescribed for the patient.
- 3) Cardiac function test results (evidence obtained in relation to past PBS treatment is acceptable).

### Injection

13718B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	675 mg	8	..	*17540.04	31.60	Enhertu [AP] (trastuzumab deruxtecan 100 mg injection, 1 vial)

### ■ TRASTUZUMAB EMTANSINE

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

#### **Authority required**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have evidence of human epidermal growth factor receptor 2 (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) either in the primary tumour or a metastatic lesion, confirmed through a pathology report from an Approved Pathology Authority, **AND**
- The condition must have progressed following treatment with pertuzumab and trastuzumab in combination; **OR**
- The condition must have progressed during or within 6 months of completing adjuvant therapy with trastuzumab, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**

- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

The following information must be provided by the prescriber at the time of application:

(a) details (date, unique identifying number/code or provider number) of the pathology report from an Approved Pathology Authority confirming evidence of HER2 gene amplification in the primary tumour or a metastatic lesion by in situ hybridisation (ISH).

(b) dates of treatment with trastuzumab and pertuzumab;

(c) date of demonstration of progression following treatment with trastuzumab and pertuzumab; or

(d) date of demonstration of progression and date of completion of adjuvant trastuzumab treatment.

If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.

All reports must be documented in the patient's medical records.

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to seeking the initial authority approval.

**Authority required**

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for metastatic (Stage IV) HER2 positive breast cancer, **AND**
- Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.

The treatment must not exceed a lifetime total of one continuous course for this PBS indication.

**Injection**

10282E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	450 mg	8	..	*7268.61	31.60	Kadcyla [RO] (trastuzumab emtansine 100 mg injection, 1 vial) Kadcyla [RO] (trastuzumab emtansine 160 mg injection, 1 vial)

**▪ TRASTUZUMAB EMTANSINE**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Increased maximum amounts can be requested where a patient's weight is greater than 125 kg.

**Authority required**

Early HER2 positive breast cancer

Treatment Phase: Initial adjuvant treatment

**Clinical criteria:**

- The treatment must be prescribed within 12 weeks after surgery, **AND**
- Patient must have, prior to commencing treatment with this drug, evidence of residual invasive cancer in the breast and/or axillary lymph nodes following completion of surgery, as demonstrated by a pathology report, **AND**
- Patient must have completed systemic neoadjuvant therapy that included trastuzumab and taxane-based chemotherapy prior to surgery, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
- The treatment must not extend beyond 42 weeks (14 cycles) duration under the initial and the continuing treatment restrictions combined.

Authority applications for initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include:

(a) details (date, unique identifying number/code or provider number) of the pathology report from an Approved Pathology Authority demonstrating evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes following completion of surgery.

The pathology report must be documented in the patient's medical records.

If the application is submitted through HPOS form upload or mail, it must include:

- (i) A completed authority prescription form; and
- (ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health

Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)  
 Or mailed to:  
 Services Australia  
 Complex Drugs  
 Reply Paid 9826  
 HOBART TAS 7001

**Authority required**

Early HER2 positive breast cancer  
 Treatment Phase: Continuing adjuvant treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
- The treatment must not extend beyond 42 weeks (14 cycles) duration under the initial and the continuing treatment restrictions combined.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Injection**

11951B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	450 mg	6	..	*7268.61	31.60	Kadcyla [RO] (trastuzumab emtansine 100 mg injection, 1 vial) Kadcyla [RO] (trastuzumab emtansine 160 mg injection, 1 vial)

*EGFR (Epidermal Growth Factor Receptor) inhibitors*

▪ **CETUXIMAB**

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12470**

Metastatic colorectal cancer  
 Treatment Phase: Continuing treatment

**Clinical criteria:**

- The treatment must be in combination with PBS-subsidised encorafenib for this condition.

**Injection**

12816M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	550 mg	11	..	*1699.77	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12483**

Metastatic colorectal cancer  
 Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be in combination with PBS-subsidised encorafenib for this condition.

**Injection**

12820R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	880 mg	..	..	*2505.36	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** A maximum lifetime supply for this indication is limited to a maximum of 8 treatments per site and to 10 treatments per site for patients in whom radiotherapy is interrupted.

**Authority required (STREAMLINED)**

**4788**

Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx  
 Treatment Phase: Continuing treatment

**Clinical criteria:**

- The treatment must be in combination with radiotherapy, **AND**
- Patient must be unable to tolerate cisplatin; OR
- Patient must have a contraindication to cisplatin according to the TGA-approved Product Information.

**Injection**

4435K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	550 mg	5	..	*1699.77	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Authority required (STREAMLINED)**

**4794**

Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be for the week prior to radiotherapy, **AND**
- Patient must have a contraindication to cisplatin according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**4785**

Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be in combination with radiotherapy, **AND**
- Patient must be unable to tolerate cisplatin.

**Injection**

4312Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	880 mg	..	..	*2505.36	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** Special Pricing Arrangements apply.

**Note** This drug is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.

**Authority required (STREAMLINED)**

**12045**

Metastatic colorectal cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have RAS wild-type metastatic colorectal cancer, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The condition must have failed to respond to first-line chemotherapy; OR
- The condition must have progressed following first-line treatment with pembrolizumab for dMMR mCRC, **AND**
- The treatment must be as monotherapy; OR
- The treatment must be in combination with chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on panitumumab are not eligible to receive PBS-subsidised cetuximab.

Patients who have developed intolerance to panitumumab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised cetuximab.

**Authority required (STREAMLINED)**

**4908**

Metastatic colorectal cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have RAS wild-type metastatic colorectal cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must be previously untreated, **AND**
- The treatment must be in combination with first-line chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

**Injection**

4436L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	880 mg	..	..	*2505.36	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

**Note** Special Pricing Arrangements apply.

- Note** This drug is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.
- Note** This drug is not PBS-subsidised when chemotherapy partners are switched whilst maintaining an anti-EGFR antibody backbone in the face of progressive disease.
- Note** The treatment must not exceed a single course of therapy with this drug for metastatic colorectal cancer in a patient's lifetime.

**Authority required (STREAMLINED)**

**4912**

Metastatic colorectal cancer  
Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have received an initial authority prescription for this drug for first-line treatment of RAS wild-type metastatic colorectal cancer, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must be in combination with first-line chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

**Injection**

10262D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	550 mg	18	..	*1699.77	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **CETUXIMAB**

- Note** Special Pricing Arrangements apply.
- Note** This drug is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.
- Note** This drug is not PBS-subsidised when chemotherapy partners are switched whilst maintaining an anti-EGFR antibody backbone in the face of progressive disease.
- Note** The treatment must not exceed a single course of therapy with this drug for metastatic colorectal cancer in a patient's lifetime.

**Authority required (STREAMLINED)**

**12016**

Metastatic colorectal cancer  
Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of first-line chemotherapy; OR
- Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of treatment with first-line pembrolizumab for dMMR mCRC, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must be as monotherapy; OR
- The treatment must be in combination with chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on panitumumab are not eligible to receive PBS-subsidised cetuximab.  
Patients who have developed intolerance to panitumumab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised cetuximab.

**Injection**

4731B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	550 mg	11	..	*1699.77	31.60	Erbitux [SG] (cetuximab 100 mg/20 mL injection, 20 mL vial) Erbitux [SG] (cetuximab 500 mg/100 mL injection, 100 mL vial)

▪ **PANITUMUMAB**

- Note** This drug is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.

**Authority required (STREAMLINED)**

**12066**

Metastatic colorectal cancer  
Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have RAS wild-type metastatic colorectal cancer, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The condition must have failed to respond to first-line chemotherapy; OR
- The condition must have progressed following first-line treatment with pembrolizumab for dMMR mCRC, **AND**
- The treatment must be as monotherapy; OR
- The treatment must be in combination with chemotherapy, **AND**

- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition. Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab. Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.

**Authority required (STREAMLINED)**

**12035**

Metastatic colorectal cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of first-line chemotherapy; OR
- Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of treatment with first-line pembrolizumab for dMMR mCRC, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must be as monotherapy; OR
- The treatment must be in combination with chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab.

Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.

**Note** This drug is not PBS-subsidised when chemotherapy partners are switched whilst maintaining an anti-EGFR antibody backbone in the face of progressive disease.

**Note** The treatment must not exceed a single course of therapy with this drug for metastatic colorectal cancer in a patient's lifetime.

**Injection**

10082P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	720 mg	5	..	*3881.60	31.60	Vectibix [AN] (panitumumab 100 mg/5 mL injection, 5 mL vial) Vectibix [AN] (panitumumab 400 mg/20 mL injection, 20 mL vial)

**▪ PANITUMUMAB**

**Note** Special Pricing Arrangements apply.

**Note** Panitumumab is not PBS-subsidised for use in combination with another anti-EGFR antibody or in combination with an anti-VEGF antibody.

**Authority required (STREAMLINED)**

**5526**

Metastatic colorectal cancer

Treatment Phase: Initial Treatment

**Clinical criteria:**

- Patient must have RAS wild-type metastatic colorectal cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must be previously untreated, **AND**
- The treatment must be in combination with first-line chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab.

Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.

**Authority required (STREAMLINED)**

**5452**

Metastatic colorectal cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have received an initial authority prescription for panitumumab for first-line treatment of RAS wild-type metastatic colorectal cancer, **AND**
- Patient must not have progressive disease, **AND**
- The treatment must be in combination with first-line chemotherapy, **AND**
- The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.

Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab.

Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.

**Note** This drug is not PBS-subsidised when chemotherapy partners are switched whilst maintaining an anti-EGFR antibody backbone in the face of progressive disease.

**Note** The treatment must not exceed a single course of therapy with this drug for metastatic colorectal cancer in a patient's lifetime.

**Injection**

10513H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	720 mg	9	..	*3881.60	31.60	Vectibix [AN] (panitumumab 100 mg/5 mL injection, 5 mL vial) Vectibix [AN] (panitumumab 400 mg/20 mL injection, 20 mL vial)

**PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors****▪ ATEZOLIZUMAB****Note** No increase in the maximum number of repeats may be authorised.**Note** Special Pricing Arrangements apply.**Authority required (STREAMLINED)****10297**

Locally advanced or metastatic non-small cell lung cancer

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- Patient must have stable or responding disease.

**Injection**

11277M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	7	..	*6835.99	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

**▪ ATEZOLIZUMAB****Note** No increase in the maximum number of repeats may be authorised.**Note** Special Pricing Arrangements apply.**Authority required (STREAMLINED)****10216**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing first-line treatment of metastatic disease - 3 weekly treatment regimen

**Treatment criteria:**

- Patient must be undergoing combination treatment with bevacizumab until disease progression, unless not tolerated.

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug in this line of treatment, **AND**
- Patient must have stable or responding disease.

**Injection**

11802E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	7	..	*6835.99	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

**▪ ATEZOLIZUMAB****Note** No increase in the maximum number of repeats may be authorised.**Note** Special Pricing Arrangements apply.**Authority required (STREAMLINED)****10215**

Locally advanced or metastatic non-small cell lung cancer

Treatment Phase: Continuing treatment - 4 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have stable or responding disease.

**Injection**

11930X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	5	..	*9534.92	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

**▪ ATEZOLIZUMAB****Note** No increase in the maximum number of repeats may be authorised.**Note** Special Pricing Arrangements apply.**Authority required (STREAMLINED)****10257**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing first-line treatment of metastatic disease, as monotherapy, where concomitant bevacizumab has ceased due to intolerance - 4 weekly treatment regimen

**Clinical criteria:**

- Patient must have experienced intolerance to combination treatment with bevacizumab, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug in this line of treatment, **AND**
- Patient must have stable or responding disease, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Injection**

12097Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	5	..	*9534.92	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

▪ **ATEZOLIZUMAB**

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**13443**

Locally advanced or metastatic non-small cell lung cancer  
Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The condition must have progressed on or after prior platinum based chemotherapy; OR
- The condition must have progressed after treatment with tepotinib.

**Injection**

11284X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	5	..	*6835.99	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

▪ **ATEZOLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10206**

Extensive-stage small cell lung cancer  
Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be previously untreated, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be in combination with etoposide and a platinum-based antineoplastic drug.

**Injection**

11926Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	3	..	*6835.99	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

▪ **ATEZOLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10521**

Extensive-stage small cell lung cancer  
Treatment Phase: Continuing treatment - 3 weekly treatment regimen

**Clinical criteria:**

- The treatment must be as monotherapy, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

**Injection**

11929W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	4	..	*6835.99	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

## ▪ ATEZOLIZUMAB

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

**13446**

Locally advanced or metastatic non-small cell lung cancer

Treatment Phase: Initial treatment - 4 weekly treatment regimen

#### **Clinical criteria:**

- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The condition must have progressed on or after prior platinum based chemotherapy; OR
- The condition must have progressed after treatment with tepotinib.

### **Injection**

11931Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	3	..	*9534.92	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

## ▪ ATEZOLIZUMAB

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

**10509**

Extensive-stage small cell lung cancer

Treatment Phase: Continuing treatment - 4 weekly treatment regimen

#### **Clinical criteria:**

- The treatment must be as monotherapy, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

### **Injection**

12078Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	3	..	*9534.92	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

## ▪ ATEZOLIZUMAB

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

**10917**

Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma

Treatment Phase: Continuing treatment of hepatocellular carcinoma - 3 weekly treatment regimen

#### **Treatment criteria:**

- Patient must be undergoing combination treatment with bevacizumab until disease progression, unless not tolerated.

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - Patient must not have developed disease progression while being treated with this drug for this condition.
- PBS supply of this drug must be through only one of the two continuing treatment regimens at any given time

### **Injection**

12168K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	8	..	*6835.99	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

## ▪ ATEZOLIZUMAB

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** Increased repeats of up to 11 may be requested for doses of 840 mg administered every 2 weeks

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

**10972**

Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma

Treatment Phase: Continuing treatment where bevacizumab is discontinued - 4 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - Patient must not have developed disease progression while being treated with this drug for this condition.
- PBS supply of this drug must be through only one of the two continuing treatment regimens at any given time

**Injection**

12174R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	5	..	*9534.92	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

▪ **ATEZOLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**13451**

Resected early stage (Stage II to IIIA) non-small cell lung cancer (NSCLC)

Treatment Phase: 1,680 mg administered once every 4 weeks, or 840 mg every 2 weeks

**Population criteria:**

- Patient must be both: (i) initiating treatment, (ii) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy; OR
- Patient must be continuing existing PBS-subsidised treatment with this drug; OR
- Patient must be both: (i) transitioning from existing non-PBS to PBS subsidised supply of this drug, (ii) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy at the time this drug was initiated.

**Clinical criteria:**

- Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug.
- AND**
- The treatment must be for the purpose of adjuvant therapy following all of: (i) surgical resection, (ii) platinum-based chemotherapy, **AND**
  - The condition must have/have had, at treatment commencement, an absence of each of the following gene abnormalities confirmed via tumour material sampling: (i) an activating epidermal growth factor receptor (EGFR) gene mutation, (ii) an anaplastic lymphoma kinase (ALK) gene rearrangement, **AND**
  - The condition must have/have had, at treatment commencement, confirmation of programmed cell death ligand 1 (PD-L1) expression on at least 50% of tumour cells, **AND**
  - The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment that does not occur beyond the following, whichever comes first: (i) the first instance of disease progression/recurrence, (ii) 12 months in total for this condition from the first administered dose; mark any remaining repeat prescriptions with the words 'cancelled' where (i)/(ii) has occurred.

**Injection**

13173H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1680 mg	5	..	*9534.92	31.60	Tecentriq [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial)

▪ **ATEZOLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**13442**

Resected early stage (Stage II to IIIA) non-small cell lung cancer (NSCLC)

Treatment Phase: 1,200 mg administered once every 3 weeks

**Population criteria:**

- Patient must be both: (i) initiating treatment, (ii) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy; OR
- Patient must be continuing existing PBS-subsidised treatment with this drug; OR
- Patient must be both: (i) transitioning from existing non-PBS to PBS subsidised supply of this drug, (ii) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy at the time this drug was initiated.

**Clinical criteria:**

- Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug.
- AND**
- The treatment must be for the purpose of adjuvant therapy following all of: (i) surgical resection, (ii) platinum-based chemotherapy, **AND**
  - The condition must have/have had, at treatment commencement, an absence of each of the following gene abnormalities confirmed via tumour material sampling: (i) an activating epidermal growth factor receptor (EGFR) gene mutation, (ii) an anaplastic lymphoma kinase (ALK) gene rearrangement, **AND**

- The condition must have/have had, at treatment commencement, confirmation of programmed cell death ligand 1 (PD-L1) expression on at least 50% of tumour cells, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment that does not occur beyond the following, whichever comes first: (i) the first instance of disease progression/recurrence, (ii) 12 months in total for this condition from the first administered dose; mark any remaining repeat prescriptions with the words 'cancelled' where (i)/(ii) has occurred.

**Injection**

13174J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	7	..	*6835.99	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

▪ **ATEZOLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13448**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment 1

**Treatment criteria:**

- Patient must be undergoing combination treatment with bevacizumab and platinum-doublet chemotherapy.

**Clinical criteria:**

- The condition must be non-squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene mutation or an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material.

**Authority required (STREAMLINED)**

**10125**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment 2

**Treatment criteria:**

- Patient must be undergoing combination treatment with bevacizumab and platinum-doublet chemotherapy.

**Clinical criteria:**

- The condition must be non-squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must have evidence of an activating epidermal growth factor receptor (EGFR) gene mutation or of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material, **AND**
- Patient must have progressive disease following treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) OR an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer.

**Injection**

11807K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	5	..	*6835.99	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

▪ **ATEZOLIZUMAB**

**Caution** The safety of atezolizumab in combination with bevacizumab has not been established in patients who have incompletely treated varices, variceal bleeding within the previous 6 months or who are at high risk of bleeding. Patients should be assessed for risk of variceal bleeding prior to treatment with this combination.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10939**

Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma

Treatment Phase: Initial treatment

**Treatment criteria:**

- Patient must be undergoing combination treatment with bevacizumab and atezolizumab until disease progression, unless not tolerated.

**Clinical criteria:**

- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must not be suitable for transarterial chemoembolisation, **AND**
- Patient must have Child Pugh class A, **AND**
- The condition must be untreated with systemic therapy; **OR**
- Patient must have developed intolerance to a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) of a severity necessitating permanent treatment withdrawal.

**Injection**

12171N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	3	..	*6835.99	31.60	Tecentriq [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial)

▪ **AVELUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10023**

Stage IV (metastatic) Merkel Cell Carcinoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a maximum dose of 10 mg per kg every 2 weeks under this restriction.

**Injection**

11671G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	11	..	*8232.78	31.60	Bavencio [SG] (avelumab 200 mg/10 mL injection, 10 mL vial)

▪ **AVELUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**8947**

Stage IV (metastatic) Merkel Cell Carcinoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed a total of 9 doses at a maximum dose of 10 mg per kg every 2 weeks under this restriction.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Injection**

11695M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	8	..	*8232.78	31.60	Bavencio [SG] (avelumab 200 mg/10 mL injection, 10 mL vial)

▪ **AVELUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**13290**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Maintenance therapy - Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Injection**

13126W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	800 mg	11	..	*5518.06	31.60	Bavencio [SG] (avelumab 200 mg/10 mL injection, 10 mL vial)

## ■ AVELUMAB

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

**13313**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Maintenance therapy - Initial treatment

#### **Clinical criteria:**

- Patient must have received first-line platinum-based chemotherapy, **AND**
- Patient must not have progressive disease following first-line platinum-based chemotherapy, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

### **Authority required (STREAMLINED)**

**13303**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Maintenance therapy - Grandfathering treatment

#### **Clinical criteria:**

- Patient must have received non-PBS-subsidised treatment with this drug for this PBS indication prior to 1 October 2022, **AND**
- Patient must have received first-line platinum-based chemotherapy prior to initiation of non-PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have progressive disease following first-line platinum-based chemotherapy, **AND**
- Patient must have had a WHO performance status of 0 or 1 prior to initiation of non-PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

### **Injection**

13122P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	800 mg	7	..	*5518.06	31.60	Bavencio [SG] (avelumab 200 mg/10 mL injection, 10 mL vial)

## ■ CEMIPILIMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

**13373**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The treatment must not exceed a total of 35 cycles or up to 24 months of treatment under both initial and continuing treatment restrictions, whichever comes first.

### **Injection**

13161Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	350 mg	6	..	*7378.62	31.60	Libtayo [SW] (cemiplimab 350 mg/7 mL injection, 7 mL vial)

## ■ CEMIPILIMAB

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required (STREAMLINED)**

**13766**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death 1 (PD-1) inhibitor or a programmed cell death ligand 1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must express programmed cell death ligand 1 (PD-L1) with a tumour proportion score (TPS) of at least 50% in the tumour sample. **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The treatment must not exceed a total of 7 doses under this restriction.

**Injection**

13169D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	350 mg	6	..	*7378.62	31.60	Libtayo [SW] (cemiplimab 350 mg/7 mL injection, 7 mL vial)

▪ **CEMIPLIMAB**

**Caution** In the first few months after starting immunotherapy, a transient tumour flare may occur that may be mistaken as disease progression despite an overall positive response to treatment.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Authority required**

Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)

Treatment Phase: Initial treatment covering the first 3 treatment cycles

**Clinical criteria:**

- The condition must be unsuitable for each of: (i) curative surgical resection, (ii) curative radiotherapy, **AND**
- Patient must have had a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Injection**

13152F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	350 mg	2	..	*7378.62	31.60	Libtayo [SW] (cemiplimab 350 mg/7 mL injection, 7 mL vial)

▪ **CEMIPLIMAB**

**Caution** In the first few months after starting immunotherapy, a transient tumour flare may occur that may be mistaken as disease progression despite an overall positive response to treatment.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Authority required**

Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised therapy with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must not be undergoing treatment with this drug as a PBS benefit where the treatment duration extends beyond the following, whichever comes first: (i) disease progression despite treatment with this drug, (ii) 24 months from treatment initiation; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

**Authority required**

Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

**Clinical criteria:**

- Patient must have received non-PBS-subsidised therapy with this drug for this condition prior to 1 November 2022, **AND**
- The condition must be unsuitable for each of: (i) curative surgical resection, (ii) curative radiotherapy, **AND**
- Patient must have had a WHO performance status of 0 or 1 prior to initiation of non-PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must not be undergoing treatment with this drug as a PBS benefit where the treatment duration extends beyond the following, whichever comes first: (i) disease progression despite treatment with this drug, (ii) 24 months from treatment initiation; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

### Injection

13159N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	350 mg	7	..	*7378.62	31.60	Libtayo [SW] (cemiplimab 350 mg/7 mL injection, 7 mL vial)

### ■ DURVALUMAB

**Note** Special Pricing Arrangements apply.

#### Authority required (STREAMLINED)

**10126**

Unresectable Stage III non-small cell lung cancer

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have received platinum based chemoradiation therapy, **AND**
- The condition must not have progressed following platinum based chemoradiation therapy, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must not have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.

#### Authority required (STREAMLINED)

**12271**

Unresectable Stage III non-small cell lung cancer

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The treatment must not exceed 12 months in total for this condition under the initial and continuing restriction combined, **AND**
- The treatment must be once in a lifetime with this drug for this condition.

### Injection

11915D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1500 mg	4	..	*11417.37	31.60	Imfinzi [AP] (durvalumab 120 mg/2.4 mL injection, 2.4 mL vial)
						Imfinzi [AP] (durvalumab 500 mg/10 mL injection, 10 mL vial)

### ■ DURVALUMAB

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required (STREAMLINED)

**14708**

Locally advanced, metastatic or recurrent biliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer)

#### **Population criteria:**

- Patient must have either of the following at treatment initiation: (i) locally advanced biliary tract cancer that is untreated with systemic anti-cancer therapy in the unresectable setting, (ii) metastatic biliary tract cancer that is untreated with systemic anti-cancer therapy in the metastatic setting.

#### **Clinical criteria:**

- Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug. **AND**
- The treatment must be/have been initiated with both: (i) gemcitabine, (ii) cisplatin (refer to Product Information of gemcitabine and cisplatin for dosing information), **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

### Injection

13767N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1500 mg	5	..	*11417.37	31.60	Imfinzi [AP] (durvalumab 120 mg/2.4 mL injection, 2.4 mL vial)
						Imfinzi [AP] (durvalumab 500 mg/10 mL injection, 10 mL vial)

### ■ DURVALUMAB

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required (STREAMLINED)

**10206**

Extensive-stage small cell lung cancer  
Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be previously untreated, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be in combination with etoposide and a platinum-based antineoplastic drug.

**Injection**

13775B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1500 mg	3	..	*11417.37	31.60	Imfinzi [AP] (durvalumab 120 mg/2.4 mL injection, 2.4 mL vial)
						Imfinzi [AP] (durvalumab 500 mg/10 mL injection, 10 mL vial)

▪ **DURVALUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**10509**

Extensive-stage small cell lung cancer  
Treatment Phase: Continuing treatment - 4 weekly treatment regimen

**Clinical criteria:**

- The treatment must be as monotherapy, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

**Injection**

13780G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1500 mg	5	..	*11417.37	31.60	Imfinzi [AP] (durvalumab 120 mg/2.4 mL injection, 2.4 mL vial)
						Imfinzi [AP] (durvalumab 500 mg/10 mL injection, 10 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**11477**

Locally advanced or metastatic non-small cell lung cancer  
Treatment Phase: Continuing treatment as second-line drug therapy

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
  - Patient must have stable or responding disease.
- Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11153B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial)
						Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**9299**

Stage IV clear cell variant renal cell carcinoma (RCC)  
Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
  - The treatment must be the sole PBS-subsidised therapy for this condition.
- Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11160J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial)

## ■ NIVOLUMAB

**Note** Special Pricing Arrangements apply.

**Note** No increase in the maximum number of repeats may be authorised.

### Authority required (STREAMLINED)

#### 9252

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Continuing treatment

#### Clinical criteria:

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must have stable or responding disease, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

### Injection

11411N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

## ■ NIVOLUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### Authority required (STREAMLINED)

#### 9321

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Maintenance treatment

#### Clinical criteria:

- Patient must have previously received of up to maximum 4 doses of PBS-subsidised combined therapy with nivolumab and ipilimumab as induction for this condition, **AND**
- The treatment must be as monotherapy for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

### Injection

11642R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

## ■ NIVOLUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

### Authority required (STREAMLINED)

#### 10155

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Initial treatment

#### Clinical criteria:

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must not have experienced disease progression whilst on adjuvant PD-1 inhibitor treatment or disease recurrence within 6 months of completion of adjuvant PD-1 inhibitor treatment if treated for resected Stage IIIB, IIIC, IIID or IV melanoma, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

### Injection

10764M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	8	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13445**

Locally advanced or metastatic non-small cell lung cancer

Treatment Phase: Initial treatment as second-line drug therapy

**Clinical criteria:**

- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The condition must have progressed on or after prior platinum based chemotherapy; OR
- The condition must have progressed after treatment with tepotinib.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11158G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	8	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**9216**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The condition must have progressed within 6 months of the last dose of prior platinum based chemotherapy, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor for this condition.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11435W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	8	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** Response Evaluation Criteria In Solid Tumours (RECIST) is defined as follows:

Complete response (CR) is disappearance of all target lesions.

Partial response (PR) is a 30% decrease in the sum of the longest diameter of target lesions.

Progressive disease (PD) is a 20% increase in the sum of the longest diameter of target lesions.

Stable disease (SD) is small changes that do not meet above criteria.

**Authority required (STREAMLINED)**

**9312**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Initial Treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**

- Patient must have progressive disease according to the Response Evaluation Criteria in Solid Tumours (RECIST) following prior treatment with a tyrosine kinase inhibitor; OR
- Patient must have developed intolerance to a tyrosine kinase inhibitor of a severity necessitating permanent treatment withdrawal, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

### Injection

11150W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	8	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ NIVOLUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required (STREAMLINED)

**13433**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial combination treatment (with ipilimumab) as first-line drug therapy

#### **Clinical criteria:**

- The condition must be squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must be in combination with platinum-based chemotherapy for the first two cycles, **AND**
- The treatment must be in combination with ipilimumab.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

#### Authority required (STREAMLINED)

**11468**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing combination treatment (with ipilimumab) of first-line drug therapy

#### **Clinical criteria:**

- The condition must be squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed 24 months in total, measured from the initial dose, or, must not extend beyond disease progression, whichever comes first, **AND**
- The treatment must be in combination with ipilimumab.

### Injection

12323N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	360 mg	13	..	*7191.12	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ NIVOLUMAB

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** An increase of number of repeats may be authorised up to 11 if the patient is receiving a weight based dosing of 3mg/kg every 2 weeks.

#### Authority required (STREAMLINED)

**11985**

Unresectable malignant mesothelioma

**Clinical criteria:**

- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be in combination with PBS-subsidised ipilimumab, unless an intolerance to ipilimumab of a severity necessitating permanent treatment withdrawal of ipilimumab, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a maximum total of 24 months in a lifetime for this condition.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Injection**

12602G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	360 mg	8	..	*7191.12	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Caution** In the first few months after starting immunotherapy, a transient tumour flare may occur that may be mistaken as disease progression despite an overall positive response to treatment.

**Note** The stated maximum amount in this listing is based on this drug's approved Product Information recommended dosing in specific cancer types - the drug may be prescribed in a quantity up to this amount, but need not be this amount for every cancer type. Refer to this drug's approved Product Information (Dose and Method of Administration or Clinical Trials sections) for the recommended dosing in the specific cancer type.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14676**

Advanced or metastatic gastro-oesophageal cancers

**Clinical criteria:**

- Patient must have/have had, at the time of initiating treatment with this drug, a WHO performance status no higher than 1, **AND**
- Patient must be untreated (up until initiating this drug) with programmed cell death-1/ligand-1 (PD-1/PD-L1) inhibitor therapy for gastro-oesophageal cancer.

**Treatment criteria:**

- Patient must not be undergoing treatment with this drug as a PBS benefit where the treatment duration extends beyond the following, whichever comes first: (i) disease progression despite treatment with this drug, (ii) 24 months from treatment initiation; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

**Population criteria:**

- Patient must be in one of the three population subsets described below.

**Population 1**

Conditions: gastric cancer, gastro-oesophageal junction cancer, oesophageal adenocarcinoma

Concomitant therapies: chemotherapy containing at least a fluoropyrimidine drug plus a platinum drug

Line of treatment: first-line drug treatment

Additional clinical finding: HER2 negative

**Population 2**

Condition: oesophageal squamous cell carcinoma (can be recurrent)

Concomitant therapies: chemotherapy containing at least a fluoropyrimidine drug plus a platinum drug

Line of treatment: first-line drug treatment

Additional clinical finding: unresectable

**Population 3**

Condition: oesophageal squamous cell carcinoma (can be recurrent)

Line of treatment: second-line drug treatment after chemotherapy containing at least a fluoropyrimidine drug plus a platinum drug

Additional clinical finding: unresectable

**Injection**

13121N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	13	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** Up to an additional 2 repeat prescriptions (7 in total) may be sought only where dosing is on a 2-weekly schedule in the first 16 weeks of treatment. This listing's stated number of repeat prescriptions is based on 4-weekly dosing.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Adjuvant treatment of stage II or III oesophageal cancer or gastro-oesophageal junction cancer

**Clinical criteria:**

- The condition must have histological evidence confirming a diagnosis of a least one of: (i) adenocarcinoma, (ii) squamous cell cancer; document this evidence in the patient's medical records, **AND**

- The condition must have been treated with neoadjuvant platinum-based chemoradiotherapy, **AND**
- The treatment must be for the purposes of adjuvant use following complete surgical resection that occurred within 16 weeks prior to initiating this drug, **AND**
- The condition must have evidence, through resected specimen, that residual disease meets the Tumour Nodes Metastases (TNM) staging system (as published by the Union for International Cancer Control) of either: (i) at least ypT1, (ii) at least ypN1; document this evidence in the patient's medical records, **AND**
- Patient must have/have had, at the time of initiating treatment with this drug, a WHO performance status no higher than 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with a dosing regimen as set out in the drug's approved Australian Product Information, **AND**
- Patient must not be undergoing PBS-subsidised treatment with this drug where this prescription extends treatment beyond whichever comes first: (i) 12 months from treatment initiation, irrespective of whether initial treatment was PBS-subsidised/non-PBS-subsidised, (ii) disease recurrence despite treatment with this drug; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

**Injection**

13240W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	5	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note A** prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk score can be calculated here: <https://www.mdcalc.com/imdc-international-metastatic-renal-cell-carcinoma>.

One point is assigned for each of:

- (i) a time of diagnosis to systemic therapy of less than 1 year
- (ii) a Karnofsky Performance Status of less than 80%
- (iii) a haemoglobin less than the lower limit of normal
- (iv) a corrected calcium level greater than the upper limit of normal
- (v) a neutrophil count greater than the upper limit of normal
- (vi) a platelet count greater than the upper limit of normal

Stated normal reference ranges may vary depending on the laboratory providing the measurement. 'Normal' here refers to the individual laboratory's stated normal reference range.

Favourable IMDC risk is a score of 0.

Intermediate IMDC risk is a score of 1 to 2.

Poor IMDC risk is a score of 3 to 6.

Document any IMDC risk score assessment in the patient's medical records.

**Authority required (STREAMLINED)**

**14001**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must not have previously been treated, **AND**
- Patient must have a prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk classification score at treatment initiation with this drug of either: (i) 1 to 2 (intermediate risk), (ii) 3 to 6 (poor risk); document the IMDC risk classification score in the patient's medical records, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The treatment must be in combination with PBS-subsidised treatment with ipilimumab as induction for this condition. Induction treatment with nivolumab must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks. The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Injection**

11636K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	360 mg	3	..	*7191.12	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be adjuvant to complete surgical resection, **AND**
- Patient must have a WHO performance status of 1 or less, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received prior PBS-subsidised treatment for this condition, **AND**
- The treatment must commence within 12 weeks of complete resection, **AND**
- Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy. Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required**

Resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously been issued with an authority prescription for this drug for adjuvant treatment following complete surgical resection, **AND**
- Patient must not have experienced disease recurrence, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy. Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Injection**

11900H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	5	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

▪ **NIVOLUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**9298**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have previously been issued with an authority prescription for this drug for this condition, **AND**
- Patient must have stable or responding disease. Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

**Authority required (STREAMLINED)**

**13839**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Maintenance treatment

**Clinical criteria:**

- Patient must have previously received of up to maximum 4 doses of PBS-subsidised combined therapy with nivolumab and ipilimumab as induction for this condition, **AND**
- The treatment must be as monotherapy for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this PBS indication.

Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Authority required (STREAMLINED)**

**13863**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements for maintenance treatment

**Clinical criteria:**

- Patient must have previously received of up to maximum 4 doses of PBS-subsidised ipilimumab combined therapy with non-PBS-subsidised nivolumab as induction for this condition prior to 1 March 2023, **AND**
- The treatment must be as monotherapy for this condition, **AND**

- Patient must not have developed disease progression while receiving treatment with this drug for this PBS indication. Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Maintenance treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

### Injection

10745M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	480 mg	11	..	*9558.60	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ NIVOLUMAB

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required (STREAMLINED)

**13853**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Induction treatment

#### **Clinical criteria:**

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, **AND**
- The condition must not be ocular or uveal melanoma, **AND**
- The treatment must be in combination with PBS-subsidised treatment with ipilimumab as induction for this condition. Induction treatment with nivolumab must not exceed a total of 4 doses at a maximum dose of 1 mg per kg every 3 weeks. Induction treatment with ipilimumab must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

#### Authority required (STREAMLINED)

**13852**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements for combination induction therapy

#### **Clinical criteria:**

- Patient must have received non-PBS-subsidised treatment with nivolumab in combination with ipilimumab for this PBS indication prior to 1 March 2023, **AND**
- Patient must have had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to commencing non-PBS-subsidised treatment, **AND**
- The condition must not be ocular or uveal melanoma, **AND**
- The treatment must be in combination with PBS-subsidised treatment with ipilimumab as induction for this condition. Induction treatment with nivolumab must not exceed a total of 4 doses at a maximum dose of 1 mg per kg every 3 weeks. Induction treatment with ipilimumab must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Maintenance treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

### Injection

11543M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	120 mg	3	..	*2456.13	31.60	Opdivo [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) Opdivo [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial)

### ■ PEMBROLIZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

#### Authority required (STREAMLINED)

**10705**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

#### **Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have previously been issued with an authority prescription for this drug for this condition, **AND**
- Patient must have stable or responding disease.

**Injection**

10436G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	7	..	*7736.12	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**10701**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Continuing treatment - 6 weekly treatment regimen

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have previously been issued with an authority prescription for this drug for this condition, **AND**
- Patient must have stable or responding disease.

**Injection**

12124D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	3	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14727**

Stage II or Stage III triple negative breast cancer

**Clinical criteria:**

- The treatment must be initiated in combination with neoadjuvant chemotherapy, **AND**
- The condition must not have progressed/recurred whilst on treatment with this drug.

**Treatment criteria:**

- Patient must not be undergoing treatment with this drug beyond 52 cumulative weeks under this restriction, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 7 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 4 repeat prescriptions.

**Injection**

13752T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	7	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**10696**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must not have experienced disease progression whilst on adjuvant PD-1 inhibitor treatment or disease recurrence within 6 months of completion of adjuvant PD-1 inhibitor treatment if treated for resected Stage IIIB, IIIC, IIID or IV melanoma, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed a total of 6 doses under this restriction.

## Injection

10493G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	5	..	*7736.12	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

### ■ PEMBROLIZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

#### Authority required (STREAMLINED)

**10689**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Initial treatment - 6 weekly treatment regimen

#### **Clinical criteria:**

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must not have experienced disease progression whilst on adjuvant PD-1 inhibitor treatment or disease recurrence within 6 months of completion of adjuvant PD-1 inhibitor treatment if treated for resected Stage IIIB, IIIC, IIID or IV melanoma, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The treatment must not exceed a total of 3 doses under this restriction.

## Injection

12128H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	2	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

### ■ PEMBROLIZUMAB

**Note** A Combined Positive Score (CPS) is determined by:

The number of PD-L1-stained cells (tumour cells, lymphocytes, macrophages) divided by the number of all viable tumour cells (i.e. the total number of: PD-L1-positive tumour cells plus PD-L1-negative tumour cells).

Although the result of the CPS calculation can exceed 100, the maximum score is defined as CPS 100.

A minimum of 100 viable tumour cells in the PD-L1-stained slide is required for the specimen to be considered adequate for PD-L1 evaluation.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required (STREAMLINED)

**14324**

Recurrent, unresectable or metastatic triple negative breast cancer

#### **Clinical criteria:**

- The condition must have been (up until this drug therapy) untreated in the unresectable/metastatic disease stage, **AND**
- The condition must have been (up until this drug therapy) untreated with programmed cell death-1/ligand 1 (PD-1/PD-L1) inhibitor therapy in breast cancer, **AND**
- Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation, **AND**
- The treatment must be in combination with chemotherapy, **AND**
- The condition must have both: (i) programmed cell death ligand 1 (PD-L1) expression confirmed by a validated test, (ii) a Combined Positive Score (CPS) of at least 10 at treatment initiation.

#### **Treatment criteria:**

- Patient must be undergoing initial treatment with this drug - this is the first prescription for this drug; OR
- Patient must be undergoing continuing treatment with this drug - both the following are true: (i) the condition has not progressed on active treatment with this drug, (ii) this prescription does not extend PBS subsidy beyond 24 cumulative months from the first administered dose, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

## Injection

13608F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13726**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have undergone an autologous stem cell transplant (ASCT) for this condition and have experienced relapsed or refractory disease post ASCT; OR
- Patient must not be suitable for ASCT for this condition and have experienced relapsed or refractory disease following at least 2 prior treatments for this condition, **AND**
- Patient must not have received prior treatment with a PD-1 (programmed cell death-1) inhibitor for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required (STREAMLINED)**

**13741**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Injection**

11330H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13727**

Relapsed or refractory primary mediastinal B-cell lymphoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be diagnosed as primary mediastinal B-cell lymphoma through histological investigation combined with at least one of: (i) positron emission tomography - computed tomography (PET-CT) scan, (ii) PET scan, (iii) CT scan, **AND**
- Patient must have been treated with rituximab-based chemotherapy for this condition, **AND**
- Patient must be experiencing relapsed/refractory disease, **AND**
- Patient must be autologous stem cell transplant (ASCT) ineligible following a single line of treatment; OR
- Patient must have undergone an autologous stem cell transplant (ASCT); OR
- Patient must have been treated with at least 2 chemotherapy treatment lines for this condition, one of which must include rituximab-based chemotherapy, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required (STREAMLINED)**

**13732**

Relapsed or refractory primary mediastinal B-cell lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Injection**

12129J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13431**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must not exceed a total of 7 doses under this restriction.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13432**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a total of 35 cycles or up to 24 months of treatment under both initial and continuing treatment restrictions, whichever comes first.

**Injection**

11494Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	6	..	*7736.12	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13739**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The condition must have progressed on or after prior platinum based chemotherapy; OR
- The condition must have progressed on or within 12 months of completion of adjuvant platinum-containing chemotherapy following cystectomy for localised muscle-invasive urothelial cancer; OR
- The condition must have progressed on or within 12 months of completion of neoadjuvant platinum-containing chemotherapy prior to cystectomy for localised muscle-invasive urothelial cancer, **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13736**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Injection**

11646Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13436**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment - 6 weekly treatment regimen

**Clinical criteria:**

- Patient must not have previously been treated for this condition in the metastatic setting; OR
- The condition must have progressed after treatment with tepotinib, **AND**
- Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must not exceed a total of 4 doses under this restriction.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13437**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)  
Treatment Phase: Continuing treatment - 6 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a total of 18 cycles or up to 24 months of treatment under both initial and continuing treatment restrictions, whichever comes first.

**Injection**

12119W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	3	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required**

Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma  
Treatment Phase: Initial treatment - 6 weekly treatment regimen

**Clinical criteria:**

- The treatment must be adjuvant to complete surgical resection, **AND**
- Patient must have a WHO performance status of 1 or less, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received prior PBS-subsidised treatment for this condition, **AND**
- The treatment must commence within 12 weeks of complete resection, **AND**
- Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required**

Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma  
Treatment Phase: Continuing treatment - 6 weekly treatment regimen

**Clinical criteria:**

- Patient must have previously been issued with an authority prescription for this drug for adjuvant treatment following complete surgical resection, **AND**
- Patient must not have experienced disease recurrence, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy.

**Injection**

12127G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	3	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Unresectable or metastatic deficient mismatch repair (dMMR) colorectal cancer  
Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must be untreated for this PBS indication (i.e untreated for each of: (i) unresectable disease, (ii) metastatic disease), **AND**
- Patient must not have received prior treatment for colorectal cancer with each of: (i) a programmed cell death-1 (PD-1) inhibitor, (ii) a programmed cell death ligand-1 (PD-L1) inhibitor, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- Patient must have deficient mismatch repair (dMMR) colorectal cancer, as determined by immunohistochemistry test.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required**

Unresectable or metastatic deficient mismatch repair (dMMR) colorectal cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have progressive disease while receiving PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Injection**

12615Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Stage IIIB, Stage IIIC or Stage IIID malignant melanoma

Treatment Phase: Initial treatment - 3 weekly treatment regimen

**Clinical criteria:**

- The treatment must be in addition to complete surgical resection, **AND**
- Patient must have a WHO performance status of 1 or less, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received prior PBS-subsidised treatment for this condition, **AND**
- The treatment must commence within 12 weeks of complete resection, **AND**
- Patient must not have received more than 12 months of therapy (irrespective of whether therapy has been partly PBS-subsidised/non-PBS-subsidised).

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** Commencing treatment within 12 weeks of complete resection means either 12 weeks after resection or 12 weeks prior to resection.

Where non-PBS-subsidised supply has occurred, the total amount of PBS-subsidised supply is intended to be the balance of 18 doses less the number of non-PBS-subsidised doses.

**Authority required**

Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma

Treatment Phase: Continuing treatment - 3 weekly treatment regimen

**Treatment criteria:**

- Patient must be undergoing continuing PBS-subsidised treatment commenced through an 'Initial treatment' listing.

**Clinical criteria:**

- Patient must not have experienced disease recurrence, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received more than 12 months of therapy (irrespective of whether therapy has been partly PBS-subsidised/non-PBS-subsidised).

**Injection**

12130K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	7	..	*7736.12	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

---

**Authority required (STREAMLINED)****14027**

Advanced, metastatic or recurrent endometrial carcinoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have received prior treatment with platinum-based chemotherapy, **AND**
- The condition must be untreated with each of: (i) programmed cell death-1/ligand-1 (PD-1/PDL-1) inhibitor therapy, (ii) tyrosine kinase inhibitor therapy, **AND**
- Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation.

**Treatment criteria:**

- Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR
- Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

---

**Authority required (STREAMLINED)****14044**

Advanced, metastatic or recurrent endometrial carcinoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR
- Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

---

**Authority required (STREAMLINED)****14028**

Advanced, metastatic or recurrent endometrial carcinoma

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

**Clinical criteria:**

- Patient must have received non-PBS-subsidised treatment with this drug for this condition prior to 1 June 2023, **AND**
- The treatment must be occurring in a patient where each of the following is true: (i) the patient had received prior treatment with platinum-based chemotherapy, (ii) the patient was untreated at treatment initiation with each of: (a) programmed cell death-1/ligand-1 (PD-1/PDL-1) inhibitor therapy, (b) tyrosine kinase inhibitor therapy, (iii) the patient's WHO performance status was no higher than 1 at treatment initiation, (iv) this drug is being prescribed in either: (a) a combination of pembrolizumab plus lenvatinib only, (b) as monotherapy where there was a contraindication/intolerance to the other drug in the combination - document the details in the patient's medical records, (v) disease progression has not occurred whilst on treatment, (vi) this prescription does not extend treatment beyond 24 months from the first administered dose.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

---

**Injection**

	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
13286G	400 mg	6	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14403**

Advanced carcinoma of the cervix

Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be at least one of (i) persistent carcinoma, (ii) recurrent carcinoma, (iii) metastatic carcinoma of the cervix, **AND**
- The condition must be unsuitable for curative treatment with either of (i) surgical resection, (ii) radiation, **AND**
- Patient must have WHO performance status no higher than 1, **AND**
- Patient must not have received prior treatment for this PBS indication.

**Treatment criteria:**

- Patient must be undergoing concomitant treatment with chemotherapy, containing a minimum of: (i) a platinum-based chemotherapy agent, plus (ii) paclitaxel, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required (STREAMLINED)**

**14404**

Advanced carcinoma of the cervix

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The condition must not have progressed while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed a total of (i) 24 months, (ii) 35 doses (based on a 3-weekly dose regimen), (iii) 17 doses (based on a 6-weekly dose regimen) whichever comes first from the first dose of this drug regardless if it was PBS/non-PBS subsidised.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Authority required (STREAMLINED)**

**14405**

Advanced carcinoma of the cervix

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

**Clinical criteria:**

- Patient must be currently receiving non-PBS-subsidised treatment with this drug for this condition, with treatment having commenced prior to 1 October 2023, **AND**
- Patient must have met all other PBS eligibility criteria that a non-Grandfather patient would ordinarily be required to meet, meaning that at the time non-PBS supply was commenced, the patient: (i) had either one of (1) persistent carcinoma, (2) recurrent carcinoma, (3) metastatic carcinoma of the cervix; (ii) had a WHO performance status no higher than 1; (iii) was unsuitable for curative treatment with either of (1) surgical resection, (2) radiation; (iv) had not received prior treatment for this PBS indication; (v) was treated concomitantly with platinum-based chemotherapy agent, plus paclitaxel, **AND**
- The condition must not have progressed while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed a total of (i) 24 months, (ii) 35 doses (based on a 3-weekly dose regimen), (iii) 17 doses (based on a 6-weekly dose regimen) whichever comes first from the first dose of this drug regardless if it was PBS/non-PBS subsidised.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Injection**

13635P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

## ▪ PEMBROLIZUMAB

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

---

### **Authority required (STREAMLINED)**

**13948**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have a prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk classification score at treatment initiation with this drug of either: (i) 1 to 2 (intermediate risk), (ii) 3 to 6 (poor risk); document the IMDC risk classification score in the patient's medical records, **AND**
- The condition must be untreated, **AND**
- Patient must have a WHO performance status of 2 or less.

#### **Treatment criteria:**

- Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR
- Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note A** prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk score can be calculated here: <https://www.mdcalc.com/imdc-international-metastatic-rcc-database-consortium-risk-model-metastatic-renal-cell-carcinoma>.

One point is assigned for each of:

- (i) a time of diagnosis to systemic therapy of less than 1 year
- (ii) a Karnofsky Performance Status of less than 80%
- (iii) a haemoglobin less than the lower limit of normal
- (iv) a corrected calcium level greater than the upper limit of normal
- (v) a neutrophil count greater than the upper limit of normal
- (vi) a platelet count greater than the upper limit of normal

Stated normal reference ranges may vary depending on the laboratory providing the measurement. 'Normal' here refers to the individual laboratory's stated normal reference range.

Favourable IMDC risk is a score of 0.

Intermediate IMDC risk is a score of 1 to 2.

Poor IMDC risk is a score of 3 to 6.

Document any IMDC risk score assessment in the patient's medical records.

---

### **Authority required (STREAMLINED)**

**13949**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition.

#### **Treatment criteria:**

- Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; OR
- Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records, **AND**
- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

---

### **Authority required (STREAMLINED)**

**13986**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

#### **Clinical criteria:**

- Patient must be currently receiving non-PBS-subsidised treatment with this drug for this condition, with treatment having commenced prior to 1 May 2023, **AND**

- Patient must have had a prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk classification score at treatment initiation with this drug of either: (i) 1 to 2 (intermediate risk), (ii) 3 to 6 (poor risk); document the IMDC risk classification score in the patient's medical records if not already documented, **AND**
- The treatment must be occurring in a patient where each of the following is true: (i) the patient's WHO performance status was no higher than 2 at treatment initiation, (ii) this drug is being prescribed in either: (a) a combination of pembrolizumab plus lenvatinib only, (b) as monotherapy where there was a contraindication/intolerance to the other drug in the combination - document the details in the patient's medical records, (iii) the condition was untreated at the time of treatment initiation, (iv) disease progression has not occurred whilst on treatment, (v) treatment is occurring with a dosing regimen specified in this drug's approved Australian Product Information, (vi) this prescription does not extend treatment beyond 24 months from the first administered dose.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note A** prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk score can be calculated here: <https://www.mdcalc.com/imdc-international-metastatic-renal-cell-carcinoma>.

One point is assigned for each of:

- (i) a time of diagnosis to systemic therapy of less than 1 year
- (ii) a Karnofsky Performance Status of less than 80%
- (iii) a haemoglobin less than the lower limit of normal
- (iv) a corrected calcium level greater than the upper limit of normal
- (v) a neutrophil count greater than the upper limit of normal
- (vi) a platelet count greater than the upper limit of normal

Stated normal reference ranges may vary depending on the laboratory providing the measurement. 'Normal' here refers to the individual laboratory's stated normal reference range.

Favourable IMDC risk is a score of 0.

Intermediate IMDC risk is a score of 1 to 2.

Poor IMDC risk is a score of 3 to 6.

Document any IMDC risk score assessment in the patient's medical records.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Injection**

13254N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

▪ **PEMBROLIZUMAB**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Patient should be treated with the recommended dose of pembrolizumab according to the TGA-approved Product Information.

**Authority required (STREAMLINED)**

**13735**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be incurable by local therapies in the locally advanced setting, **AND**
- Patient must not have had systemic therapy for this condition in the recurrent or metastatic setting prior to initiating PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have experienced disease recurrence within 6 months of completion of systemic therapy if previously treated in the locally advanced setting, **AND**
- Patient must have had a WHO performance status of 0 or 1, **AND**
- The treatment must be either: (i) the sole PBS-subsidised therapy where the condition expresses programmed cell death ligand 1 (PD-L1) with a combined positive score (CPS) greater than or equal to 20 in the tumour sample, (ii) in combination with platinum-based chemotherapy, unless contraindicated or not tolerated.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**13731**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Authority required (STREAMLINED)**

**13738**

Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

**Clinical criteria:**

- Patient must have previously received non-PBS-subsidised treatment with this drug for this condition prior to 1 October 2022, **AND**
- Patient must not have had systemic therapy for this condition in the recurrent or metastatic setting prior to initiating non-PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have experienced disease recurrence within 6 months of completion of systemic therapy if treated in the locally advanced setting prior to non-PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must have been initiated as non-PBS-subsidised therapy as either: (i) the sole therapy where the condition expressed programmed cell death ligand 1 (PD-L1) with a combined positive score (CPS) greater than or equal to 20 in the tumour sample, (ii) in combination with platinum-based chemotherapy, unless contraindicated or not tolerated, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- Patient must have had a WHO performance status of 0 or 1 prior to initiation of non-PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 6 repeat prescriptions; OR
- Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 3 repeat prescriptions, **AND**
- Patient must not be undergoing continuing PBS-subsidised treatment where this benefit is extending treatment beyond 24 cumulative months from the first administered dose, once in a lifetime.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

**Note** A patient may only qualify for PBS-subsidised treatment under this restriction once.

**Note** Following completion of the initial PBS subsidised course, further applications for treatment will be assessed under the continuing treatment restriction.

**Injection**

13131D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	400 mg	6	..	*15383.62	31.60	Keytruda [MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)

**VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors**

▪ **BEVACIZUMAB**

**Injection**

12479T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1800 mg	7	..	*2284.62	31.60	Abevmy [AF] (bevacizumab 100 mg/4 mL injection, 4 mL vial) Abevmy [AF] (bevacizumab 400 mg/16 mL injection, 16 mL vial) Bevaciptin [LR] (bevacizumab 100 mg/4 mL injection, 4 mL vial) Bevaciptin [LR] (bevacizumab 400 mg/16 mL injection, 16 mL vial) Mvasi [AN] (bevacizumab 100 mg/4 mL injection, 4 mL vial) Mvasi [AN] (bevacizumab 400 mg/16 mL injection, 16 mL vial)

**Other monoclonal antibodies and antibody drug conjugates**

▪ **BLINATUMOMAB**

**Caution** Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).  
Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)  
Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)  
Or mailed to:  
Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Authority required**

Acute lymphoblastic leukaemia  
Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must be relapsed or refractory B-precursor cell ALL, with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, **AND**
- The condition must not be present in the central nervous system or testis, **AND**
- Patient must have previously received a tyrosine kinase inhibitor (TKI) if the condition is Philadelphia chromosome positive, **AND**
- Patient must have received intensive combination chemotherapy for initial treatment of ALL or for subsequent salvage therapy, **AND**
- Patient must not have received more than 1 line of salvage therapy, **AND**
- The condition must be one of the following: (i) untreated with this drug for measurable residual disease, (ii) treated with this drug for measurable residual disease, but the condition has not relapsed within 6 months of completing that course of treatment, **AND**
- The condition must have more than 5% blasts in bone marrow, **AND**
- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime.

According to the TGA-approved Product Information, hospitalisation is recommended at minimum for the first 9 days of the first cycle and the first 2 days of the second cycle. For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for 4 or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 651 microgram will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 1. An amount of 784 microgram, which may be obtained under Induction treatment - balance of supply restriction, will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 2.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Acute Lymphoblastic Leukaemia PBS Authority Application - Supporting Information Form; and
- (3) date of most recent chemotherapy, and if this was the initial chemotherapy regimen or salvage therapy, including what line of salvage; and
- (4) if applicable, the date of completion of blinatumomab treatment for measurable residual disease and the date of the patient's subsequent relapse; and
- (5) the percentage blasts in bone marrow count that is no more than 4 weeks old at the time of application.

**Injection**

11118E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	651 mcg	..	..	*66317.34	31.60	Blinicyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)

▪ **BLINATUMOMAB**

**Caution** Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Authority required**

Acute lymphoblastic leukaemia  
Treatment Phase: Induction treatment - balance of supply

**Clinical criteria:**

- The condition must be relapsed or refractory B-precursor cell ALL, with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, **AND**
- The condition must not be present in the central nervous system or testis, **AND**
- Patient must have previously received a tyrosine kinase inhibitor (TKI) if the condition is Philadelphia chromosome positive, **AND**

- Patient must have received insufficient therapy with this agent for this condition under the Induction treatment restriction to complete a maximum of 2 treatment cycles in a lifetime.

According to the TGA-approved Product Information, hospitalisation is recommended at minimum for the first 9 days of the first cycle and the first 2 days of the second cycle. For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for 4 or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 784 mcg will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 2.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

## Injection

11120G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	784 mcg	..	..	*77355.46	31.60	Blinicyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)

## ■ BLINATUMOMAB

**Caution** Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Note** A complete remission is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a full recovery of peripheral blood counts with platelets of greater than 100,000 per microliter, and absolute neutrophil count (ANC) of greater than 1,000 per microliter.

**Note** A complete remission with partial haematological recovery is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a partial recovery of peripheral blood counts with platelets of greater than 50,000 per microliter, and absolute neutrophil count (ANC) of greater than 500 per microliter.

**Note** Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time when an assessment is required must cease PBS-subsidised therapy with this agent.

### Authority required

Acute lymphoblastic leukaemia

Treatment Phase: Consolidation treatment

### Clinical criteria:

- Patient must have previously received PBS-subsidised induction treatment with this drug for this condition, **AND**
- Patient must have achieved a complete remission; OR
- Patient must have achieved a complete remission with partial haematological recovery, **AND**
- The treatment must not be more than 3 treatment cycles under this restriction in a lifetime, **AND**
- Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug.

## Injection

11117D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	784 mcg	2	..	*77355.46	31.60	Blinicyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)

## ■ BLINATUMOMAB

**Caution** Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** A complete remission is defined as bone marrow blasts of less than or equal to 5%, no evidence of disease and a full recovery of peripheral blood counts with platelets of greater than 100,000 per microliter, and absolute neutrophil count (ANC) of greater than 1,000 per microliter.

### Authority required

Measurable residual disease of precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL)

Treatment Phase: Initial treatment of measurable residual disease of Pre-B-cell ALL

### Treatment criteria:

- Must be treated by a physician experienced in the treatment of haematological malignancies.

### Clinical criteria:

- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, **AND**
- The condition must not be present in the central nervous system or testis, **AND**
- Patient must have achieved complete remission following intensive combination chemotherapy for initial treatment of acute lymphoblastic leukaemia (ALL) or for subsequent salvage therapy, **AND**
- Patient must have measurable residual disease based on measurement in bone marrow, documented after an interval of at least 2 weeks from the last course of systemic chemotherapy given as intensive combination chemotherapy treatment of ALL/as subsequent salvage therapy, whichever was the later, measured using flow cytometry/molecular methods, **AND**

### **AND**

- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime.

According to the TGA-approved Product Information, hospitalisation is recommended at minimum for the first 3 days of the first cycle and the first 2 days of the second cycle.

For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for four or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 784 mcg will be sufficient for a continuous infusion of blinatumomab over 28 days in each cycle.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The authority application must be made in writing and must include:

- (1) a completed authority prescription form; and
- (2) a completed Measurable residual disease positive Acute Lymphoblastic Leukaemia PBS Authority Application - Supporting Information Form; and
- (3) date of most recent chemotherapy, and if this was the initial chemotherapy regimen or salvage therapy; and
- (4) the percentage blasts in bone marrow count that is no more than 4 weeks old at the time of application.

Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time where an assessment is required must cease PBS-subsidised therapy with this agent.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Authority required**

Measurable residual disease of precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL)

Treatment Phase: Continuing treatment of previously measurable residual disease of Pre-B-cell ALL

**Treatment criteria:**

- Must be treated by a physician experienced in the treatment of haematological malignancies.

**Clinical criteria:**

- Patient must have previously received PBS-subsidised initial treatment with this drug for this condition, **AND**
- Patient must have achieved a complete remission, **AND**
- The condition must be negative for measurable residual disease using the same method used to determine initial PBS eligibility, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition, **AND**
- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime.

For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for four or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 784 microgram will be sufficient for a continuous infusion of blinatumomab over 28 days in each cycle.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

Patients who fail to demonstrate a response to PBS-subsidised treatment with this agent at the time where an assessment is required must cease PBS-subsidised therapy with this agent.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Injection**

11850Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	784 mcg	1	..	*77355.46	31.60	Blinicyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)

**▪ BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Authority required**

CD30 positive systemic anaplastic large cell lymphoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- The treatment must be for curative intent, **AND**
- Patient must have undergone appropriate prior front-line curative intent chemotherapy, **AND**
- Patient must demonstrate relapsed or chemotherapy-refractory disease, **AND**
- Patient must have responded to PBS-subsidised treatment with this drug if previously used for initial treatment of CD30 positive peripheral T-cell lymphoma, non-cutaneous type, **AND**
- The treatment must not exceed 4 cycles under this restriction.

Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include:

(a) details (date, unique identifying number or provider number) of a histology report showing evidence of the tumour's CD30 positivity; and

(b) The date of initial diagnosis of systemic anaplastic large cell lymphoma; and

(c) Dates of commencement and completion of front-line curative intent chemotherapy; and

(d) a declaration of whether the patient's disease is relapsed or refractory, and the date and means by which the patient's disease was assessed as being relapsed or refractory.

All reports must be documented in the patient's medical records.

If the application is submitted through HPOS form upload or mail, it must include:

(i) A completed authority prescription form; and

(ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

**Injection**

10166C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	3	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

**▪ BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Authority required**

CD30 positive systemic anaplastic large cell lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed 12 cycles under this restriction in a lifetime.

**Injection**

10171H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	11	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

**▪ BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Authority required**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have undergone a primary autologous stem cell transplant (ASCT), **AND**
- Patient must have experienced a relapsed CD30+ Hodgkin lymphoma post ASCT; OR
- Patient must have experienced a refractory CD30+ Hodgkin lymphoma post ASCT, **AND**
- Patient must not receive more than 4 cycles of treatment under this restriction.

Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail.

If the application is submitted through HPOS upload or mail, it must include:

- (a) a completed authority prescription form; and
- (b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

**Injection**

11073T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	3	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

▪ **BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Authority required**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must not have undergone an autologous stem cell transplant (ASCT) for this condition, **AND**
- Patient must not be suitable for ASCT for this condition; OR
- Patient must not be suitable for treatment with multi-agent chemotherapy for this condition, **AND**
- Patient must have experienced a relapsed CD30+ Hodgkin lymphoma following at least two prior treatments for this condition; OR
- Patient must have experienced a refractory CD30+ Hodgkin lymphoma following at least two prior treatments for this condition, **AND**
- Patient must not receive more than 4 cycles of treatment under this restriction.

Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail.

If the application is submitted through HPOS upload or mail, it must include:

- (a) a completed authority prescription form; and
- (b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

**Injection**

11079D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	3	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

▪ **BRENTUXIMAB VEDOTIN**

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** No increase in the maximum number of repeats may be authorised.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must not have undergone an autologous stem cell transplant (ASCT) for this condition, **AND**

- Patient must not be suitable for ASCT for this condition; OR
- Patient must not be suitable for treatment with multi-agent chemotherapy for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not receive more than 12 cycles of treatment under this restriction.  
The treatment must not exceed a total of 16 cycles of combined initial and continuing treatment in a lifetime.

### Injection

11087M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	11	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

### ▪ BRENTUXIMAB VEDOTIN

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** No increase in the maximum number of repeats may be authorised.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required

Relapsed or Refractory Hodgkin lymphoma

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have undergone a primary autologous stem cell transplant (ASCT) for this condition, **AND**
- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not receive more than 12 cycles of treatment under this restriction.  
The treatment must not exceed a total of 16 cycles of combined initial and continuing treatment in a lifetime.

### Injection

11096B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	11	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

### ▪ BRENTUXIMAB VEDOTIN

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

#### Authority required

CD30 positive cutaneous T-cell lymphoma

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have pathologically confirmed CD30 positive cutaneous T-cell lymphoma, **AND**
- Patient must have CD30 positivity of at least 3% of malignant cells, **AND**
- Patient must have a diagnosis of mycosis fungoides; OR
- Patient must have a diagnosis of Sezary syndrome; OR
- Patient must have a diagnosis of primary cutaneous anaplastic large cell lymphoma, **AND**
- Patient must have received prior systemic treatment for this condition, **AND**
- The condition must be relapsed or refractory, **AND**
- The treatment must not exceed 4 cycles under this restriction in a lifetime, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition.  
The authority application must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include:

(a) details (date, unique identifying number/code or provider number) of the histopathology report from an Approved Pathology Authority demonstrating the patient has a diagnosis of either mycosis fungoides, Sezary syndrome or primary cutaneous anaplastic large cell lymphoma; and

(b) details (date, unique identifying number/code or provider number) of a histology report on the tumour sample or of a flow cytometric analysis of lymphoma cells of the blood showing CD30 positivity of at least 3% of malignant cells; and

(c) Date of commencement and completion of the most recent prior systemic treatment.

All reports must be documented in the patient's medical records.

If the application is submitted through HPOS form upload or mail, it must include:

(i) A completed authority prescription form; and

(ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

**Injection**

11660Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	180 mg	3	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

▪ **BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Authority required**

CD30 positive cutaneous T-cell lymphoma

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must have achieved an objective response with this drug, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition, **AND**
- The treatment must not exceed 12 cycles under this restriction in a lifetime.

An objective response is defined as the demonstration of response by clinical observation of skin lesions, or response by positron-emission tomography (PET) and/or computed tomography (CT) standard criteria.

**Injection**

11664X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	180 mg	11	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

▪ **BRENTUXIMAB VEDOTIN**

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au)

Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos))

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia  
Complex Drugs  
Reply Paid 9826  
HOBART TAS 7001

**Note** This product is not PBS-subsidised for the treatment of previously untreated CD30 positive cutaneous T-cell lymphoma.

**Authority required**

CD30 positive peripheral T-cell lymphoma, non-cutaneous type

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have histological confirmation of CD30 expression in at least 3% of malignant cells, **AND**
- The treatment must be for first line therapy for this condition, **AND**
- The treatment must be for curative intent, **AND**
- The treatment must be in combination with cyclophosphamide, doxorubicin and prednisone, **AND**
- The treatment must not be more than 6 treatment cycles under this restriction in a lifetime.

Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include:

- (a) details (date, unique identifying number/code or provider number) of a histology report on the tumour sample from an Approved Pathology Authority showing CD30 positivity of at least 3% malignant cells; and
- (b) The date of initial diagnosis of Peripheral T-cell lymphoma.

All reports must be documented in the patient's medical records.

If the application is submitted through HPOS form upload or mail, it must include:

- (i) A completed authority prescription form; and
- (ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

## Injection

12646N	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	5	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

## ▪ BRENTUXIMAB VEDOTIN

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Note** This product is not PBS-subsidised for the treatment of previously untreated CD30 positive cutaneous T-cell lymphoma.

### Authority required

CD30 positive peripheral T-cell lymphoma, non-cutaneous type

Treatment Phase: Continuing treatment

### **Clinical criteria:**

- The treatment must be in combination with cyclophosphamide, doxorubicin and prednisone, **AND**
- Patient must have completed 6 initial cycles of PBS-subsidised treatment with this drug for this indication, **AND**
- Patient must have achieved at least a partial response to the 6 initial cycles of treatment with a combination of this drug and cyclophosphamide, doxorubicin and prednisone for this indication, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime.

Partial response is defined using Lugano Response Criteria for Non-Hodgkin Lymphoma as:

- (a) Positron emission tomography-based response: lymph nodes and extralymphatic sites - a score of 4 (uptake moderately > liver), or 5 (uptake markedly higher than liver and/or new lesions), with reduced uptake compared with baseline and residual mass(es) of any size; nonmeasured lesions - not applicable; organ enlargement - not applicable; new lesions - none; bone marrow - residual uptake higher than uptake in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in the marrow in the context of a nodal response, consideration should be given to further evaluation with MRI or biopsy or an interval scan; OR
- (b) Computed tomography-based response: lymph nodes and extralymphatic sites - greater than or equal to 50% decrease in the sum of the product of the perpendicular diameters for multiple lesions, of up to six (6) target measurable nodes and extranodal sites; non-measured lesions - absent/normal, regressed but no increase; new lesions - none; bone marrow - not applicable.

## Injection

12657E	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	200 mg	1	..	*18708.62	31.60	Adcetris [TK] (brentuximab vedotin 50 mg injection, 1 vial)

## ▪ ELOTUZUMAB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

### Authority required

Relapsed and/or refractory multiple myeloma

Treatment Phase: Continuing treatment

### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
  - The treatment must be in combination with lenalidomide and dexamethasone, **AND**
  - Patient must not have developed disease progression while receiving treatment with this drug for this condition.
- Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or

- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

12983H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	5	..	*5038.65	31.60	Empliciti [BQ] (elotuzumab 300 mg injection, 1 vial) Empliciti [BQ] (elotuzumab 400 mg injection, 1 vial)

▪ **ELOTUZUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

**Authority required**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Initial treatment

**Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with lenalidomide and dexamethasone, **AND**
- Patient must have progressive disease after at least one prior therapy, **AND**
- Patient must have undergone or be ineligible for a stem cell transplant, **AND**
- Patient must not have previously received this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

12989P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	9	..	*5038.65	31.60	Empliciti [BQ] (elotuzumab 300 mg injection, 1 vial) Empliciti [BQ] (elotuzumab 400 mg injection, 1 vial)

▪ **ENFORTUMAB VEDOTIN**

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14416**

Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer

**Clinical criteria:**

- The condition must have progressed on/following both: (i) platinum-based chemotherapy, (ii) programmed cell death 1/ligand 1 (PD-1/PD-L1) inhibitor therapy; OR
- The condition must have progressed on/following platinum-based chemotherapy, whilst PD-1/PD-L1 inhibitor therapy resulted in an intolerance that required treatment cessation, **AND**
- Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug. **AND**
- The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication.

**Treatment criteria:**

- Patient must be undergoing treatment with this drug for the first time; OR

- Patient must be undergoing continuing treatment with this drug, with each of the following being true: (i) all other PBS eligibility criteria in this restriction are met, (ii) disease progression is absent.

### Injection

13648H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	125 mg	8	..	*6212.01	31.60	Padcev [LL] (enfortumab vedotin 20 mg injection, 1 vial)
						Padcev [LL] (enfortumab vedotin 30 mg injection, 1 vial)

### ▪ GEMTUZUMAB OZOGAMICIN

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

#### Authority required

Acute Myeloid Leukaemia

Treatment Phase: Induction treatment

#### **Clinical criteria:**

- Patient must have confirmed CD33-positive AML prior to initiation of treatment, **AND**
  - The condition must be de novo, **AND**
  - The condition must be previously untreated at the time of initiation (except for prior essential treatment with hydroxyurea or leukapheresis for patients with hyperleukocytic AML), **AND**
  - Patient must have confirmed intermediate/favourable cytogenetic risk; OR
  - Patient must have unknown cytogenetic risk due to inconclusive test results, **AND**
  - Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less, **AND**
  - The condition must not be acute promyelocytic leukaemia, **AND**
  - The treatment must be in combination with standard intensive remission induction chemotherapy for this condition, which must include cytarabine and an anthracycline, **AND**
  - The treatment must not be used in combination with a tyrosine kinase inhibitor, **AND**
  - The condition must not be internal tandem duplication (ITD) or tyrosine kinase domain (TKD) FMS tyrosine kinase 3 (FLT3) mutation positive, **AND**
  - Patient must not receive more than 1 induction cycle under this restriction in a lifetime.
- This drug is not PBS-subsidised if it is prescribed to an in-patient in a public hospital setting.

### Injection

12844B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	5 mg	2	..	*9255.62	31.60	Mylotarg [PF] (gemtuzumab ozogamicin 5 mg injection, 1 vial)

### ▪ GEMTUZUMAB OZOGAMICIN

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

#### Authority required

Acute Myeloid Leukaemia

Treatment Phase: Consolidation treatment

#### **Clinical criteria:**

- Patient must have achieved a complete remission following induction treatment with this drug for this condition, **AND**
- The treatment must be in combination with standard intensive remission consolidation chemotherapy for this condition, which must include cytarabine and an anthracycline, **AND**
- Patient must not receive more than 2 consolidation cycles under this restriction in a lifetime.

This drug is not PBS-subsidised if it is prescribed to an in-patient in a public hospital setting.

A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.

Complete remission following induction is defined as fewer than 5% blasts in a normocellular marrow and an absolute neutrophil count of more than  $1.0 \times 10^9$  cells/L with a platelet count of  $100 \times 10^9$ /L or more in the peripheral blood in the absence of transfusion.

Progressive disease is defined as the presence of any of the following:

- Leukaemic cells in the CSF;
- Re-appearance of circulating blast cells in the peripheral blood, not attributable to overshoot following recovery from myeloablative therapy;
- Greater than 5 % blasts in the marrow not attributable to bone marrow regeneration or another cause;
- Extramedullary leukaemia.

### Injection

12861X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	5 mg	1	..	*9255.62	31.60	Mylotarg [PF] (gemtuzumab ozogamicin 5 mg injection, 1 vial)

▪ **IPILIMUMAB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**11478**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial combination treatment (with nivolumab) as first-line drug therapy

**Clinical criteria:**

- The condition must be squamous type non-small cell lung cancer (NSCLC), **AND**
- Patient must not have previously been treated for this condition in the metastatic setting, **AND**
- Patient must have a WHO performance status of 0 or 1, **AND**
- The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, **AND**
- The treatment must be in combination with platinum-based chemotherapy for the first two cycles, **AND**
- The treatment must be in combination with nivolumab.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**11391**

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing combination treatment (with nivolumab) of first-line drug therapy

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must not exceed 24 months in total, measured from the initial dose, or, must not extend beyond disease progression, whichever comes first, **AND**
- The treatment must be in combination with nivolumab.

**Injection**

12322M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	120 mg	4	..	*16966.38	31.60	Yervoy [BQ] (ipilimumab 50 mg/10 mL injection, 10 mL vial)

▪ **IPILIMUMAB**

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Authority required (STREAMLINED)**

**11930**

Unresectable malignant mesothelioma

**Clinical criteria:**

- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be in combination with PBS-subsidised nivolumab for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must not exceed a maximum total of 24 months in a lifetime for this condition.

**Injection**

12583G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	120 mg	3	..	*16966.38	31.60	Yervoy [BQ] (ipilimumab 50 mg/10 mL injection, 10 mL vial)

▪ **IPILIMUMAB**

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Note** In the first few months after start of immunotherapy, some patients can have a transient tumour flare with subsequent disease response. When progression is suspected, this should be confirmed through a confirmatory scan, taken at least 4 weeks later.

**Note A** prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk score can be calculated here: <https://www.mdcalc.com/imdc-international-metastatic-renal-cell-carcinoma>.

One point is assigned for each of:

- (i) a time of diagnosis to systemic therapy of less than 1 year
- (ii) a Karnofsky Performance Status of less than 80%
- (iii) a haemoglobin less than the lower limit of normal
- (iv) a corrected calcium level greater than the upper limit of normal
- (v) a neutrophil count greater than the upper limit of normal
- (vi) a platelet count greater than the upper limit of normal

Stated normal reference ranges may vary depending on the laboratory providing the measurement. 'Normal' here refers to the individual laboratory's stated normal reference range.

Favourable IMDC risk is a score of 0.

Intermediate IMDC risk is a score of 1 to 2.

Poor IMDC risk is a score of 3 to 6.

Document any IMDC risk score assessment in the patient's medical records.

---

**Authority required (STREAMLINED)**

**8555**

Stage IV clear cell variant renal cell carcinoma (RCC)

Treatment Phase: Induction treatment

**Clinical criteria:**

- The condition must not have previously been treated, **AND**
- The condition must be classified as intermediate to poor risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), **AND**
- Patient must have a WHO performance status of 2 or less, **AND**
- The treatment must be in combination with PBS-subsidised treatment with nivolumab as induction therapy for this condition.

Induction treatment with ipilimumab must not exceed a total of 4 doses at a maximum dose of 1 mg per kg every 3 weeks.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Injection**

	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
11628B	120 mg	3	..	*16966.38	31.60	Yervoy [BQ] (ipilimumab 50 mg/10 mL injection, 10 mL vial)

▪ **IPIILIMUMAB**

**Caution** Combination treatment with ipilimumab and nivolumab is associated with an increased incidence and severity of immune-related adverse reactions compared with monotherapy with these agents. Monitoring at least prior to each dose is recommended.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

---

**Authority required (STREAMLINED)**

**6562**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Induction treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must not have received prior treatment with ipilimumab, **AND**
- The treatment must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Note** For patients who commence therapy with ipilimumab:

- (i) Decisions concerning efficacy should await completion of the entire induction regimen (four doses) and should be made in conjunction with established criteria for immunological responses. However induction may be ceased or delayed if symptomatic progressive disease or intolerable adverse events occur and if, in the opinion of the clinician, continuation of treatment poses a risk to the patient;
- (ii) Tumour responses may occur beyond the initial 12 week induction phase and evaluation for potential later responses should be undertaken regularly for the first year.

---

**Authority required (STREAMLINED)**

**6585**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Re-induction treatment

**Clinical criteria:**

- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- Patient must have progressive disease after achieving an initial objective response to the most recent course of ipilimumab treatment (induction or re-induction), **AND**
- The treatment must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

An initial objective response to treatment is defined as either:

- (i) sustained stable disease of greater than or equal to 3 months duration measured from at least 2 weeks after the date of completion of the most recent course of ipilimumab; or

(ii) a partial or complete response.

The patient's body weight must be documented in the patient's medical records at the time treatment with ipilimumab is initiated.

**Authority required (STREAMLINED)**

**13841**

Unresectable Stage III or Stage IV malignant melanoma

Treatment Phase: Induction treatment

**Clinical criteria:**

- Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma, **AND**
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, **AND**
- The condition must not be ocular or uveal melanoma, **AND**
- The treatment must be in combination with PBS-subsidised treatment with nivolumab as induction therapy for this condition.

Induction treatment with nivolumab must not exceed a total of 4 doses at a maximum dose of 1 mg per kg every 3 weeks.

Induction treatment with ipilimumab must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks.

The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.

**Injection**

2641B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	360 mg	3	..	*45095.98	31.60	Yervoy [BQ] (ipilimumab 200 mg/40 mL injection, 40 mL vial) Yervoy [BQ] (ipilimumab 50 mg/10 mL injection, 10 mL vial)

▪ **SACITUZUMAB GOVITECAN**

**Caution** This medicine contains a cytotoxic component and causes chemotherapy-like toxicity, in particular, it can cause severe or life-threatening neutropenia and severe diarrhoea. For further information, refer to the Product Information.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12669**

Unresectable locally advanced or metastatic triple-negative breast cancer

Treatment Phase: Continuing treatment

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this PBS indication.

**Injection**

12945H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	13	..	*10480.75	31.60	Trodely [GI] (sacituzumab govitecan 180 mg injection, 1 vial)

▪ **SACITUZUMAB GOVITECAN**

**Caution** This medicine contains a cytotoxic component and causes chemotherapy-like toxicity, in particular, it can cause severe or life-threatening neutropenia and severe diarrhoea. For further information, refer to the Product Information.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12656**

Unresectable locally advanced or metastatic triple-negative breast cancer

Treatment Phase: Initial treatment

**Clinical criteria:**

- Patient must have progressive disease following two or more prior systemic therapies, at least one of them in the locally advanced or metastatic setting, **AND**
- The condition must be inoperable, **AND**
- Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation, **AND**
- The treatment must be the sole PBS-subsidised therapy for this PBS indication.

**Injection**

12966K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1200 mg	7	..	*10480.75	31.60	Trodely [GI] (sacituzumab govitecan 180 mg injection, 1 vial)

**OTHER ANTINEOPLASTIC AGENTS**

*Platinum compounds*

## ■ CARBOPLATIN

### Injection

4309T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	900 mg	5	..	*141.78	31.60	Carboplatin Accord [OC] (carboplatin 450 mg/45 mL injection, 45 mL vial)

## ■ CISPLATIN

### Injection

4319H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	220 mg	14	..	*137.59	31.60	Cisplatin Accord [OC] (cisplatin 100 mg/100 mL injection, 100 mL vial) Cisplatin Accord [OC] (cisplatin 50 mg/50 mL injection, 50 mL vial)

## ■ OXALIPLATIN

### Injection

4542C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	300 mg	11	..	*133.52	31.60	Oxaliplatin Accord [OC] (oxaliplatin 100 mg/20 mL injection, 20 mL vial) Oxaliplatin SUN [RA] (oxaliplatin 100 mg/20 mL injection, 20 mL vial) Oxaliplatin SUN [RA] (oxaliplatin 200 mg/40 mL injection, 40 mL vial)

### Proteasome inhibitors

## ■ BORTEZOMIB

### Restricted benefit

Multiple myeloma

### Restricted benefit

Newly diagnosed systemic light chain amyloidosis

Treatment Phase: Administration on Days 1, 8, 15 and 22 of six treatment cycles (28 days per cycle) in total

### Treatment criteria:

- Patient must be undergoing concurrent treatment with PBS-subsidised daratumumab for this PBS indication.

### Injection

12227M	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3000 mcg	15	..	*313.65	31.60	Bortezomib [CR] (bortezomib 3.5 mg injection, 1 vial) Bortezomib Accord [OC] (bortezomib 1 mg injection, 1 vial) Bortezomib Accord [OC] (bortezomib 2.5 mg/mL injection, 1 mL vial) Bortezomib Accord [OC] (bortezomib 3.5 mg injection, 1 vial) Bortezomib Accord [OC] (bortezomib 3.5 mg/1.4 mL injection, 1.4 mL vial) Bortezomib Baxter [BX] (bortezomib 3.5 mg injection, 1 vial) Bortezomib Ever Pharma [IT] (bortezomib 2.5 mg/mL injection, 1 mL vial) Bortezomib Ever Pharma [IT] (bortezomib 3.5 mg/1.4 mL injection, 1.4 mL vial) Bortezomib Juno [JU] (bortezomib 2.5 mg injection, 1 vial) Bortezomib Juno [JU] (bortezomib 3.5 mg injection, 1 vial) Bortezomib Sandoz [SZ] (bortezomib 3.5 mg injection, 1 vial) BORTEZOMIB-TEVA [TB] (bortezomib 3.5 mg injection, 1 vial) DBL Bortezomib [PF] (bortezomib 1 mg injection, 1 vial) DBL Bortezomib [PF] (bortezomib 2.5 mg injection, 1 vial) DBL Bortezomib [PF] (bortezomib 3 mg injection, 1 vial) DBL Bortezomib [PF] (bortezomib 3.5 mg injection, 1 vial) Velcade [JC] (bortezomib 1 mg injection, 1 vial) Velcade [JC] (bortezomib 3 mg injection, 1 vial) Velcade [JC] (bortezomib 3.5 mg injection, 1 vial)

## ■ CARFILZOMIB

**Note** No increase in the maximum number of repeats may be authorised.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

### Authority required (STREAMLINED)

**12934**

Multiple myeloma

Treatment Phase: Initial treatment - twice weekly treatment regimen

**Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with dexamethasone, **AND**
- Patient must have progressive disease after at least one prior therapy, **AND**
- Patient must have undergone or be ineligible for a stem cell transplant, **AND**
- Patient must not have previously received this drug for this condition, **AND**
- Patient must not receive more than three cycles of treatment under this restriction.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Authority required (STREAMLINED)**

**12930**

Multiple myeloma

Treatment Phase: Continuing treatment - twice weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with dexamethasone, **AND**
- Patient must not develop disease progression while receiving treatment with this drug for this condition, **AND**
- Patient must not receive more than 3 cycles of treatment per continuing treatment course authorised under this restriction.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

11229B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	120 mg	17	..	*2499.60	31.60	Kyprolis [AN] (carfilzomib 10 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 30 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 60 mg injection, 1 vial)

▪ **CARFILZOMIB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** No increase in the maximum amount or number of units may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**12694**

Multiple myeloma

Treatment Phase: Initial treatment - once weekly treatment regimen

**Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with dexamethasone, **AND**
- Patient must have progressive disease after at least one prior therapy, **AND**
- Patient must have undergone or be ineligible for a stem cell transplant, **AND**
- Patient must not have previously received this drug for this condition, **AND**
- Patient must not receive more than three cycles of treatment under this restriction.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Authority required (STREAMLINED)**

**12849**

Multiple myeloma

Treatment Phase: Continuing treatment - once weekly treatment regimen

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with dexamethasone, **AND**
- Patient must not develop disease progression while receiving treatment with this drug for this condition, **AND**
- Patient must not receive more than 3 cycles of treatment per continuing treatment course authorised under this restriction. Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

12244K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	160 mg	8	..	*3303.27	31.60	Kyprolis [AN] (carfilzomib 10 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 30 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 60 mg injection, 1 vial)

▪ **CARFILZOMIB**

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required (STREAMLINED)**

**14389**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Initial treatment for Cycles 1 to 3

**Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with lenalidomide and dexamethasone, **AND**
- Patient must have progressive disease after at least one prior therapy, **AND**
- Patient must not have previously received this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein. Provide details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of the most recent treatment cycle; the basis of the diagnosis of progressive disease or failure to respond; and which disease activity parameters will be used to assess response once only through the Authority application for lenalidomide.

**Authority required (STREAMLINED)**

**14363**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Continuing treatment for Cycles 3 to 12

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with lenalidomide and dexamethasone, **AND**
- Patient must not have progressive disease while receiving treatment with this drug for this condition. Progressive disease is defined as at least 1 of the following:
  - (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
  - (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
  - (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
  - (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
  - (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
  - (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
  - (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Authority required (STREAMLINED)**

**14364**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Continuing treatment for Cycles 13 onwards

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with lenalidomide and dexamethasone, **AND**
- Patient must not have progressive disease while receiving treatment with this drug for this condition. Progressive disease is defined as at least 1 of the following:
  - (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
  - (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
  - (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
  - (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
  - (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
  - (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
  - (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

**Injection**

13638T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	60 mg	17	..	*1294.11	31.60	Kyprolis [AN] (carfilzomib 10 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 30 mg injection, 1 vial) Kyprolis [AN] (carfilzomib 60 mg injection, 1 vial)

*Other antineoplastic agents*

▪ **ARSENIC**

**Authority required (STREAMLINED)**

**6018**

Acute promyelocytic leukaemia

Treatment Phase: Induction and consolidation treatment

**Clinical criteria:**

- The condition must be characterised by the presence of the t(15:17) translocation or PML/RAR-alpha fusion gene transcript.

**Injection**

10691Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	18 mg	140	..	*205.54	31.60	Arsenic Trioxide Accord [OC] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials)

Arsenic Trioxide-AFT [AE] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL ampoules)  
 Arsenic Trioxide Juno [JU] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials)  
 Phenasen [FF] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials)

## ■ ARSENIC

### **Authority required (STREAMLINED)**

**4793**

Acute promyelocytic leukaemia

Treatment Phase: Induction and consolidation treatment

#### **Clinical criteria:**

- The condition must be characterised by the presence of the t(15:17) translocation or PML/RAR-alpha fusion gene transcript, **AND**
- The condition must be relapsed, **AND**
- Patient must be arsenic naive at induction.

### **Authority required (STREAMLINED)**

**5997**

Acute promyelocytic leukaemia

#### **Clinical criteria:**

- The condition must be characterised by the presence of the t(15:17) translocation or PML/RAR-alpha fusion gene transcript.

## Injection

4371C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	18 mg	89	..	*205.54	31.60	Arsenic Trioxide Accord [OC] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials) Arsenic Trioxide-AFT [AE] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL ampoules) Arsenic Trioxide Juno [JU] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials) Phenasen [FF] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials)

## ■ ERIBULIN

**Note** A patient who has progressive disease with eribulin is no longer eligible for PBS-subsidised eribulin.

### **Authority required (STREAMLINED)**

**4649**

Locally advanced or metastatic breast cancer

#### **Clinical criteria:**

- Patient must have progressive disease, **AND**
- Patient must have failed at least two prior chemotherapeutic regimens for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

## Injection

10144X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3 mg	13	..	*772.62	31.60	Halaven [EI] (eribulin mesilate 1 mg/2 mL injection, 2 mL vial)

## ■ ERIBULIN

**Note** No increase in the maximum number of repeats may be authorised.

### **Authority required (STREAMLINED)**

**7258**

Advanced (unresectable and/or metastatic) liposarcoma

Treatment Phase: Initial treatment

#### **Clinical criteria:**

- Patient must have an ECOG performance status of 2 or less, **AND**
- The condition must be dedifferentiated, myxoid, round-cell or pleomorphic subtype, **AND**
- Patient must have received prior chemotherapy treatment including an anthracycline and ifosfamide (unless contraindicated) for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

#### **Population criteria:**

- Patient must be aged 18 years or older.

### **Authority required (STREAMLINED)**

**7280**

Advanced (unresectable and/or metastatic) liposarcoma

Treatment Phase: Continuing treatment

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not develop progressive disease while being treated with this drug for this condition, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition.

**Population criteria:**

- Patient must be aged 18 years or older.

**Injection**

11212D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	3 mg	7	..	*772.62	31.60	Halaven [E] (eribulin mesilate 1 mg/2 mL injection, 2 mL vial)



---

# Related Pharmaceutical Benefits for Public Hospital use

---

ALIMENTARY TRACT AND METABOLISM.....	160
ANTIEMETICS AND ANTINAUSEANTS.....	160
ANTIEMETICS AND ANTINAUSEANTS .....	160
<hr/>	
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS .....	163
ANTINEOPLASTIC AGENTS .....	163
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES.....	163
IMMUNOSTIMULANTS .....	169
IMMUNOSTIMULANTS .....	169
<hr/>	
VARIOUS .....	169
ALL OTHER THERAPEUTIC PRODUCTS .....	169
ALL OTHER THERAPEUTIC PRODUCTS.....	169

## ALIMENTARY TRACT AND METABOLISM

### ANTIEMETICS AND ANTINAUSEANTS

#### ANTIEMETICS AND ANTINAUSEANTS

##### *Serotonin (5HT<sub>3</sub>) antagonists*

#### ▪ FOSNETUPITANT + PALONOSETRON

**Note** This medicine is not PBS-subsidised for nausea and vomiting associated with radiotherapy being used to treat malignancy.

**Note** Various sources of information outline the emetic risk associated with cancer treatment. Examples include the National Comprehensive Cancer Network guidelines (USA), eviQ guidelines and approved Product Information of individual drugs. These examples are not a comprehensive list of which anti-cancer drugs that have moderate to high emesis risk.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum number of repeats may be authorised.

##### **Authority required**

Nausea and vomiting

##### **Clinical criteria:**

- The treatment must be for prevention of nausea and vomiting associated with moderate to highly emetogenic anti-cancer therapy, **AND**
- The treatment must be in combination with dexamethasone, unless contraindicated, **AND**
- Patient must be unable to swallow; OR
- Patient must be contraindicated to oral anti-emetics.

##### **fosnetupitant 235 mg + palonosetron 250 microgram injection, 1 vial**

13650K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	5	..	91.27	31.60	Akynzeo IV [JZ]

#### ▪ GRANISETRON

##### **Restricted benefit**

Nausea and vomiting

##### **Clinical criteria:**

- The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

##### **granisetron 3 mg/3 mL injection, 3 mL ampoule**

5899L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
	1	..	..	2.50	3.90	<sup>a</sup> Granisetron-AFT [AE] <sup>a</sup> Kytril [IX]	<sup>a</sup> Granisetron Kabi [PK]

##### **granisetron 2 mg tablet, 1**

5898K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	2	..	..	*16.58	17.98	Kytril [IX]

#### ▪ NETUPITANT + PALONOSETRON

**Note** This medicine is not PBS-subsidised for nausea and vomiting associated with radiotherapy being used to treat malignancy.

**Note** Various sources of information outline the emetic risk associated with cancer treatment. Examples include the National Comprehensive Cancer Network guidelines (USA), eviQ guidelines and approved Product Information of individual drugs. These examples are not a comprehensive list of which anti-cancer drugs that have moderate to high emesis risk.

**Note** No increase in the maximum number of repeats may be authorised.

##### **Authority required (STREAMLINED)**

**14443**

Nausea and vomiting

##### **Clinical criteria:**

- The treatment must be in combination with dexamethasone, unless contraindicated, **AND**
- The treatment must be for prevention of nausea and vomiting associated with moderate to highly emetogenic anti-cancer therapy.

##### **netupitant 300 mg + palonosetron 500 microgram capsule, 1**

10714X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	‡1	5	..	81.66	31.60	Akynzeo [JZ]

#### ▪ ONDANSETRON

##### **Restricted benefit**

Nausea and vomiting

##### **Clinical criteria:**

- The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

#### ondansetron 4 mg/5 mL oral liquid, 50 mL

5848T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	‡1	..	..	80.78	31.60	Zofran syrup 50 mL [AS]

#### ondansetron 4 mg tablet, 4

5967C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
	1	..	..	3.50	4.90	<sup>a</sup> APO-Ondansetron [TX] <sup>a</sup> Ondansetron AN [EA] <sup>a</sup> Ondansetron Mylan Tablets [AF] <sup>a</sup> Zofran [AS]	<sup>a</sup> APX-Ondansetron [TY] <sup>a</sup> Ondansetron-DRLA [RZ] <sup>a</sup> Ondansetron SZ [HX] <sup>a</sup> Zotren 4 [RF]

#### ondansetron 8 mg tablet, 4

5968D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
	1	..	..	4.33	5.73	<sup>a</sup> APO-Ondansetron [TX] <sup>a</sup> Ondansetron AN [EA] <sup>a</sup> Ondansetron Mylan Tablets [AF] <sup>a</sup> Zofran [AS]	<sup>a</sup> APX-Ondansetron [TY] <sup>a</sup> Ondansetron-DRLA [RZ] <sup>a</sup> Ondansetron SZ [HX] <sup>a</sup> Zotren 8 [RF]

### ▪ ONDANSETRON

#### Restricted benefit

Nausea and vomiting

#### Clinical criteria:

- The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

#### ondansetron 4 mg orally disintegrating tablet, 4

5857G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
	1	..	..	3.50	4.90	<sup>a</sup> APX-Ondansetron ODT [TY] <sup>a</sup> Ondansetron Mylan ODT [AF] <sup>a</sup> Ondansetron SZ ODT [HX]	<sup>a</sup> Ondansetron AN ODT [EA] <sup>a</sup> Ondansetron ODT-DRLA [RZ] <sup>a</sup> Zotren ODT [RF]

#### ondansetron 8 mg orally disintegrating tablet, 4

5858H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
	1	..	..	4.33	5.73	<sup>a</sup> APX-Ondansetron ODT [TY] <sup>a</sup> Ondansetron Mylan ODT [AF] <sup>a</sup> Ondansetron SZ ODT [HX]	<sup>a</sup> Ondansetron AN ODT [EA] <sup>a</sup> Ondansetron ODT-DRLA [RZ] <sup>a</sup> Zotren ODT [RF]

### ▪ PALONOSETRON

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** This drug is not PBS-subsidised for administration with oral 5-HT3 antagonists.

#### Restricted benefit

Nausea and vomiting

#### Clinical criteria:

- The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

#### palonosetron 250 microgram/5 mL injection, 5 mL vial

5853C	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
	1	..	..	22.04	23.44	<sup>a</sup> Aloxi [JZ]	<sup>a</sup> Palonosetron Dr.Reddy's [RZ]

### ▪ TROPISETRON

#### Restricted benefit

Nausea and vomiting

#### Clinical criteria:

- The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.

#### tropisetron 5 mg/5 mL injection, 5 mL ampoule

5987D	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	..	..	4.00	5.40	Tropisetron-AFT [AE]

*Other antiemetics*

## ■ APREPITANT

**Note** Aprepitant is not PBS-subsidised for nausea and vomiting associated with radiotherapy being used to treat malignancy.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

### Authority required (STREAMLINED)

**4223**

Nausea and vomiting

#### **Clinical criteria:**

- The condition must be associated with cytotoxic chemotherapy being used to treat malignancy, **AND**
- The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone, **AND**
- Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following agents: altretamine; carmustine; cisplatin when a single dose constitutes a cycle of chemotherapy; cyclophosphamide at a dose of 1500 mg per square metre per day or greater; dacarbazine; procarbazine when a single dose constitutes a cycle of chemotherapy; streptozocin.

No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.

### Authority required (STREAMLINED)

**4216**

Nausea and vomiting

#### **Clinical criteria:**

- The condition must be associated with cytotoxic chemotherapy being used to treat breast cancer, **AND**
- The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone, **AND**
- Patient must be scheduled to be co-administered cyclophosphamide and an anthracycline.

No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.

### Authority required (STREAMLINED)

**6464**

Nausea and vomiting

#### **Clinical criteria:**

- The condition must be associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy, **AND**
- The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle, **AND**
- Patient must have had a prior episode of chemotherapy induced nausea or vomiting, **AND**
- Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous chemotherapy agents: arsenic trioxide; azacitidine; cyclophosphamide at a dose of less than 1500 mg per square metre per day; cytarabine at a dose of greater than 1 g per square metre per day; dactinomycin; daunorubicin; doxorubicin; epirubicin; fotemustine; idarubicin; ifosfamide; irinotecan; melphalan; methotrexate at a dose of 250 mg to 1 g per square metre; raltitrexed.

No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.

Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle.

### Authority required (STREAMLINED)

**6383**

Nausea and vomiting

#### **Clinical criteria:**

- The condition must be associated with cytotoxic chemotherapy being used to treat malignancy, **AND**
- The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle, **AND**
- Patient must be scheduled to be administered a chemotherapy regimen that includes either carboplatin or oxaliplatin.

No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.

Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle.

### aprepitant 165 mg capsule, 1

2550F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
	1	5	..	62.30	31.60	<sup>a</sup> Aprepitant APOTEX [TX]	<sup>a</sup> APREPITANT SCP [XC]

## ■ FOSAPREPITANT

**Note** This medicine is not PBS-subsidised for nausea and vomiting associated with radiotherapy being used to treat malignancy.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

### Authority required (STREAMLINED)

**6886**

Nausea and vomiting

#### **Clinical criteria:**

- The condition must be associated with cytotoxic chemotherapy being used to treat malignancy, **AND**
- The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone, **AND**
- Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following agents: altretamine; carmustine; cisplatin when a single dose constitutes a cycle of chemotherapy; cyclophosphamide at a dose

of 1500 mg per square metre per day or greater; dacarbazine; procarbazine when a single dose constitutes a cycle of chemotherapy; streptozocin.

No more than 1 vial of fosaprepitant 150 mg injection will be authorised per cycle of cytotoxic chemotherapy.

**Authority required (STREAMLINED)**

**6891**

Nausea and vomiting

**Clinical criteria:**

- The condition must be associated with cytotoxic chemotherapy being used to treat breast cancer, **AND**
- The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone, **AND**
- Patient must be scheduled to be co-administered cyclophosphamide and an anthracycline.

No more than 1 vial of fosaprepitant 150 mg injection will be authorised per cycle of cytotoxic chemotherapy.

**Authority required (STREAMLINED)**

**6887**

Nausea and vomiting

**Clinical criteria:**

- The condition must be associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy, **AND**
- The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle, **AND**
- Patient must have had a prior episode of chemotherapy induced nausea or vomiting, **AND**
- Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous chemotherapy agents: arsenic trioxide; azacitidine; cyclophosphamide at a dose of less than 1500 mg per square metre per day; cytarabine at a dose of greater than 1 g per square metre per day; dactinomycin; daunorubicin; doxorubicin; epirubicin; fotemustine; idarubicin; ifosfamide; irinotecan; melphalan; methotrexate at a dose of 250 mg to 1 g per square metre; raltitrexed.

No more than 1 vial of fosaprepitant 150 mg injection will be authorised per cycle of cytotoxic chemotherapy.

Concomitant use of a 5HT3 antagonist should not occur with fosaprepitant on days 2 and 3 of any chemotherapy cycle.

**Authority required (STREAMLINED)**

**6852**

Nausea and vomiting

**Clinical criteria:**

- The condition must be associated with cytotoxic chemotherapy being used to treat malignancy, **AND**
- The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle, **AND**
- Patient must be scheduled to be administered a chemotherapy regimen that includes either carboplatin or oxaliplatin.

No more than 1 vial of fosaprepitant 150 mg injection will be authorised per cycle of cytotoxic chemotherapy.

Concomitant use of a 5HT3 antagonist should not occur with fosaprepitant on days 2 and 3 of any chemotherapy cycle.

**fosaprepitant 150 mg injection, 1 vial**

11103J	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
	1	5	..	69.23	31.60	<sup>a</sup> Emend IV [MK] <sup>a</sup> FOSAPREPITANT MSN [RQ]	<sup>a</sup> FOSAPREPITANT-AFT [AE]

**ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS**  
**ANTINEOPLASTIC AGENTS**  
**MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES**  
*CD38 (Clusters of Differentiation 38) inhibitors*

**DARATUMUMAB**

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Continuing treatment of second-line drug therapy from week 25 until disease progression (administered every 4 weeks)

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or

Related

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

### daratumumab 1.8 g/15 mL injection, 15 mL vial

12682L	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	5	..	7010.28	31.60	Darzalex SC [JC]

#### ■ DARATUMUMAB

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required

Relapsed and/or refractory multiple myeloma

Treatment Phase: Continuing treatment of second-line drug therapy for weeks 10 to 24 (administered every 3 weeks)

#### **Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**
- The treatment must be in combination with bortezomib and dexamethasone, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

### daratumumab 1.8 g/15 mL injection, 15 mL vial

12745T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	4	..	7010.28	31.60	Darzalex SC [JC]

#### ■ DARATUMUMAB

**Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

#### Authority required

Relapsed and/or refractory multiple myeloma

Treatment Phase: Initial treatment as second-line drug therapy for weeks 1 to 9 (administered once weekly)

#### **Clinical criteria:**

- The condition must be confirmed by a histological diagnosis, **AND**
- The treatment must be in combination with bortezomib and dexamethasone, **AND**
- Patient must have progressive disease after only one prior therapy (i.e. use must be as second-line drug therapy; use as third-line drug therapy or beyond is not PBS-subsidised).

#### **Treatment criteria:**

- Patient must be undergoing treatment with this drug in one of the following situations: (i) for the first time, irrespective of whether the diagnosis has been reclassified (i.e. the diagnosis has changed between multiple myeloma/amyloidosis), (ii) changing the drug's form (intravenous/subcutaneous) within the first 9 weeks of treatment for the same PBS indication.

Progressive disease is defined as at least 1 of the following:

- (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or
- (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

Details of: the histological diagnosis of multiple myeloma; prior treatments including name(s) of drug(s) and date of most recent treatment cycle; the basis of the diagnosis of progressive disease or failure to respond; and which disease activity parameters will be used to assess response, must be documented in the patient's medical records.

Confirmation of eligibility for treatment with current diagnostic reports of at least one of the following must be documented in the patient's medical records:

- (a) the level of serum monoclonal protein; or
- (b) Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or
- (c) the serum level of free kappa and lambda light chains; or
- (d) bone marrow aspirate or trephine; or
- (e) if present, the size and location of lytic bone lesions (not including compression fractures); or
- (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or
- (g) if present, the level of hypercalcaemia, corrected for albumin concentration.

As these parameters must be used to determine response, results for either (a) or (b) or (c) should be documented for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) must be documented in the patient's medical records. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be documented in the patient's medical records.

A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner.

A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity, with the exception to this being the need to attain a sufficient response for stem cell transplantation to proceed. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.

**daratumumab 1.8 g/15 mL injection, 15 mL vial**

12746W	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	8	..	7010.28	31.60	Darzalex SC [JC]

▪ **DARATUMUMAB**

**Note** The intravenously administered presentation of this drug is not PBS listed for this indication at the request of the sponsor.

**Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

**Authority required**

Newly diagnosed systemic light chain amyloidosis

Treatment Phase: Continuing treatment from week 25 onwards (administered once every four weeks)

**Clinical criteria:**

- Patient must have previously received PBS-subsidised treatment with this drug for this condition.

**Treatment criteria:**

- Must be treated by a haematologist (this does not exclude treatment via a multidisciplinary team, but the PBS authority application must be sought by the treating haematologist), **AND**
- Patient must be undergoing continuing treatment that does not extend treatment duration beyond whichever comes first: (i) disease progression, (ii) 96 cumulative weeks from the first administered dose, once in a lifetime.

**daratumumab 1.8 g/15 mL injection, 15 mL vial**

13203X	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	5	..	7010.28	31.60	Darzalex SC [JC]

## ▪ DARATUMUMAB

- Note** This drug is not PBS-subsidised for use in patients with multiple myeloma who have received two or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or, who are refractory to both a PI and an immunomodulatory agent, as monotherapy.
- Note** Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/HPOS](http://www.servicesaustralia.gov.au/HPOS)) or by telephone by contacting Services Australia on 1800 888 333.
- Note** No increase in the maximum number of repeats may be authorised.
- Note** Special Pricing Arrangements apply.
- Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.
- Note** This grandfather restriction will cease to operate from 3 months after the date specified in the clinical criteria.

### **Authority required**

Relapsed and/or refractory multiple myeloma

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

### **Clinical criteria:**

- Patient must have been on treatment with this drug in the subcutaneous form for this condition prior to 1 November 2021, **AND**
- Patient must have met all initial treatment PBS-eligibility criteria applying to a non-grandfathered patient prior to having commenced treatment with this drug, which are: (i) the condition was confirmed by histological diagnosis, (ii) the treatment is/was being used as part of triple combination therapy with bortezomib and dexamethasone, (iii) the condition progressed (see definition of progressive disease below) after one prior therapy, but not after more than two prior lines of therapies (i.e. this drug was commenced as second-line treatment), (iv) the treatment was/is not to be used in combination with another PBS-subsidised drug indicated for this condition outside of the intended combination where stated, and (v) the patient had never been treated with this drug, **AND**
- Patient must not have developed disease progression while receiving treatment with this drug for this condition.

Progressive disease is defined as at least 1 of the following:

- at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or
- at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or
- in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or
- at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or
- an increase in the size or number of lytic bone lesions (not including compression fractures); or
- at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or
- development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein. Details of: the histological diagnosis of multiple myeloma; prior treatments including name(s) of drug(s) and date of most recent treatment cycle; the basis of the diagnosis of progressive disease or failure to respond; and which disease activity parameters will be used to assess response, must be documented in the patient's medical records.

Confirmation of eligibility for treatment with current diagnostic reports of at least one of the following must be documented in the patient's medical records:

- the level of serum monoclonal protein; or
- Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or
- the serum level of free kappa and lambda light chains; or
- bone marrow aspirate or trephine; or
- if present, the size and location of lytic bone lesions (not including compression fractures); or
- if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or
- if present, the level of hypercalcaemia, corrected for albumin concentration.

As these parameters must be used to determine response, results for either (a) or (b) or (c) should be documented for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) must be documented in the patient's medical records. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be documented in the patient's medical records.

A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner.

A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity, with the exception to this being the need to attain a sufficient response for stem cell transplantation to proceed. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.

### **daratumumab 1.8 g/15 mL injection, 15 mL vial**

12673B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	7	..	7010.28	31.60	Darzalex SC [JC]

## ▪ DARATUMUMAB

**Note** The intravenously administered presentation of this drug is not PBS listed for this indication at the request of the sponsor.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 888 333. Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at [www.servicesaustralia.gov.au](http://www.servicesaustralia.gov.au). Applications for authorisation under this restriction should be made in real time using the Online PBS Authorities system (see [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)).

Alternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health Professional Online Services (HPOS) at [www.servicesaustralia.gov.au/hpos](http://www.servicesaustralia.gov.au/hpos)

Or mailed to:

Services Australia

PBS Authorities

GPO Box 9826

[Your capital city]

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Special Pricing Arrangements apply.

### **Authority required**

Newly diagnosed systemic light chain amyloidosis

Treatment Phase: Initial treatment from week 0 to week 24

#### **Clinical criteria:**

- The condition must have histological evidence consistent with a diagnosis of systemic light-chain amyloidosis, **AND**
- The condition must be untreated with drug therapy, including this drug, irrespective of whether the diagnosis has been reclassified (i.e. the diagnosis changes between multiple myeloma/amyloidosis), **AND**
- Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of no higher than 2 at treatment initiation.

#### **Treatment criteria:**

- Must be treated by a haematologist (this does not exclude treatment via a multidisciplinary team, but the PBS authority application must be sought by the treating haematologist), **AND**
- Patient must be undergoing concomitant treatment limited to each of: (i) bortezomib, (ii) cyclophosphamide, (iii) dexamethasone, at certain weeks of treatment as outlined in the drug's approved Product Information.

The authority application must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail, and must include:

Details of the histological evidence supporting the diagnosis of systemic light chain amyloidosis, limited to: (i) the name of pathologist/pathology provider, (ii) the site of biopsy

If the application is submitted through HPOS form upload or mail, it must include:

- (i) A completed authority prescription form; and
- (ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

### **Authority required**

Newly diagnosed systemic light chain amyloidosis

Treatment Phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

#### **Clinical criteria:**

- Patient must be continuing treatment with this drug that was commenced as non-PBS-subsidised supply prior to 1 January 2023, **AND**
- The condition must have histological evidence consistent with a diagnosis of systemic light-chain amyloidosis, **AND**
- The condition must have been, prior to the first dose of the non-PBS-subsidised supply, untreated with drug therapy, including this drug, irrespective of whether the diagnosis had been reclassified (i.e. the diagnosis changes between multiple myeloma/amyloidosis), **AND**
- Patient must have had a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 2 at the time non-PBS supply was initiated.

#### **Treatment criteria:**

- Must be treated by a haematologist (this does not exclude treatment via a multidisciplinary team, but the PBS authority application must be sought by the treating haematologist), **AND**
- Patient must be undergoing concomitant treatment limited to each of: (i) bortezomib, (ii) cyclophosphamide, (iii) dexamethasone, at certain weeks of treatment as outlined in the drug's approved Product Information, **AND**
- Patient must be undergoing continuing treatment that does not extend treatment duration beyond whichever comes first: (i) disease progression, (ii) 96 cumulative weeks from the first administered dose, once in a lifetime.

The authority application must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail, and must include:

Details of the histological evidence supporting the diagnosis of systemic light chain amyloidosis, limited to: (i) the name of pathologist/pathology provider, (ii) the site of biopsy

If the application is submitted through HPOS form upload or mail, it must include:

- (i) A completed authority prescription form; and
- (ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

Determine an appropriate number of repeat prescriptions for this authority application in line with either:

## ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

(i) Where the patient has received less than 10 non-PBS-subsidised doses, prescribe a number of repeat prescriptions up to the balance of: 15 doses less the number of non-PBS-subsidised doses; or

(ii) Where the patient has received at least 10 non-PBS-subsidised doses, prescribe no more than 5 repeat prescriptions.

**Note** Patients may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a 'Grandfathered' patient must qualify under the 'Continuing treatment' criteria.

**Note** This grandfather restriction will cease to operate from 12 months after the date specified in the clinical criteria.

### daratumumab 1.8 g/15 mL injection, 15 mL vial

13201T	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	15	..	7010.28	31.60	Darzalex SC [JC]

### HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors

#### ▪ TRASTUZUMAB

**Note** Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

**Note** No increase in the maximum number of repeats may be authorised.

#### Authority required (STREAMLINED)

10212

Early HER2 positive breast cancer

Treatment Phase: 3 weekly treatment regimen

#### Clinical criteria:

- Patient must have undergone surgery (adjuvant) or be preparing for surgery (neoadjuvant), **AND**
  - The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure, **AND**
  - Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR
  - Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance.
- Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

### trastuzumab 600 mg/5 mL injection, 5 mL vial

10743K	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	3	..	1470.22	31.60	Herceptin SC [RO]

#### ▪ TRASTUZUMAB

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

#### Authority required (STREAMLINED)

9353

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Initial treatment

#### Clinical criteria:

- Patient must have evidence of human epidermal growth factor receptor 2 (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) either in the primary tumour or a metastatic lesion, **AND**
- The treatment must not be in combination with nab-paclitaxel, **AND**
- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition.

### trastuzumab 600 mg/5 mL injection, 5 mL vial

10811B	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	..	..	1470.22	31.60	Herceptin SC [RO]

#### ▪ TRASTUZUMAB

**Note** No increase in the maximum quantity or number of units may be authorised.

**Note** No increase in the maximum number of repeats may be authorised.

**Note** Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

#### Authority required (STREAMLINED)

9462

Metastatic (Stage IV) HER2 positive breast cancer

Treatment Phase: Continuing treatment

#### Clinical criteria:

- Patient must have previously received PBS-subsidised treatment with this drug for this condition, **AND**

- The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure.

**trastuzumab 600 mg/5 mL injection, 5 mL vial**

10817H	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	3	..	1470.22	31.60	Herceptin SC [RO]

## ■ IMMUNOSTIMULANTS

### IMMUNOSTIMULANTS

#### *Other immunostimulants*

## ■ MYCOBACTERIUM BOVIS BCG DANISH STRAIN

**Restricted benefit**

Primary and relapsing superficial urothelial carcinoma of the bladder

**Mycobacterium bovis BCG Danish strain 30 mg injection, 4 vials**

12925G	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	±3	1	..	*1317.00	31.60	VesiCulture [LM]

## ■ MYCOBACTERIUM BOVIS BCG TICE STRAIN

**Restricted benefit**

Primary and relapsing superficial urothelial carcinoma of the bladder

**Mycobacterium bovis BCG Tice strain 500 million CFU injection, 3 vials**

5902P	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	1	..	399.49	31.60	OncoTICE [MK]

## ■ VARIOUS

## ■ ALL OTHER THERAPEUTIC PRODUCTS

### ALL OTHER THERAPEUTIC PRODUCTS

#### *Detoxifying agents for antineoplastic treatment*

## ■ FOLINIC ACID

**folinic acid 100 mg/10 mL injection, 10 x 10 mL ampoules**

1904F	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	1	..	43.80	31.60	Leucovorin Calcium (Pfizer Australia Pty Ltd) [PF]

**folinic acid 50 mg/5 mL injection, 10 x 5 mL ampoules**

1899Y	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	2	..	38.90	31.60	Leucovorin Calcium (Pfizer Australia Pty Ltd) [PF]

## ■ FOLINIC ACID

**Restricted benefit**

Megaloblastic anaemias

**Clinical criteria:**

- The condition must be a result of folic acid deficiency from the use of folic acid antagonists.

**folinic acid 15 mg tablet, 10**

5904R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	..	..	76.00	31.60	Leucovorin Calcium (Hospira Pty Limited) [PF]

## ■ MESNA

**Restricted benefit**

Urothelial toxicity

Treatment Phase: Prophylaxis or reduction of toxicity

**Clinical criteria:**

- The treatment must be adjunctive therapy to ifosfamide or high dose cyclophosphamide.

**mesna 1 g/10 mL injection, 15 x 10 mL ampoules**

5961R	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	5	..	117.16	31.60	Uromitexan [BX]

## VARIOUS

---

### mesna 400 mg/4 mL injection, 15 x 4 mL ampoules

5960Q	Max. Amount	No. of Rpts	Premium \$	DPMA \$	MRVSN \$	Brand Name and Manufacturer
	1	5	..	51.74	31.60	Uromitexan [BX]

---

Related

---

# Index of Manufacturers' Code

<b>Code</b>	<b>Manufacturer</b>
<b>AE</b>	AFT Pharmaceuticals (AU) Pty Ltd
<b>AF</b>	Alphapharm Pty Ltd
<b>AN</b>	Amgen Australia Pty Limited
<b>AP</b>	AstraZeneca Pty Ltd
<b>AS</b>	Aspen Pharmacare Australia Pty Limited
<b>BQ</b>	Bristol-Myers Squibb Australia Pty Ltd
<b>BX</b>	Baxter Healthcare Pty Limited
<b>CR</b>	Pharmacor Pty Limited
<b>EA</b>	Amneal Pharmaceuticals Pty Ltd
<b>EI</b>	Eisai Australia Pty Ltd
<b>EW</b>	Celltrion Healthcare Australia Pty Ltd
<b>FB</b>	Pierre Fabre Australia Pty Ltd
<b>FF</b>	Phebra Pty Ltd
<b>GI</b>	Gilead Sciences Pty Limited
<b>HX</b>	Sandoz Pty Ltd
<b>IT</b>	InterPharma Pty Ltd
<b>IX</b>	Clinect Pty Ltd
<b>JC</b>	Janssen-Cilag Pty Ltd
<b>JO</b>	Juno Pharmaceuticals Pty Ltd
<b>JU</b>	Juno Pharmaceuticals Pty Ltd
<b>JZ</b>	Juniper Biologics Pty Ltd
<b>LL</b>	Astellas Pharma Australia Pty Ltd
<b>LM</b>	Link Medical Products Pty Ltd
<b>LR</b>	Cipla Australia Pty Ltd
<b>MF</b>	Mundipharma Pty Limited
<b>MK</b>	Merck Sharp & Dohme (Australia) Pty Ltd
<b>OC</b>	Accord Healthcare Pty. Ltd.
<b>OD</b>	Accord Healthcare Pty. Ltd.
<b>OE</b>	Omegapharm Pty Ltd
<b>PF</b>	Pfizer Australia Pty Ltd
<b>PK</b>	Fresenius Kabi Australia Pty Limited
<b>RA</b>	Sun Pharma ANZ Pty Ltd
<b>RF</b>	Arrow Pharma Pty Ltd
<b>RO</b>	Roche Products Pty Ltd
<b>RQ</b>	Reach Pharmaceuticals Pty Ltd
<b>RZ</b>	Dr Reddy's Laboratories (Australia) Pty Ltd
<b>SG</b>	Merck Healthcare Pty Ltd
<b>SW</b>	sanofi-aventis Australia Pty Ltd
<b>SZ</b>	Sandoz Pty Ltd
<b>TB</b>	Teva Pharma Australia Pty Ltd
<b>TK</b>	Takeda Pharmaceuticals Australia Pty. Ltd.
<b>TS</b>	Specialised Therapeutics Australia Pty Ltd
<b>TX</b>	Apotex Pty Ltd
<b>TY</b>	Apotex Pty Ltd
<b>XC</b>	Southern Cross Pharma Pty Ltd
<b>ZL</b>	Specialised Therapeutics Pharma Pty Ltd

---

# Generic/Proprietary Index

Abevmy[AF] (bevacizumab 100 mg/4 mL injection, 4 mL vial) .....	62, 138	Bortezomib Baxter[BX] (bortezomib 3.5 mg injection, 1 vial) .....	76, 152
Abevmy[AF] (bevacizumab 400 mg/16 mL injection, 16 mL vial) .....	62, 138	Bortezomib Ever Pharma[IT] (bortezomib 2.5 mg/mL injection, 1 mL vial) .....	76, 152
Abraxane[TS] (paclitaxel (as nanoparticle albumin-bound) 100 mg injection, 1 vial).....	14, 90	Bortezomib Ever Pharma[IT] (bortezomib 3.5 mg/1.4 mL injection, 1.4 mL vial) .....	76, 152
Adcetris[TK] (brentuximab vedotin 50 mg injection, 1 vial) .....	66, 67, 68, 69, 70, 142, 143, 144, 145, 146	Bortezomib Juno[JU] (bortezomib 2.5 mg injection, 1 vial) .....	76, 152
Adriamycin[PF] (doxorubicin hydrochloride 200 mg/100 mL injection, 100 mL vial).....	15, 91	Bortezomib Juno[JU] (bortezomib 3.5 mg injection, 1 vial) .....	76, 152
Adriamycin[PF] (doxorubicin hydrochloride 50 mg/25 mL injection, 25 mL vial) .....	15, 91	Bortezomib Sandoz[SZ] (bortezomib 3.5 mg injection, 1 vial) .....	76, 152
Akynzeo IV(JZ) .....	160	BORTEZOMIB-TEVA[TB] (bortezomib 3.5 mg injection, 1 vial).....	76, 152
Akynzeo(JZ).....	160	BRENTUXIMAB VEDOTIN 65, 66, 67, 68, 69, 70, 141, 142, 143, 144, 145, 146	
Aloxi(JZ).....	161	CABAZITAXEL .....	13, 89
APO-Ondansetron(TX) .....	161	Cabazitaxel Accord[OC] (cabazitaxel 60 mg/3 mL injection, 3 mL vial) .....	13, 89
APREPITANT .....	162	Cabazitaxel Ever Pharma[IT] (cabazitaxel 60 mg/6 mL injection, 6 mL vial) .....	13, 89
Aprepitant APOTEX(TX).....	162	Cabazitaxel Juno[JU] (cabazitaxel 60 mg/1.5 mL injection [1.5 mL vial] (& inert substance diluent [4.5 mL vial], 1 pack) .....	13, 89
APREPITANT SCP (XC).....	162	Caelyx[BX] (doxorubicin hydrochloride (as pegylated liposomal) 20 mg/10 mL injection, 10 mL vial).....	15, 91
APX-Ondansetron (TY).....	161	Caelyx[BX] (doxorubicin hydrochloride (as pegylated liposomal) 50 mg/25 mL injection, 25 mL vial).....	15, 91
APX-Ondansetron ODT(TY).....	161	CARBOPLATIN .....	76, 152
ARSENIC .....	79, 80, 155, 156	Carboplatin Accord[OC] (carboplatin 450 mg/45 mL injection, 45 mL vial) .....	76, 152
Arsenic Trioxide Accord[OC] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials).....	79, 80, 155, 156	CARFILZOMIB .....	76, 77, 78, 152, 153, 154
Arsenic Trioxide Juno[JU] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials).....	80, 156	CEMIPLIMAB .....	40, 41, 116, 117
Arsenic Trioxide-AFT[AE] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL ampoules).....	80, 156	CETUXIMAB .....	30, 31, 32, 106, 107, 108
ATEZOLIZUMAB .....	34, 35, 36, 37, 38, 110, 111, 112, 113, 114	CIPLA BLEOMYCIN[LR] (bleomycin sulfate 15 000 international units injection, 1 vial) .....	16, 92
AVELUMAB .....	39, 40, 115, 116	CISPLATIN .....	76, 152
Bavencio[SG] (avelumab 200 mg/10 mL injection, 10 mL vial) .....	39, 40, 115, 116	Cisplatin Accord[OC] (cisplatin 100 mg/100 mL injection, 100 mL vial) .....	76, 152
BENDAMUSTINE .....	9, 85	Cisplatin Accord[OC] (cisplatin 50 mg/50 mL injection, 50 mL vial) .....	76, 152
Bendamustine Juno[JU] (bendamustine hydrochloride 100 mg injection, 1 vial) .....	9, 85	CLADRIBINE	
Bendamustine Juno[JU] (bendamustine hydrochloride 25 mg injection, 1 vial) .....	9, 85	.Chemotherapy items for Private Hospital use .....	11
Bendamustine Sandoz[SZ] (bendamustine hydrochloride 100 mg injection, 1 vial).....	9, 85	.Chemotherapy items for Public Hospital use .....	87
Bendamustine Sandoz[SZ] (bendamustine hydrochloride 25 mg injection, 1 vial).....	9, 85	CYCLOPHOSPHAMIDE.....	10, 86
Bendamustine Viatris[AF] (bendamustine hydrochloride 100 mg injection, 1 vial).....	9, 85	CYCLOPHOSPHAMIDE-REACH[RQ] (cyclophosphamide 1 g injection, 1 vial).....	10, 86
Bendamustine Viatris[AF] (bendamustine hydrochloride 25 mg injection, 1 vial) .....	9, 85	CYCLOPHOSPHAMIDE-REACH[RQ] (cyclophosphamide 500 mg injection, 1 vial) .....	10, 86
Besponsa[PF] (inotuzumab ozogamicin 1 mg injection, 1 vial) .....	19, 20, 95, 96	CYTARABINE .....	12, 88
Bevaciptin[LR] (bevacizumab 100 mg/4 mL injection, 4 mL vial) .....	62, 138	DARATUMUMAB20, 21, 22, 96, 97, 98, 163, 164, 165, 166, 167	
Bevaciptin[LR] (bevacizumab 400 mg/16 mL injection, 16 mL vial).....	62, 138	Darzalex SC(JC) .....	164, 165, 166, 168
BEVACIZUMAB .....	62, 138	Darzalex[JC] (daratumumab 100 mg/5 mL injection, 5 mL vial).....	21, 22, 23, 97, 98, 99
BLEOMYCIN.....	16, 92	Darzalex[JC] (daratumumab 400 mg/20 mL injection, 20 mL vial) .....	21, 22, 23, 97, 98, 99
BLINATUMOMAB .....	62, 63, 64, 138, 139, 140	DBL Bleomycin Sulfate[PF] (bleomycin sulfate 15 000 international units injection, 1 vial) .....	16, 92
Blinicyto[AN] (blinatumomab 38.5 microgram injection [1 vial] (& inert substance solution [10 mL vial], 1 pack) 63, 64, 65, 139, 140, 141		DBL Bortezomib[PF] (bortezomib 1 mg injection, 1 vial) .....	76, 152
Bortezom[CR] (bortezomib 3.5 mg injection, 1 vial). 76, 152		DBL Bortezomib[PF] (bortezomib 2.5 mg injection, 1 vial)76, 152	
BORTEZOMIB .....	76, 152	DBL Bortezomib[PF] (bortezomib 3 mg injection, 1 vial) .....	76, 152
Bortezomib Accord[OC] (bortezomib 1 mg injection, 1 vial) .....	76, 152	DBL Bortezomib[PF] (bortezomib 3.5 mg injection, 1 vial)76, 152	
Bortezomib Accord[OC] (bortezomib 2.5 mg/mL injection, 1 mL vial).....	76, 152	DBL Docetaxel Concentrated Injection[PF] (docetaxel 160 mg/16 mL injection, 16 mL vial) .....	13, 89
Bortezomib Accord[OC] (bortezomib 3.5 mg injection, 1 vial) .....	76, 152		
Bortezomib Accord[OC] (bortezomib 3.5 mg/1.4 mL injection, 1.4 mL vial) .....	76, 152		

DBL Docetaxel Concentrated Injection[PF] (docetaxel 80 mg/8 mL injection, 8 mL vial).....	13, 89	Fluorouracil Ebewe[SZ] (fluorouracil 1 g/20 mL injection, 20 mL vial).....	12, 88
DBL Gemcitabine Injection[PF] (gemcitabine 1 g/26.3 mL injection, 26.3 mL vial).....	12, 88	Fluorouracil Ebewe[SZ] (fluorouracil 5 g/100 mL injection, 100 mL vial).....	12, 88
DBL Gemcitabine Injection[PF] (gemcitabine 2 g/52.6 mL injection, 52.6 mL vial).....	12, 88	FOLINIC ACID.....	169
DBL Methotrexate[PF] (methotrexate 1 g/10 mL injection, 10 mL vial).....	10, 86	Folotyn[MF] (pralatrexate 20 mg/mL injection, 1 mL vial) 11,	87
DBL Methotrexate[PF] (methotrexate 5 mg/2 mL injection, 5 x 2 mL vials).....	10, 86	FOSAPREPITANT.....	162
DBL Methotrexate[PF] (methotrexate 50 mg/2 mL injection, 5 x 2 mL vials).....	10, 86	FOSAPREPITANT MSN(RQ).....	163
DBL Methotrexate[PF] (methotrexate 500 mg/20 mL injection, 20 mL vial).....	10, 86	FOSAPREPITANT-AFT (AE).....	163
DBL Vinblastine[PF] (vinblastine sulfate 10 mg/10 mL injection, 5 x 10 mL vials).....	12, 88	FOSNETUPITANT + PALONOSETRON.....	160
DBL Vincristine Sulfate[PF] (vincristine sulfate 1 mg/mL injection, 5 x 1 mL vials).....	12, 88	Gazyva[RO] (obinutuzumab 1 g/40 mL injection, 40 mL vial).....	17, 18, 19, 93, 94, 95
DOCETAXEL.....	13, 89	GEMCITABINE.....	12, 88
Docetaxel Accord[OC] (docetaxel 160 mg/8 mL injection, 8 mL vial).....	13, 89	GEMTUZUMAB OZOGAMICIN.....	72, 148
Docetaxel Accord[OC] (docetaxel 80 mg/4 mL injection, 4 mL vial).....	13, 89	GRANISETRON.....	160
DOXORUBICIN.....	15, 91	Granisetron Kabi (PK).....	160
Doxorubicin ACC[OC] (doxorubicin hydrochloride 200 mg/100 mL injection, 100 mL vial).....	15, 91	Granisetron-AFT(AE).....	160
DOXORUBICIN HYDROCHLORIDE (AS PEGYLATED LIPOSOMAL).....	15, 91	Halaven[EI] (eribulin mesilate 1 mg/2 mL injection, 2 mL vial).....	80, 81, 156, 157
DURVALUMAB.....	42, 43, 118, 119	Herceptin SC(RO).....	168, 169
ELOTUZUMAB.....	70, 71, 146, 147	Herzuma[EW] (trastuzumab 150 mg injection, 1 vial)25, 26,	27, 28, 101, 102, 103, 104
Emend IV(MK).....	163	Herzuma[EW] (trastuzumab 440 mg injection [1 vial] (& inert substance diluent [20 mL vial], 1 pack)....	25, 26, 27, 28, 101, 102, 103, 104
Empliciti[BQ] (elotuzumab 300 mg injection, 1 vial). 71, 147		Holoxan[BX] (ifosfamide 1 g injection, 1 vial).....	10, 86
Empliciti[BQ] (elotuzumab 400 mg injection, 1 vial). 71, 147		Holoxan[BX] (ifosfamide 2 g injection, 1 vial).....	10, 86
Endoxan[BX] (cyclophosphamide 1 g injection, 1 vial) ...	10, 86	Hycamtin[SZ] (topotecan 4 mg injection, 5 vials).....	14, 90
Endoxan[BX] (cyclophosphamide 2 g injection, 1 vial) ...	10, 86	IDARUBICIN.....	16, 92
Endoxan[BX] (cyclophosphamide 500 mg injection, 1 vial).....	10, 86	IFOSFAMIDE.....	10, 86
ENFORTUMAB VEDOTIN.....	71, 147	Imfinzi[AP] (durvalumab 120 mg/2.4 mL injection, 2.4 mL vial).....	42, 43, 118, 119
Enhertu[AP] (trastuzumab deruxtecan 100 mg injection, 1 vial).....	28, 104	Imfinzi[AP] (durvalumab 500 mg/10 mL injection, 10 mL vial).....	42, 43, 118, 119
EPIRUBICIN.....	16, 92	INOTUZUMAB OZOGAMICIN.....	19, 95
Epirubicin Accord[OC] (epirubicin hydrochloride 200 mg/100 mL injection, 100 mL vial).....	16, 92	IPILIMUMAB.....	72, 73, 74, 149, 150
Erbitux[SG] (cetuximab 100 mg/20 mL injection, 20 mL vial).....	30, 31, 32, 106, 107, 108	IRINOTECAN.....	14, 90
Erbitux[SG] (cetuximab 500 mg/100 mL injection, 100 mL vial).....	30, 31, 32, 106, 107, 108	Irinotecan Accord[OC] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial).....	14, 90
ERIBULIN.....	80, 156	Irinotecan Accord[OC] (irinotecan hydrochloride trihydrate 500 mg/25 mL injection, 25 mL vial).....	14, 90
Etopophos[LM] (etoposide phosphate 1.136 g (etoposide 1 g) injection, 1 vial).....	13, 89	Irinotecan Alphapharm[AF] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial).....	14, 90
ETOPOSIDE.....	13, 89	Irinotecan Alphapharm[AF] (irinotecan hydrochloride trihydrate 500 mg/25 mL injection, 25 mL vial).....	14, 90
Etoposide Ebewe[SZ] (etoposide 100 mg/5 mL injection, 5 x 5 mL vials).....	13, 89	IRINOTECAN BAXTER[BX] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial).....	14, 90
FLUDARABINE.....	11, 87	Kadcyla[RO] (trastuzumab emtansine 100 mg injection, 1 vial).....	29, 30, 105, 106
Fludarabine Ebewe[SZ] (fludarabine phosphate 50 mg/2 mL injection, 5 x 2 mL vials).....	11, 87	Kadcyla[RO] (trastuzumab emtansine 160 mg injection, 1 vial).....	29, 30, 105, 106
Fludarabine Juno[JO] (fludarabine phosphate 50 mg injection, 1 vial).....	11, 87	Kanjinti[JU] (trastuzumab 150 mg injection, 1 vial)....	25, 26, 27, 28, 101, 102, 103, 104
FLUOROURACIL.....	12, 88	Kanjinti[JU] (trastuzumab 420 mg injection, 1 vial)....	25, 26, 27, 28, 101, 102, 103, 104
Fluorouracil Accord[OC] (fluorouracil 1 g/20 mL injection, 20 mL vial).....	12, 88	Keytruda[MK] (pembrolizumab 100 mg/4 mL injection, 4 mL vial)....	51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 127, 128, 129, 130, 131, 132, 133, 134, 135, 137, 138
Fluorouracil Accord[OC] (fluorouracil 2.5 g/50 mL injection, 50 mL vial).....	12, 88	Kyprolis[AN] (carfilzomib 10 mg injection, 1 vial). 77, 78, 79,	153, 154, 155
Fluorouracil Accord[OC] (fluorouracil 5 g/100 mL injection, 100 mL vial).....	12, 88	Kyprolis[AN] (carfilzomib 30 mg injection, 1 vial). 77, 78, 79,	153, 154, 155
Fluorouracil Accord[OC] (fluorouracil 500 mg/10 mL injection, 10 mL vial).....	12, 88	Kyprolis[AN] (carfilzomib 60 mg injection, 1 vial). 77, 78, 79,	153, 154, 155
Fluorouracil Accord[OC] (fluorouracil 500 mg/10 mL injection, 10 mL vial).....	12, 88	Kytril(IX).....	160
		Leucovorin Calcium (Hospira Pty Limited)(PF).....	169
		Leucovorin Calcium (Pfizer Australia Pty Ltd)(PF).....	169
		Leustatin[IX] (cladribine 10 mg/10 mL injection, 10 mL vial).....	11, 87

<i>Libtayo</i> [SW] (cemiplimab 350 mg/7 mL injection, 7 mL vial) ..... 40, 41, 42, 116, 117, 118	<i>Opdivo</i> [BQ] (nivolumab 40 mg/4 mL injection, 4 mL vial) 43, 44, 45, 46, 47, 48, 49, 50, 119, 120, 121, 122, 123, 124, 125, 126
<i>Liposomal Doxorubicin SUN</i> [RA] (doxorubicin hydrochloride (as pegylated liposomal) 20 mg/10 mL injection, 10 mL vial) ..... 16, 92	OXALIPLATIN ..... 76, 152
<i>Liposomal Doxorubicin SUN</i> [RA] (doxorubicin hydrochloride (as pegylated liposomal) 50 mg/25 mL injection, 25 mL vial) ..... 16, 92	<i>Oxaliplatin Accord</i> [OC] (oxaliplatin 100 mg/20 mL injection, 20 mL vial) ..... 76, 152
<i>Litak</i> [AF] (cladribine 10 mg/5 mL injection, 5 mL vial) 11, 87	<i>Oxaliplatin SUN</i> [RA] (oxaliplatin 100 mg/20 mL injection, 20 mL vial) ..... 76, 152
<i>MEDITAB IRINOTECAN</i> [LR] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) ..... 14, 90	<i>Oxaliplatin SUN</i> [RA] (oxaliplatin 200 mg/40 mL injection, 40 mL vial) ..... 76, 152
<i>MEDITAB IRINOTECAN</i> [LR] (irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 2 mL vial) ..... 14, 90	PACLITAXEL ..... 14, 90
MESNA ..... 169	<i>Paclitaxel Accord</i> [OC] (paclitaxel 300 mg/50 mL injection, 50 mL vial) ..... 14, 90
METHOTREXATE	<i>Paclitaxel Ebewe</i> [SZ] (paclitaxel 300 mg/50 mL injection, 50 mL vial) ..... 14, 90
.Chemotherapy items for Private Hospital use ..... 10	<i>Padcev</i> [LL] (enfortumab vedotin 20 mg injection, 1 vial) . 72, 148
.Chemotherapy items for Public Hospital use ..... 86	<i>Padcev</i> [LL] (enfortumab vedotin 30 mg injection, 1 vial) . 72, 148
<i>Methotrexate Accord</i> [OD] (methotrexate 1 g/10 mL injection, 10 mL vial) ..... 10, 86	PALONOSETRON ..... 161
<i>Methotrexate Ebewe</i> [SZ] (methotrexate 5 g/50 mL injection, 50 mL vial) ..... 10, 86	<i>Palonosetron Dr.Reddy's (RZ)</i> ..... 161
MITOZANTRONE ..... 16, 92	PANITUMUMAB ..... 32, 33, 108, 109
<i>Mitozantrone Ebewe</i> [SZ] (mitozantrone 20 mg/10 mL injection, 10 mL vial) ..... 16, 92	PEMBROLIZUMAB ... 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 126, 127, 128, 129, 130, 131, 132, 133, 135, 136, 137
<i>MSN Cabazitaxel</i> [RQ] (cabazitaxel 60 mg/1.5 mL injection [1.5 mL vial] (& inert substance diluent [4.5 mL vial], 1 pack) ..... 13, 89	PEMETREXED ..... 10, 86
<i>Mvasi</i> [AN] (bevacizumab 100 mg/4 mL injection, 4 mL vial) ..... 62, 138	<i>Pemetrexed Accord</i> [OD] (pemetrexed 1 g injection, 1 vial) ..... 10, 86
<i>Mvasi</i> [AN] (bevacizumab 400 mg/16 mL injection, 16 mL vial) ..... 62, 138	<i>Pemetrexed Accord</i> [OD] (pemetrexed 100 mg injection, 1 vial) ..... 10, 86
MYCOBACTERIUM BOVIS BCG DANISH STRAIN ..... 169	<i>Pemetrexed Accord</i> [OD] (pemetrexed 500 mg injection, 1 vial) ..... 10, 86
MYCOBACTERIUM BOVIS BCG TICE STRAIN ..... 169	<i>Pemetrexed APOTEX</i> [TX] (pemetrexed 500 mg injection, 1 vial) ..... 10, 86
<i>Mylotarg</i> [PF] (gemtuzumab ozogamicin 5 mg injection, 1 vial) ..... 72, 148	<i>Pemetrexed Ever Pharma</i> [IT] (pemetrexed 1 g/40 mL injection, 40 mL vial) ..... 10, 86
NANOPARTICLE ALBUMIN-BOUND PACLITAXEL 13, 14, 89, 90	<i>Pemetrexed Ever Pharma</i> [IT] (pemetrexed 100 mg/4 mL injection, 4 mL vial) ..... 11, 87
<i>Navelbine</i> [FB] (vinorelbine 10 mg/mL injection, 1 mL vial) ..... 13, 89	<i>Pemetrexed Ever Pharma</i> [IT] (pemetrexed 500 mg/20 mL injection, 20 mL vial) ..... 11, 87
<i>Navelbine</i> [FB] (vinorelbine 50 mg/5 mL injection, 5 mL vial) ..... 13, 89	<i>Pemetrexed SUN</i> [RA] (pemetrexed 1 g injection, 1 vial) . 11, 87
NETUPITANT + PALONOSETRON ..... 160	<i>Pemetrexed SUN</i> [RA] (pemetrexed 100 mg injection, 1 vial) ..... 11, 87
NIVOLUMAB.. 43, 44, 45, 46, 47, 48, 49, 50, 119, 120, 121, 122, 123, 124, 125, 126	<i>Pemetrexed SUN</i> [RA] (pemetrexed 500 mg injection, 1 vial) ..... 11, 87
OBINUTUZUMAB ..... 16, 17, 18, 92, 93, 94	<i>Perjeta</i> [RO] (pertuzumab 420 mg/14 mL injection, 14 mL vial) ..... 24, 100
<i>Ogivri</i> [AF] (trastuzumab 150 mg injection, 1 vial) 25, 26, 27, 28, 101, 102, 103, 104	PERTUZUMAB ..... 23, 24, 99, 100
<i>Omegapharm Irinotecan</i> [OE] (irinotecan hydrochloride trihydrate 100 mg/5 mL injection, 5 mL vial) ..... 14, 90	<i>Pfizer Australia Pty Ltd</i> [PF] (cytarabine 100 mg/5 mL injection, 5 x 5 mL vials) ..... 12
<i>Omegapharm Irinotecan</i> [OE] (irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 2 mL vial) ..... 14, 90	.Chemotherapy items for Private Hospital use ..... 12
<i>OncoTICE</i> (MK) ..... 169	.Chemotherapy items for Public Hospital use ..... 88
ONDANSETRON ..... 160, 161	<i>Pfizer Australia Pty Ltd</i> [PF] (methotrexate 1 g/10 mL injection, 10 mL vial) ..... 10
<i>Ondansetron AN ODT</i> (EA) ..... 161	.Chemotherapy items for Private Hospital use ..... 10
<i>Ondansetron AN</i> (EA) ..... 161	.Chemotherapy items for Public Hospital use ..... 86
<i>Ondansetron Mylan ODT</i> (AF) ..... 161	<i>Phenasen</i> [FF] (arsenic trioxide 10 mg/10 mL injection, 10 x 10 mL vials) ..... 80, 156
<i>Ondansetron Mylan Tablets</i> (AF) ..... 161	PRALATREXATE ..... 11, 87
<i>Ondansetron ODT-DRLA</i> (RZ) ..... 161	RALTITREXED ..... 11, 87
<i>Ondansetron SZ</i> (HX) ..... 161	<i>Ribomustin</i> [JC] (bendamustine hydrochloride 100 mg injection, 1 vial) ..... 9, 85
<i>Ondansetron SZ ODT</i> (HX) ..... 161	<i>Ribomustin</i> [JC] (bendamustine hydrochloride 25 mg injection, 1 vial) ..... 9, 85
<i>Ondansetron-DRLA</i> (RZ) ..... 161	RITUXIMAB
<i>Onkotrone</i> [BX] (mitozantrone 20 mg/10 mL injection, 10 mL vial) ..... 16, 92	.Chemotherapy items for Private Hospital use ..... 19
<i>Onkotrone</i> [BX] (mitozantrone 25 mg/12.5 mL injection, 12.5 mL vial) ..... 16, 92	.Chemotherapy items for Public Hospital use ..... 95
<i>Opdivo</i> [BQ] (nivolumab 100 mg/10 mL injection, 10 mL vial) ... 43, 44, 45, 46, 47, 48, 49, 50, 119, 120, 121, 122, 123, 124, 125, 126	<i>Riximyo</i> [SZ] (rituximab 100 mg/10 mL injection, 2 x 10 mL vials) ..... 19, 95

<i>Riximyo</i> [SZ] (rituximab 500 mg/50 mL injection, 50 mL vial) .....	19, 95	<i>Truxima</i> [EW] (rituximab 100 mg/10 mL injection, 2 x 10 mL vials) .....	19, 95
<i>Ruxience</i> [PF] (rituximab 100 mg/10 mL injection, 10 mL vial) .....	19, 95	<i>Truxima</i> [EW] (rituximab 500 mg/50 mL injection, 50 mL vial) .....	19, 95
. Chemotherapy items for Private Hospital use .....	19	<i>Uromitexan</i> (BX) .....	169, 170
. Chemotherapy items for Public Hospital use .....	95	<i>Vectibix</i> [AN] (panitumumab 100 mg/5 mL injection, 5 mL vial) .....	33, 34, 109, 110
<i>Ruxience</i> [PF] (rituximab 500 mg/50 mL injection, 50 mL vial) .....	19, 95	<i>Vectibix</i> [AN] (panitumumab 400 mg/20 mL injection, 20 mL vial) .....	33, 34, 109, 110
. Chemotherapy items for Private Hospital use .....	19	<i>Velcade</i> [JC] (bortezomib 1 mg injection, 1 vial) .....	76, 152
. Chemotherapy items for Public Hospital use .....	95	<i>Velcade</i> [JC] (bortezomib 3 mg injection, 1 vial) .....	76, 152
SACITUZUMAB GOVITECAN .....	75, 151	<i>Velcade</i> [JC] (bortezomib 3.5 mg injection, 1 vial) .....	76, 152
<i>Tecentriq</i> [RO] (atezolizumab 1.2 g/20 mL injection, 20 mL vial) .....	34, 35, 36, 38, 39, 110, 111, 112, 114, 115	<i>VesiCulture</i> (LM) .....	169
<i>Tecentriq</i> [RO] (atezolizumab 840 mg/14 mL injection, 14 mL vial) .....	34, 35, 36, 37, 110, 111, 112, 113	VINBLASTINE .....	12, 88
<i>Tomudex</i> [PF] (raltitrexed 2 mg injection, 1 vial) .....	11, 87	VINCRIStINE .....	12, 88
TOPOTECAN .....	14, 90	VINOReLBINE .....	13, 89
<i>Topotecan Accord</i> [OC] (topotecan 4 mg/4 mL injection, 5 x 4 mL vials) .....	14, 90	<i>Vinorelbine Ebewe</i> [SZ] (vinorelbine 10 mg/mL injection, 1 mL vial) .....	13, 89
TRABECTEDIN .....	14, 15, 90, 91	<i>Vinorelbine Ebewe</i> [SZ] (vinorelbine 50 mg/5 mL injection, 5 mL vial) .....	13, 89
TRASTUZUMAB .....	24, 25, 26, 27, 100, 101, 102, 103, 168	<i>Yervoy</i> [BQ] (ipilimumab 200 mg/40 mL injection, 40 mL vial) .....	75, 151
TRASTUZUMAB DERUXTECAN .....	28, 104	<i>Yervoy</i> [BQ] (ipilimumab 50 mg/10 mL injection, 10 mL vial) .....	73, 74, 75, 149, 150, 151
TRASTUZUMAB EMTANSINE .....	28, 29, 104, 105	<i>Yondelis</i> [ZL] (trabectedin 1 mg injection, 1 vial) .....	15, 91
<i>Trazimera</i> [PF] (trastuzumab 150 mg injection, 1 vial) .....	25, 26, 27, 28, 101, 102, 103, 104	<i>Zavedos Solution</i> [PF] (idarubicin hydrochloride 5 mg/5 mL injection, 5 mL vial) .....	16, 92
<i>Trazimera</i> [PF] (trastuzumab 60 mg injection, 1 vial) .....	25, 26, 27, 28, 101, 102, 103, 104	<i>Zofran syrup 50 mL</i> (AS) .....	161
<i>Trodelyv</i> [GI] (sacituzumab govitecan 180 mg injection, 1 vial) .....	75, 151	<i>Zofran</i> (AS) .....	161
TROPISETRON .....	161	<i>Zotren 4</i> (RF) .....	161
<i>Tropisetron-AFT</i> (AE) .....	161	<i>Zotren 8</i> (RF) .....	161
		<i>Zotren ODT</i> (RF) .....	161